At least 21 days must have elapsed from prior systemic therapy (chemotherapy or radiation)
Patients must have at least one lesion that has not previously been irradiated (and is not within a previously radiated field) and for which palliative radiation is potentially indicated and could be safely delivered at the radiation doses specified in this protocol; this lesion must not be the only measurable lesion so that it is still possible to determine the response rate outside of the radiation treatment field; this lesion must not be within the central nervous system (CNS) (brain or spinal cord) or requiring urgent or emergent palliative radiation given the timing of radiation specified on this protocol; furthermore, this lesion: \r\n* For cohort 1 (NSCLC cohort) – the lesion to be irradiated must be in the lung, lymph nodes, adrenal gland or liver \r\n* For cohort 2 (colorectal cohort) – the lesion to be irradiated must be in the liver
No prior intra-thoracic radiation therapy; NOTE: previous radiotherapy as part of treatment for head and neck, breast, or other non-thoracic cancer is permitted so long as possible radiation fields would not overlap; previous chemotherapy or surgical resection specifically for the lung cancer being treated on this protocol is NOT permitted; no prior lung resection on the ipsilateral side
Participants who have received any other investigational agents within the 4 weeks prior to enrollment; concurrent radiation therapy is not permitted, except palliative (limited-field) radiation therapy, if all of the following criteria are met:\r\n* Repeat imaging demonstrates no new sites of bone metastases\r\n* The lesion being considered for palliative radiation is not a target lesion
Underwent hepatic radiation, chemoembolization, and radiofrequency ablation <4 weeks prior to Day 1.
Prior radiotherapy to the region of the liver that would result in excessive doses to normal tissues due to overlap of radiation therapy fields
Therapy-related MDS (defined as the occurrence of MDS due to prior exposure to systemic chemotherapy and/or radiation for malignancy)
At least 14 days after local palliative radiation therapy (XRT) (small port); at least 150 days must have elapsed if prior traumatic brain injury (TBI), craniospinal XRT or if >= 50% radiation of pelvis; at least 42 days must have elapsed if other substantial bone marrow radiation, including therapeutic doses of Iobenguane (MIBG)
Enrolled on SJMB12 and completed protocol directed radiation therapy
Patients who received radiation therapy within the last 4 weeks; radiation exposure may not exceed 30% of marrow area
All women who undergo breast conserving therapy must receive concomitant radiotherapy; radiation after mastectomy is to be administered according to pre-specified institutional guidelines; radiation must be completed at least 21 days prior to registration
Patients must have completed either breast-conserving surgery or total mastectomy, with negative margins and appropriate axillary staging; a negative margin is defined as no evidence of tumor or ductal carcinoma in situ (DCIS) at the line of resection; additional operative procedures may be performed to obtain clear margins\r\n* Patients who had breast-conserving surgery must have completed whole breast radiation; use of regional nodal basin radiation will be at the discretion of the investigator according to institutional guidelines\r\n* Patients with >= 4 positive lymph nodes must have completed breast/chest wall and nodal basin radiation therapy according to standard of care guidelines before randomization; omission of radiation therapy is not allowed in this high-risk population of patients\r\n* Patients must be registered at least 21 days after completion of radiation therapy and must have recovered (=< grade 1) from any of the effects of radiation
No neoadjuvant radiation therapy
STEP I: Patients must have received no more than one cycle (4 weeks or less) of prior chemotherapy and no more than 160 mg of prior dexamethasone (or equivalent dose of prednisone) for treatment of symptomatic myeloma; they should not have been exposed to lenalidomide, bortezomib or carfilzomib for treatment of symptomatic myeloma; prior radiation therapy to symptomatic lesions is allowed provided there are no residual toxicity related to radiation and blood counts that meet the study requirements
Patients must have completed any prior radiation therapy and hormonal therapy at least 14 days prior to registration
No radiation therapy =< 4 weeks before pre-registration
Prior radiotherapy must in general have been completed >= 2 weeks prior to randomization and patients must have recovered from the toxicity of the radiation\r\n* NOTE: Patients may receive concurrent radiation therapy to painful sites of bony disease or areas of impending fracture as long as sites of measurable or non-measurable disease outside the radiation therapy port are available to follow
Prior breast or thoracic radiation therapy (RT) for any condition
Patients cannot have had prior chemotherapy or biologic therapy for small cell lung cancer for front line treatment; patients receiving prior whole brain radiation cannot register within 7 days after completion of radiation, and must have resolved adverse events attributed to radiation to =< grade 1
Patients must not have had prior radiation therapy within 14 days prior to registration
Patients may have received prior radiation therapy, but must have measurable disease outside the radiation port; at least 14 days must have elapsed since completion of prior radiation therapy; patients must have recovered from all associated toxicities at the time of registration
No prior radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks prior to registration
No treatment with radiation therapy =< 28 days before study registration
Patients for whom radiation therapy (RT) to the affected breast or chest wall and regional nodal areas is clinically indicated as per NCCN treatment guidelines, should receive RT after randomization when possible, and receive MK-3475 (pembrolizumab) concurrent with RT, if randomized to the experimental arm; however, RT administered, or initiated, prior to registration is also allowed; pembrolizumab may be added to ongoing radiation, or started after its completion, if randomized to the experimental arm, provided there are no > grade 2 radiation-related skin toxicities; patients who have not yet started radiation must specify at the time of screening registration whether or not they will receive RT and the extent of intended RT
External beam radiation therapy within 4 weeks of registration
Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy fields
For patients pre-registering after the completion of radiation therapy, documentation of a bone marrow aspirate and biopsy containing < 10% clonal plasma cells prior to start of radiation therapy
For all patients:\r\n* Radiation dose should range from 4500 cGy to 6000 cGy\r\n* No treatment for this disease following radiation therapy
Patients who have received prior chemotherapy or radiation therapy are not eligible
Participants may not have had radiation to the lung fields within four weeks (28 days) of starting treatment; for patients receiving palliative radiation to thoracic vertebrae, ribs or other sites where the radiation field includes the lungs, radiation must be completed at least two weeks before starting treatment; for all palliative radiation to all other sites, at least 7 days must have elapsed prior to starting to treatment; at least six months (180 days) must have elapsed from radiation given with curative intent
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
No other chemotherapy or radiation therapy within 14 days prior to registration
Patients who have received any previous chemotherapy or radiation therapy are not eligible
At least one site of metastatic disease or primary disease must be determined by radiation oncologist to be treatable with radiation.
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiation therapy to the pelvis that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Patients planning to receive EPP must also be evaluated for appropriateness of radiation therapy (RT) by a radiation oncologist within 14 days prior to step 2 registration
Patients having received palliative radiotherapy for extracranial metastasis(es) are eligible as long as there are 2 cancerous deposits that have not received prior radiation therapy (RT) and they meet the following criteria\r\n* No prior radiation therapy (> 5 Gy) to the metastasis intended to be treated with SBRT
>= 2 weeks must have elapsed since local palliative radiation therapy (XRT) (small port); >= 6 weeks must have elapsed since treatment with therapeutic doses of M-Iodobenzylguanidine (MIBG); >= 3 months must have elapsed if prior craniospinal XRT was received, if >= 50% of the pelvis was irradiated, or if total-body irradiation (TBI) was received; >= 6 weeks must have elapsed if other substantial bone marrow irradiation was given\r\n* Subjects should not have any clinically relevant ongoing complications from prior radiation therapy (i.e., radiation esophagitis or other inflammation of the viscera)
Prior radiation therapy (RT) (any site) with concurrent lapatinib defined as 1 or more days on which the patient received both radiation therapy and lapatinib on the same day
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields except patients who have progressed following stereotactic radiosurgery for 1-3 brain metastases, with at least one new lesion
No radiation therapy (other than to the brain) within 14 days of day 1 of protocol chemotherapy except radiation to brain metastases, which must be completed 7 days prior to start of chemotherapy
No large (>= 2 cm) hemorrhagic or symptomatic brain metastases until local treatment has been administered (radiation therapy or surgery); treatment may begin >= 7 days after completion of local treatment; patients with small (< 2 cm) and asymptomatic brain metastases are allowed and may be treated with radiation therapy and/or surgery concurrently with Arm A or cycles 1 and 2 of Arm B if deemed medically indicated; radiation therapy should not be given concurrently with high-dose carboplatin or etoposide
Prior treatment\r\n* Cohort A: No prior therapy received other than surgery\r\n* Cohort B: Prior radiation therapy required (any type of prior radiation is allowed)\r\n** For patients treated with external beam radiation therapy, interstitial brachytherapy or radiosurgery, an interval of >= 3 months must have elapsed from completion of radiation therapy to registration\r\n** Recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or less toxicity attributed to radiation with exception of alopecia, fatigue\r\n* For patients enrolling on Cohort A or Cohort B:\r\n** For patients treated with surgery, an interval of >= 21 days must have elapsed prior to registration\r\n** No prior treatment with BRAF or MEK inhibitors\r\n** Steroid dosing stable for at least 4 days prior to registration
Prior radiation therapy is allowed; patients must not have received minimal radiation therapy (=< 5% of their total marrow volume) within 3 weeks prior to the initiation of study treatment; otherwise, patients must not have received radiation therapy (> 5% of their total marrow volume) within 4 weeks prior to the initiation of study treatment; patients who have received prior radiation to 50% or more of their total marrow volume will be excluded
Prior radiation therapy within 28 days of starting the study treatment
Planned surgery or radiation therapy during protocol treatment
Washout period should be at least 2 weeks for prior chemotherapy or radiation therapy
Prior radiotherapy within 2 weeks of initiating treatment; Must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis
Subject is within 12 weeks of completion of radiation.
Have received only one prior radiation treatment course; prior radiation course must have been with curative intent
At least 4 weeks since prior treatment (chemotherapy, radiation therapy, hormonal therapy)
Patients must have histologic proof of malignancy suitable for thoracic radiation therapy
Any chemotherapy, external beam radiation therapy, or anticancer antibodies within 2 weeks
Patients who received radiation therapy > 5 years ago for malignancies other than breast cancer and whose radiation therapy field is not overlapping with the 20% isodose line of current radiation field are eligible, provided that radiation therapy was completed > 5 years ago and that there is no evidence of the second malignancy at the time of study entry
Patients must have failed prior radiation therapy and must have an interval of greater than or equal to 42 days from the completion of radiation therapy to study entry; Note: patients with an indication for craniospinal radiotherapy (i.e., extensive leptomeningeal disease) but have refused palliative craniospinal radiotherapy are eligible
Prior radiation therapy or radionuclide therapy for the treatment of metastasis
Prior surgery or radiotherapy within 14 days of initiating study drug(s). Patients must have recovered from all radiation-related toxicities, not required corticosteroids and have not had radiation pneumonitis.
Patients may not receive or have received any radiation therapy at the biopsy sites.
Received radiation therapy to the lung > 30 Gy within 6 months of first dose of study treatment.
Receipt of radiation therapy within 3 weeks of scheduled C1D1 dosing, unless the radiation comprised a limited field to non-visceral structures (e.g., limb bone metastasis).
Received more than 30 Gy of radiation in the thoracic region within 26 weeks prior to study enrollment
Meningioma that have resulted from prior radiation therapy are allowed
For patients treated with external beam radiation, interstitial brachytherapy or radiosurgery, an interval >= 24 weeks must have elapsed from completion of radiation therapy (XRT) to registration
Patients must be a candidate for surgery (as per treating surgeon) and be able to tolerate proton radiation and chemotherapy (as per treating radiation oncologist and medical oncologist)
Treatment with radiation therapy within 2 weeks prior to the initiation of study drug.
Patients must have histologically confirmed glioblastoma that is progressive or recurrent following radiation therapy and temozolomide according to the Response Assessment in Neuro-Oncology (RANO) criteria with:\r\n* New contrast-enhancing lesion outside of radiation field on decreasing, stable, or increasing doses of corticosteroids\r\n* Increase by >= 25% in the sum of the products of perpendicular diameters between the postradiotherapy scan with the smallest tumor measurement and a scan at least 12 weeks from completion of radiation therapy (RT) + temozolomide (TMZ), on stable or increasing doses of corticosteroids\r\n** Note: clinical deterioration not attributable to concurrent medication or comorbid conditions is sufficient to declare progression on current treatment but not for entry onto a clinical trial for recurrence
Patients must be in first recurrence of glioblastoma following radiation therapy and temozolomide
No prior immunotherapy allowed or prior alkylating agents or prior radiation to the brain
>= 2 weeks must have elapsed for local palliative radiation therapy (XRT) (small port) and enrollment on study; at least 24 weeks must have elapsed since prior total body irradiation (TBI), radiation to >= 50% of pelvis, or craniospinal radiation; >= 6 weeks must have elapsed if the patient has received other substantial bone marrow radiation
Prior surgery or radiotherapy within 14 days of initiating therapy. Patients must have recovered from all radiation-related toxicities, and not required corticosteroids.
Patients with a history of prior cranial radiation are ineligible
Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry; palliative radiation (=< 10 fractions) must have been completed at least 48 hours prior to study entry; stereotactic or small field brain irradiation must have completed at least 2 weeks prior to study entry; whole brain radiation must have completed at least 4 weeks prior to study entry
Prior radiation therapy to the chest [Period 2]
Radiation therapy to ipsilateral breast [Period 1]
Radiation therapy for breast cancer within 2 weeks of dosing and planning to have radiation therapy during participation in this study.
Post-ASCT anti-lymphoma or investigational therapy; immediate post-ASCT consolidative radiation therapy is allowed as long as it occurs prior to initiation of study therapy; baseline imaging and pulmonary function tests (PFTs) must be performed after completion of radiation
Prior radiation therapy:\r\n* Patients may have received prior radiation therapy in either the metastatic or early-stage setting\r\n* Radiation therapy must be completed at least 14 days prior to registration
Prior to registration, patients must be ? 14 days for local palliative radiation therapy (XRT) (small port); ? 90 days must have elapsed if prior total body irradiation (TBI), craniospinal XRT or if ? 50% radiation of pelvis; ? 45 days must have elapsed if other substantial bone marrow radiation
Radiation therapy within 4 weeks of enrollment
Previous radiation in the current area of disease requiring radiation
Prior radiation therapy (RT) of greater dose intensity than 100 Gy2 based on a biological effective dose (BED) calculation
Cutaneous, subcutaneous soft tissue, or superficial lymphatic metastasis that is amenable to injection and irradiation and > 10 mm in longest dimension\r\n* Cutaneous metastasis in a region of previous radiation therapy is amenable to radiation therapy as part of this protocol if at least 6 months has elapsed since prior radiotherapy and the dose of radiotherapy previously administered did not exceed an equivalent dose of 60 Gy in 2 Gy equivalent fractions at the skin surface (using linear-quadratic modeling with alpha/beta = 11.5)
Patients who have had chemotherapy (e.g., purine analogues, alkylating agents), radiation therapy, or participation in any investigational drug treatment within 4 weeks of initiation of DMF or at any time during the study
Must have failed previous radiation treatment or combined treatment with temozolomide and radiation.
If progression of disease occurs within three months of conformal radiation, it must be outside of the radiation field or proven by biopsy/resection.
Patient has completed chemo-radiation within the last three months, unless new contrast enhancement is outside of radiation field, or there is tissue proven recurrence or progression.
Radiation within 2 weeks of starting study treatment
Prior therapy:\r\n* There is no limit on the number of prior surgeries, radiation therapy, radiosurgery treatments or systemically administered therapeutic agents\r\n* Patients may have been treated with standard external beam radiation or radiosurgery in any combination, however, an interval of >= 12 weeks (84 days) must have elapsed from the completion of the radiation therapy to start of study therapy unless there is histopathologic confirmation of recurrent tumor or there is new enhancing tumor outside the radiation field (beyond the high dose region or the 80% isodose line)\r\n** In addition, there must be subsequent evidence of tumor progression after completion of radiation therapy\r\n* An interval of >= 28 days and full recovery (no ongoing safety issues) from surgical resection (>= 7 days from stereotactic biopsy)\r\n* For prior systemic agents, participants must be at least 4 weeks (or 5 half-lives, whichever is shorter) from other prior cytotoxic chemotherapy (6 weeks from nitrosoureas) or biologic therapies
Prior radiation therapy is allowed; patients must not have received radiation therapy within 4 weeks prior to the initiation of study treatment
Radiation therapy (XRT): at least 14 days after local palliative XRT (small port); 6 weeks must have elapsed since treatment with therapeutic doses of 131-meta-iodobenzylguanidine sulfate (I^131-MIBG); at least 150 days must have elapsed if prior traumatic brain injury (TBI), craniospinal XRT, or if >= 50% radiation of pelvis; at least 42 days must have elapsed if other substantial brain metastases (BM) radiation
Radiation therapy
Participants must have developed progressive disease after receiving prior radiation therapy and must have an interval of at least 12 weeks from the completion of any radiation therapy to study entry (unless progressive tumor growth is outside the radiation field or there is histopathological confirmation of recurrent tumor)
Prior radiation therapy within 2 weeks prior to the first dose of the study regimen
Any radiation therapy in prior 2 weeks
Radiation therapy within 7 days before the first dose of cabozantinib; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible
Radiation therapy less than or equal to 4 weeks prior to registration
Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before planned first dose of study drug. Systemic treatment with radionuclides within 6 weeks before planned first dose of study drug. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible
Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol; consolidative radiation therapy (RT) after completion of planned course and/or concurrent intrathecal chemotherapy for central nervous system (CNS) disease prophylaxis is permissible
Had therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment or palliative radiation therapy within 2 weeks before study drug treatment.
Prior radiation therapy is acceptable but there cannot be major overlap of the previously irradiated tissues with the new radiation treatment volumes anticipated to be delivered for the purposes of this protocol, in such a way that curative intent with radiation cannot be met; furthermore, the total dose from all radiation delivered and expected to be delivered should not exceed the suggested dose constraints given for normal structures
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields in such a way that curative intent with radiation cannot be met
Patients with widespread superficial multifocal BCC who are considered unresectable due to breadth of involvement and do not have a single definable area of disease amenable to radiation therapy targeting\r\n* Note: if an area including one or more lesions is definable for radiation therapy targeting, the patient may be eligible for treatment on study using the designated target lesion(s) identified by the investigator
Participants who have received radiation therapy within 2 weeks of starting study drug; Note: participants who have received radiation therapy to a small volume (e.g. stereotactic radiosurgery to the CNS) will be eligible if completed > 1 week prior to starting study drug
Prior palliative radiation must have been completed at least 2 weeks prior to study entry
Patients must have been previously treated with radiation therapy and temozolomide (bevacizumab-naive – groups 1 and 3) or radiation therapy, temozolomide and bevacizumab (bevacizumab-exposed – groups 2 and 4); therapy with these agents may be given together or sequentially in the past
Prior radiation requirements\r\n* For bevacizumab-naive patients (groups 1 and 3) a minimum of 6 months must have elapsed since completion of initial radiation therapy for study entry, and there is no minimum time since completion of last chemotherapy\r\n* For bevacizumab-exposed patients (groups 2 and 4) minimum of 3 months must have elapsed since completion of initial radiation therapy and there is no minimum time since completion of last chemotherapy
ENDOCRINE RESISTANT COHORT: Prior treatment of this cancer including:\r\n* Surgery\r\n* Radiation therapy\r\n* Chemotherapy
Prior treatment with radiation to the thoracic region
Radiation therapy within 14 days prior to first dose
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Androgen deprivation therapy prior to radiation is allowed. However, it is not acceptable if continued during radiation or as adjuvant therapy.
Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment
Prior radiation therapy encompassing >25% of skeleton
Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before the first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible
Radiation to all target lesions within 12 weeks of study baseline,
No prior radiation to > 25% of the marrow.
Prior local therapy:\r\n* Prior surgery, whole brain radiation or SRS is allowed as long as the most recent brain progression is amenable to SRS treatment
Prior liver radiation therapy (RT) is an exclusion unless subject participation is approved by the principal investigator (PI)
Prior radiation therapy within 14 days prior to study entry
Participants must be >= 2 weeks since any prior radiation, including central nervous system (CNS) radiation
Prior radiotherapy or radiosurgery (including prophylactic cranial radiation and/or thoracic radiation) must have been completed at least 2 weeks prior to randomization
PHASE II INCLUSION CRITERIA: Prior radiotherapy or radiosurgery (including prophylactic cranial radiation and/or thoracic radiation) must have been completed at least 2 weeks prior to randomization
Radiation therapy within 2 weeks of study treatment
Any chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks of the first dose of mRNA-4157 or pembrolizumab
Has recovered from all radiation-related toxicities, does not require corticosteroids, and has not had radiation pneumonitis
Patients who have received prior radiation or chemotherapy may be enrolled on this study
Any external beam radiation treatment for hepatic disease; prior external beam radiation therapy to more than 25% of the bone marrow\r\n* Prior systemic peptide receptor radionuclide therapy (PRRT) treatment is allowed, if it was performed at least six months prior
received external beam radiation therapy within 4 weeks
Participants must be >= 2 weeks since any prior radiation, including central nervous system (CNS) radiation
Radiation within 2 weeks prior to registration
At least 3 weeks must have elapsed from prior radiation therapy; the prior site of radiotherapy must be documented as reirradiation of the same site is not allowed in this protocol
Patients must have least 1 non-central nervous system (CNS) based lesion; palliative radiation must be potentially indicated for at least one lesion, and this lesion must be a reasonable candidate for radiation to a dose of 8 Gy in 3-5 fractions as deemed by a treating radiation oncologist in terms of the ability to meet standardly accepted radiation dose constraints; any unirradiated lesions must not require urgent palliative local treatment
Prior radiation therapy: patients must be at least 2 weeks from prior radiation therapy
May have received prior radiation therapy or surgery; however, at least 21 days must have elapsed since completion of radiation therapy or surgery and subject must have recovered from all side effects at the time of registration
Pre-planned concurrent cytotoxic chemotherapy, surgery, or radiation therapy during protocol treatment; radiation therapy is not permitted while on study
Palliative radiation therapy may have been received but not within the 30 days prior to study treatment
Treatment with radiation therapy within 2 weeks prior to the initiation of study drug administration.
Prior systemic radiation therapy (either IV, intrahepatic or oral) completed at least 4 weeks prior to study drug administration.
Prior radiation therapy:\r\n* Patients must be at least 3 months from prior radiation therapy\r\n* Re-irradiation of the same field is not allowed
Received more than one course of radiation therapy or more than a total dose of 75 Gy.
Patients must be adequately recovered from surgery, radiation therapy, or any surgical complications prior to enrollment
Patients may have received prior radiation therapy in either the metastatic or early-stage setting; radiation therapy must be completed at least 14 days prior to study participation and patients should have recovered from adverse effects of radiation to grade =< 1
Must be proceeding with breast/chest wall and nodal radiation therapy including internal mammary node treatment
Patients must not have received any prior chemotherapy, radiation therapy, immunotherapy or bone marrow transplant for the treatment of DIPG; prior dexamethasone and/or surgery are allowed
Patients may not have therapy for this recurrence (including radiation)
Prior adjuvant or salvage radiation or not a candidate for radiation based upon clinical assessment of disease characteristics and patient co-morbidities.
Not recovered from radiation and chemotherapy-induced AEs
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
At least 4 weeks (wks) since prior radiation
Prior treatment with systemic radiopharmaceuticals (e.g., radium-223 and strontium-89). Radiopharmaceuticals for the purpose of imaging are permitted. Focal palliative radiation to treat cancer-related pain is permitted provided that the last treatment with radiation is at least 14 days prior to Cycle 1, Day 1.
Patients must not have received any prior chemotherapy, immunotherapy or bone marrow transplant for the treatment of their tumor; prior use of temozolomide during radiation at maximum of the standard pediatric dosing (defined as 90 mg/m^2 /dose continuously during radiation therapy for 42 days) or dexamethasone is allowed
No prior radiation to the ipsilateral breast
Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment, with the exception of patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation which must be completed within 4 weeks of the first dose of study treatment.
Prior radiation therapy allowed
Radiation therapy in the previous 4 weeks prior to first dose.
May be candidate for, have failed, or does not wish to undergo radiation therapy
Prior history of radiation therapy to the affected site
>= 2 weeks off radiation therapy
Concomitant chemotherapy, radiation therapy, or immunotherapy
Prior radiation therapy within 30 days prior to study Cycle 1 Day 1 and/or persistence of radiation-related adverse effects
Prior radiation to the primary and/or regional radiotherapy for melanoma and/or NSCLC is acceptable
All patients must have developed recurrent disease/progression (evidence of recurrence to be established by MRI or CT scan with contrast; there is no limit to the number of relapses) after receiving all standard treatments, which must include the following: \r\n* Surgical resection, if possible;\r\n* Definitive radiation therapy for unresectable meningioma, or for recurrent meningioma after resection\r\n* (Note: At registration, patients must be at least 28 days post-surgery, and must be at least 28 days post-radiation therapy, with resolution of related cytotoxicities down to grade 2)
No prior radiation therapy to the region for separate cancer
Treatment includes localized radiation therapy with or without chemotherapy
Prior receipt of ipsilateral breast or chest wall radiation that would result in significant overlap of radiation therapy fields; prior contralateral radiotherapy for breast cancer is allowed
external beam radiation within 2 weeks of enrollment
Received radiation therapy to the lung that is > 30 Gy within 6 months of the first dose of study drug.
Patient must not have received prior radiation for this lung cancer
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Patient has received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1
?14 days for chemotherapy, targeted small molecule therapy, or radiation therapy. Subjects must also not have had radiation pneumonitis as a result of treatment, and cannot participate in the study if they are on chronic corticosteroids for radiation pneumonitis. A 1-week washout is permitted for palliative radiation to non-central nervous system (CNS) disease with sponsor approval. Note: Bisphosphonates and denosumab are permitted medications.
The patient has received treatment with chemotherapy, external-beam radiation, or other systemic anticancer therapy within 28 days prior to C1D1
XRT: At least 14 days since the last treatment except for radiation delivered with palliative intent to a non-target site.
Radiation therapy within prior 6 months (prophylactic radiotherapy to prevent gynecomastia within 4 weeks prior to randomization is allowed)
Recent chemotherapy or radiation therapy (within 14 days before first dose of lenzilumab)
Patients may not have received prior radiation therapy to a site of recurrence which would require overlap of appreciable radiation dose
Radiation w/in 4 wks, or limited field radiation w/in 2 wks, prior to study drug, or w/unresolved Grade ?1 side effects
History of radiation therapy, either via external beam or brachytherapy within 28 days prior to registration
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Radiation therapy (palliative setting is allowed.): ?4 weeks
For patients following definitive radiation therapy or cryotherapy: a rise in PSA of > 2 ng/mL above the nadir (per Radiation Therapy Oncology Group [RTOG]-American Society of Therapeutic Radiation Oncology [ASTRO] consensus criteria)
Any radiation treatment to metastatic site within 28 days of Cycle 1, Day 1
Recent prior therapy:\r\n* Systemic chemotherapy =< 2 weeks (6 weeks for clofarabine or nitrosoureas) or radiation therapy =< 3 weeks prior to apheresis;\r\n** Exceptions:\r\n*** There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of such;\r\n*** Subjects receiving hydroxyurea may be enrolled provided there has been no increase in dose for at least 2 weeks prior to starting apheresis;\r\n*** Patients who are on standard ALL maintenance type chemotherapy (vincristine, 6-mercaptopurine, oral methotrexate, or a tyrosine kinase inhibitor for patients with Philadelphia chromosome positive [Ph+] ALL) may be enrolled provided that chemotherapy is discontinued at least 1 week prior to apheresis\r\n*** Subjects receiving steroids may be enrolled, provided there has been no increase in dose for at least 1 week prior to starting apheresis;\r\n*** For radiation therapy: radiation therapy must have been completed at least 3 weeks prior to enrollment (including CNS radiation), with the exception that there is no time restriction if the volume of bone marrow treated is less than 10% and also the subject has measurable/evaluable disease outside the radiation port
Patients must have disease that is not amenable to potentially curative resection; either primary in-situ (or locally-recurrent) tumor must be present and, in the opinion of radiation oncology, be amenable to radiation therapy as planned in the protocol or an extrapancreatic lesion which in the opinion of the radiation oncologist is amenable to radiation; each case will be discussed at gastrointestinal (GI) tumor board with multidisciplinary team
Patients that have been treated with prior mantle field radiation
Patients with a history of prior cranial radiation are ineligible
Radiation therapy to a study target tumor within 1 year prior to enrollment, or any radiation therapy within 4 weeks prior to enrollment
Prior radiation is permitted; however, at least 2 weeks must have elapsed since the completion of prior radiation therapy and patients must have recovered from all radiation-associated toxicities to no greater than grade 1 at the time of registration
Prior radiation dose of at least 50 gray (Gy)
History of radiation to the pelvis
Minimum interval since completion of radiation treatment is 12 weeks
Patients requiring emergency radiation therapy are eligible for enrollment on this trial
No prior chemotherapy or radiation for lung cancer
All previous cancer therapy including radiation, chemotherapy, and surgery, must have been discontinued at least 4 weeks prior to treatment in this study
Must be candidates for radiation treatment to bone lesions
Prior radiation to the breast or thorax.
Prior radiation therapy and/or chemotherapy, including cyclophosphamide, are permitted
Prior radiation therapy is allowed but there should not be overlap with the prior high dose regions unless approved by the protocol directors
Prior radiation therapy must be completed at least 14 days prior to registration for protocol therapy
Patients who have previously received radiation therapy
Patients may have received prior systemic and/or radiation therapy. All adverse events associated with prior systemic therapy or radiation therapy must have resolved to =< grade 1 prior to start of study
Prior radiation therapy with 400 cGY or more of TBI.
Has a known contraindication to radiation therapy, including inherited syndromes associated with hypersensitivity to ionizing radiation such as ataxia-telangiectasia and Nijmegen breakage syndrome.
Is eligible for palliative radiotherapy as determined by the treating radiation oncologist.
Local palliative radiation therapy (XRT) (small port) ?2 weeks before first dose of study drug
Prior radiation allowed
Patients should have discontinued all previous intensive therapy, chemotherapy or radiotherapy for 2 weeks prior to commencing therapy on this study\r\n* NOTE: low dose chemotherapy or maintenance chemotherapy given within 7 days of planned study enrollment is permitted; these include hydroxyurea, 6-meraptopurine, oral methotrexate, vincristine, oral etoposide, and tyrosine kinase inhibitors (TKIs); FLT-3 inhibitors can also be given up to 3 days before conditioning regimen\r\n* All patients with prior radiation treatment to the lung, liver, and kidney will be excluded; for other scenarios of prior radiation treatment, up to 2000 centigray (cGY) at 2 gray (Gy) per day will be allowed; inclusion of patients with previous radiation exposure will be determined based on the radiation oncologist medical doctor (MD) evaluation and judgment
Patients who have received radiation therapy, radionuclide therapy or undergone major surgery within 4 weeks of enrollment; a biopsy will not preclude a patient from starting study
Prior history of radiation to the mediastinum
Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=< 2 weeks of radiotherapy) to non-central nervous system (CNS) disease
Prior thoracic radiation is allowable if degree of overlap with the esophageal radiotherapy treatment is deemed to be safe by the treating radiation oncologist
Prior irradiation to the planned radiation target lesion.
Patients who have received radiation therapy, radionuclide therapy or undergone surgery within certain duration (4 weeks) of enrollment
Prior major surgical procedure or radiation therapy within 4 weeks of initiation of therapy (this does not include limited course of radiation used for management of bone pain within 7 days of initiation of therapy)
Concurrent therapy considered investigational\r\n* NOTE: patients must not be planning to receive any radiation therapy (except localized radiation for palliative care that must be completed prior to starting cycle 1, day 1)
Prior radiation treatment to the brain
Concomitant use of any other anti-cancer therapy or radiation therapy. Palliative radiation therapy to non-target lesions is permitted
Prior radiation therapy that would exclude the use of TMLI
Has had prior thermal ablation, embolotherapy, radioembolization, or external beam radiation
Previous radiation therapy with anything other than standard radiation therapy (i.e., focally directed radiation) administered as first line therapy.
Systemic chemotherapy ? 2 weeks (6 weeks for clofarabine or nitrosoureas) or radiation therapy ? 3 weeks prior to apheresis; exceptions:\r\n* There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of such\r\n* Subjects receiving hydroxyurea may be enrolled provided there has been no increase in dose for at least 2 weeks prior to starting apheresis\r\n* Patients who are on standard ALL maintenance type chemotherapy (vincristine, 6-mercaptopurine, oral methotrexate or tyrosine kinase inhibitors in patients with Philadelphia [Ph]+ ALL) may be enrolled provided that chemotherapy is discontinued at least 1 week prior to apheresis\r\n* Subjects receiving steroid therapy are allowed provided there has been no increase in dose for at least 1 week prior to starting apheresis; patients on physiologic steroids will not be excluded\r\n* For radiation therapy: Radiation therapy must have been completed at least 3 weeks prior to enrollment, with the exception that there is no time restriction if the volume of bone marrow treated is less than 10% and also the subject has measurable / evaluable disease outside the radiation port
1 week for prior palliative radiation therapy, or 2 weeks if prior brain radiation therapy.
Prior radiation therapy with 400cGy or more of TBI.
STRATUM A: Participants must have had their last fraction of radiation at least 4 weeks prior to study enrollment; participants who received radiation therapy for palliation must have had their last fraction of radiation at least 2 weeks prior to study enrollment
STRATUM B: Participants must have had their last fraction of radiation at least 4 weeks prior to study enrollment; participants who received radiation therapy for palliation must have had their last fraction of radiation at least 2 weeks prior to study enrollment
STRATUM C: Participants must have had their last fraction of radiation at least 4 weeks prior to study enrollment; participants who received radiation therapy for palliation must have had their last fraction of radiation at least 2 weeks prior to study enrollment
Participants must not have had prior radiation therapy (defined as > 10% of prior prescription dose) to the area planning to be treated with SBRT
Had prior treatment of glioblastomas (GBM) with radiation and temozolomide
Chemotherapy, targeted therapy, growth factors or radiation therapy within 14 days of C1D1
Agreeable to consider radiation therapy (RT) for the urothelial cancer: patients have to be evaluated by a radiation oncologist and deemed to be candidates for RT
Patients will be excluded from randomization if they meet any of the following criteria:\r\n* Any of the exclusion criteria; \r\n* Complete response to osimertinib or prior treatment to all visible lesions, such that no lesion is amenable to LCT. Note that patients can receive palliative radiation therapy prior to randomization to CNS lesions or those requiring urgent treatment (e.g. for pain or bleeding), but are only eligible for the study if they have one site amenable to further radiation therapy. In addition, these lesions will be counted towards the total number of metastases, and will also be counted as target lesions
Treatment with radiation therapy within 2 weeks
Stereotactic radiosurgery candidate per radiation oncologist
Previous whole brain radiation therapy
Previous radiation therapy to lesion to be resected
Planned adjuvant focal therapy including additional radiation therapy to the brain
Must have completed prior chemotherapy or radiation therapy at least 2 weeks prior to registration
Subjects may have previously treated brain or central nervous system (CNS) metastasis with radiation completed at least 2 weeks prior to registration; prior radiation to places other than CNS disease must be completed at least 14 days prior to registration; any number of prior radiation therapy regimens is allowed provided all toxicity of prior therapy is resolved to grade 1 or less.
Subjects must have received definitive therapy with curative intent, which consist of at least 4 weeks of treatment with cisplatin and a minimum of 40Gy external beam radiation therapy (EBRT).
Radiation therapy within 4 weeks of investigational product.
Radiation
Patients must be in first recurrence of glioblastoma following radiation therapy and temozolomide
Patients must have recovered from severe toxicity of prior therapy; an interval of at least 12 weeks must have elapsed since the completion of radiation therapy or placement of Gliadel wafers, and at least 6 weeks must have elapsed from the last dose of temozolomide (TMZ); no prior therapies are allowed other than radiation, temozolomide, and Gliadel wafers (placed during the first surgery at diagnosis of GBM)
Patients who had undergone any palliative radiation within 2 weeks of study enrollment
Subjects who have received prior radiation therapy for extramedullary disease within 2 weeks of first dose
Prior radiation therapy to the chest, neck or axilla
Prior radiation therapy to the abdomen that would overlap with treatment field
Prior radiation to affected area
Subjects must not have received chemotherapy within 2 weeks of planned first (1st) day of radiation therapy (RT)
Prior radiation treatment to the upper abdomen
Patients who have received maximally allowed doses (given in 2 Gy fractionations, or equivalent) of previous radiation therapy to various organs; patients who previously have received a higher than allowed dose of radiation to a small lung, liver and brain volume, will be evaluated by the radiation oncologist to determine if the patient is eligible for study
Must have received prior radiation therapy for brain metastases or be ineligible for radiation therapy
Previous radiation therapy to the lung per investigator discretion
Receipt of any biological therapy, chemotherapy, or radiation within 1 week of the Screening Visit and at least 3 weeks prior to Day 1, except for patients receiving maintenance trastuzumab.
Recovery to baseline from acute toxicity related to prior therapy, including surgery and radiation; (28 days removed from last systemic therapy, 14 days removed from last radiation therapy)
History of grade >= 2 radiation proctitis
Eligible for treatment with radiation therapy
Subjects who have had radiation therapy within 2 weeks prior to first dose of drug
Patients with prior salvage chemo-immunotherapy, radiation therapy, autologous transplantation are included
Prior radiation therapy must be completed at least 2 weeks prior to study enrollment
Received definitive chemotherapy and radiotherapy prior to recurrence/progression or who are unable to receive radiation therapy due to genetic disorders that put them at significant risk for radiation-induced secondary malignancies (i.e. Gorlin’s syndrome or NF1 mutation)
Radiation therapy =< 28 days prior to registration; Note: patients with prior pelvic radiation therapy > 54 Gy are ineligible
Prior therapeutic radiation to the bladder
Patients who have had radiation to the lung fields within four weeks of starting treatment; for patients receiving palliative radiation to thoracic vertebrae, ribs or other sites where the radiation field includes the lungs, radiation must be completed at least two weeks before starting treatment; for all palliative radiation to all other sites, at least 7 days must have elapsed prior to starting to treatment; at least six months must have elapsed from radiation given with curative intent
Radiation therapy within 14 days of starting study treatment
Participants must otherwise be indicated for proton radiation therapy
Two progressive scans at least 4 weeks apart after the completion of standard external beam radiation therapy and temozolomide
Prior history of brain SRS, (patients who have received external beam radiation per standard of care are allowed)
Scheduled radiation treatment using intensity-modulated pencil beam scanning (PBS) proton therapy
Any prior therapeutic radiation therapy > 500 cGy has been delivered
Prior radiation to the same site deemed to be too high of level of radiation for retreatment
Lactation and a radiation field which would include the breast or nipple or deemed to place the mother or child at elevated risk of radiation exposure (evaluated by MRP, ARM, WR, WW)
The target lesion is one that either has never received external beam radiation or has been previously irradiated and has since demonstrated progression; any local irradiation of the target lesion or any non-target lesions via external beam, conformal or stereotactic radiation treatments must have occurred more than 4 weeks prior to study drug administration; any full cranial-spinal radiation, whether or not a target lesion is included in the field, must have occurred more than 3 months prior to study drug administration
External beam radiation to both kidneys (scatter doses of < 500 cGy to a single kidney or radiation to < 50% of a single kidney is acceptable)
Candidate for radiotherapy (as determined by treatment physician); these patients can have symptomatic disease and/or asymptomatic disease; a minimum of one site of radiation is required to any osseous and/or any extra-osseous disease; radiation to any bony parts of the head and neck, skull, spine, ribs, and/or extremities are allowed; radiation to any bony part for documented lytic disease is allowed; radiation to any soft tissue plasmacytoma (including osseous and extra-osseous plasmacytoma) is allowed; the only exclusion criteria for radiation, is central nervous system (CNS) metastases
Prior treatment must include external beam radiation, radiosurgery, or combination of both
Ability to tolerate radiation therapy (e.g. lie flat and hold position for treatment)
Prior radiation therapy of any type within 7 days of first dose of study medication
No prior radiation therapy (external beam or brachytherapy) to the pelvis or prostate
Subjects must be at least 2 weeks from prior anti-lymphoma therapy (including radiation therapy)
Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks, or palliative radiation therapy within 2 weeks of the first dose of study drug treatment.
Patients must have histologically confirmed locally recurrent adenocarcinoma of the prostate after prior radiation (external beam radiation therapy [EBRT] or brachytherapy)
Prior major surgical procedure or radiation therapy within 4 weeks of the first dose of study treatment (this does not include limited course of radiation used for management of bone pain within 7 days of first dose of study therapy)
Prior history of scalp radiation or intolerance to standard course of radiation treatment
History of radiation therapy to the brain for prior diagnosis of glioma
Patients with a history of prior thoracic radiation > 30 gray (Gy)
Participants may have had prior chemotherapy, targeted biological therapy (i.e. sorafenib), surgery, transarterial chemoembolization (TACE), radiofrequency ablation, or cryosurgery for their disease as long as the prior therapy occurred more than 3 weeks before the first radiation treatment; patients may not have had prior liver directed radiation, including radioembolization
Participants who have had prior liver directed radiation treatment, including selective internal radiation (SIRspheres or Theraspheres)
Has had prior radiation therapy (defined as > 10% of prior prescription dose) to the area planning to be treated with SBRT
Determination by the treating radiation oncologist that the patient is a candidate for SRT (i.e., radiation therapy with a stereotactic setup)\r\n* Note: All brain metastases will receive SRT
Major surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of study drug administration (6 weeks for mitomycin C or nitrosoureas). Palliative radiotherapy to a limited field is allowed after consultation with the medical monitor at any time during study participation, including during screening, unless it’s clearly indicative of disease progression. For Arm G, subjects who require extended field radiation therapy will be excluded.
A diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe radiation therapy.
Has had prior radiation therapy within the past 3 months where the high dose area of the prior radiation would overlap with the high dose area of the intended radiation based on the judgement of the treatment oncologist.
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
External beam radiation therapy < 4 weeks prior to initiation of therapy on this protocol
Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before the first dose of study treatment; systemic treatment with radionuclides within 6 weeks before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible
Have at least one site of lymphomatous disease amenable to external beam radiation therapy (EBRT)
Has had prior radiation therapy to the potential radiation target such that additional radiation therapy is considered unsafe by the treating radiation oncologist
Patients must not have had radiotherapy encompassing > 20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to day 1 of protocol therapy
Patients must be >= 2 weeks from most recent systemic therapy or radiation therapy
Prior local radiation therapy would be allowed as long as there is at least one non-irradiated index lesion
Prior external beam radiation therapy to the liver (defined as > 1 gray [Gy])
Radiation therapy (except palliative to relieve bone pain) within 7 days of study entry; palliative radiation (=< 10 fractions) must have been completed at least 48 hours prior to study entry; stereotactic or small field brain irradiation must have been completed at least 7 days prior to study entry; whole brain radiation and radiation for leptomeningeal metastasis must have been completed at least 2 weeks prior to study entry; acute effects of radiation must have resolved to baseline severity or to CTCAE grade =< 1 except for AEs that in the investigator’s judgment do not constitute a safety risk for the patient
Patients who have received radiation therapy must have completed this at least 4 weeks prior to starting therapy with cabozantinib, with the following exceptions:\r\n* Local radiation therapy to enhance bone healing of a pathologic fracture may have been performed, as long as it was completed at least 2 weeks prior to starting cabozantinib\r\n* Local radiation therapy to treat post-fracture pain that is refractory to analgesics may have been performed, as long as it was completed at least 2 weeks prior to starting cabozantinib
external beam radiation within 2 weeks of enrollment
If the patient received previous radiation therapy, the total absorbed radiation dose at the bone marrow level must be ? 1 Gy
Patient who underwent chemotherapy, radiation therapy within 15 days before the screening period
Previous use of radiation to metastatic site(s) at any time prior to enrollment is allowed, provided that this site is not the only measurable disease present or unless that solitary site is progressing following radiation
Prior radiation therapy within the last 14 days
STUDY TREATMENT: Patients must have received systemic radiosensitizing chemotherapy with definitive pelvic radiation therapy; patients may have received partial amount of chemotherapy and radiation (both) to be eligible
Radiation therapy (other than palliative radiation to bony metastases) as cancer therapy within 4 weeks prior to initiation of study treatment
Prior therapy wash-out period requirements\r\n* Participants must be at least 4 weeks from prior surgical procedures and surgical incisions must be healed\r\n* Participants must have had their last fraction of external beam radiation therapy at least 4 weeks prior to enrollment; participants with prior radiation therapy must be at least 4 weeks post therapy and have had progression of disease outside the radiation port\r\n* Participants must have had their last dose of cytotoxic chemotherapy at least 28 days prior to enrollment, their last dose of biological therapy, such as biological response modifiers (e.g., cytokines), immunomodulatory agents, vaccines, differentiating agents, used to treat their cancer at least 28 days prior to enrollment, their last dose of a monoclonal antibody at least 28 days prior to enrollment, and their last dose of any investigational agent at least 28 days prior to enrollment\r\n* Participants must have recovered from the acute toxic effects of prior therapy to a grade 1 (Common Terminology Criteria for Adverse Events [CTCAE] v.4.0) level prior to enrollment (does not apply to alopecia)
Patients with prior chemotherapy or radiation therapy for their diagnosis of esophageal or gastric cancer. Patients with prior radiation therapy to same site for another diagnosis of cancer. Note: Patients may receive palliative radiation to their symptomatic sites of metastases but not definitive local therapy to esophageal or gastric primary prior to randomization. All patients may be enrolled on protocol then start systemic therapy; if they do not have evidence of disease progression at re-staging following initial therapy, they may be randomized
Prior systemic therapy or radiation therapy for treatment of the current lung cancer
Patients with prior radiation therapy to the same bronchopulmonary segment
Able to tolerate prone body positioning during radiation therapy
If palliative radiotherapy administered, completion of palliative radiation therapy must be >= 2 weeks prior to cycle 1 day 1 of protocol therapy
Patients may have received prior radiation therapy in either the metastatic or early-stage setting; radiation therapy must be completed at least 14 days prior to study registration
No prior mediastinal or thoracic radiation
Treatment plan for bladder must include at least 4 weeks of daily radiation treatment (most patients will receive chemotherapy concurrent with radiation, but this is not required for trial enrollment)
Patient must undergo TraceIT hydrogel placement within 8 weeks prior to starting radiation therapy for bladder cancer
Unable to have TraceIT hydrogel placement < 8 weeks prior to beginning radiation treatment
Patients who have received chemotherapy, small molecule targeted therapy or radiation within the 2 weeks of first dose of study drugs
Patients who have had chemotherapy or radiation therapy within 2 weeks prior to beginning protocol therapy
At least 6 weeks must have elapsed prior to enrollment since the patient received any prior radiation therapy
Treatment with any chemotherapy, radiation therapy, biologics for cancer, or investigational therapy within 28 days of first administration of study treatment
Ongoing radiation therapy, chemotherapy, or hormonal therapy. Point radiation to a site of bone pain will be allowed.
At least 28 days from prior definitive treatment of their CNS disease by surgical resection, stereotactic body radiation therapy (SBRT) or whole brain radiation treatment (WBRT) at the time of registration
Radiation to the abdominal area within 28 days of first dose of therapy
Prior radiation to the pelvis.
Patients who received radiation therapy > 5 years ago for malignancies other than pancreatic cancer and whose radiation therapy field is not overlapping with the 20% isodose line of current radiation field are eligible, provided that radiation therapy was completed > 5 years ago and that there is no evidence of the second malignancy at the time of study entry
Patients with bulky disease are eligible for study provided that the patient not undergo radiation therapy until 30 days after the end of blinatumomab administration
Have had prior radiation therapy to the brain or prior treatment for their brain tumor (except prior biopsy or subtotal resection)
Prior radiation therapy will be allowed if active measurable disease was not previously treated with radiation therapy
Subjects requiring palliative radiation therapy at presentation
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy for the current diagnosis of EGC
Radiation therapy within 14 days of enrollment
Patient who has had chemotherapy, radiation, hormonal, or biological cancer therapy within 28 days prior to the first dose of study drug
Prior radiation that precludes delivery of hypofractionated radiotherapy
Prior salvage or adjuvant radiation therapy is allowed but not mandated; radiation therapy must have been completed for at least 6 months
Prior external beam radiation involving kidneys (scatter doses of < 500 cGy to a single kidney or radiation to < 50% of a single kidney is acceptable)
Willing to undergo the following therapy: (1st) systemic chemo-hormonal therapy with up to 6-months (around 24 weeks) of neoadjuvant androgen deprivation and up to 6 cycles of chemotherapy, (2nd) definitive local tumor control with adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions; additionally, must be willing to be treated with a full two years of androgen deprivation
Palliative (limited-field) radiation therapy is permitted, if all of the following criteria are met:\r\n* Repeat imaging demonstrates no new sites of bone metastases\r\n* The lesion being considered for palliative radiation is not a target lesion
Patients must not be eligible for therapy with curative intent (i.e. surgery, radiation, etc)
If during treatment planning, the target dose of radiation cannot be achieved within published limits of dose limiting organs in the opinion of the treating radiation oncologist, the patient will be ruled ineligible and treated off protocol
Prior radiation at the site of interest within 6 months
Patients who have received radiation to brain and/or spine, including whole brain radiation, stereotactic radiosurgery, or stereotactic body radiation therapy (SBRT), are eligible, but must have completed radiation treatment at least 7 days prior to the start of treatment
No prior radiation therapy or radionuclide therapy for the treatment of metastasis within four weeks prior to enrollment
PRE-SCREENING: If prior radiation, measurable lesion outside radiation portal
Prior chemotherapy including cetuximab or radiation therapy
Patients must not have had radiation therapy =< 12 weeks prior to starting study treatment
Discontinued use of chemotherapy, radiation therapy, or growth factors for at least 2 weeks prior to first study treatment, with the exception of hydroxyurea.
An interval of >= 12 weeks from the end of prior radiation therapy is required unless there is either:\r\n* Histopathologic confirmation of recurrent tumor, or\r\n* New enhancement on MRI outside of the radiation treatment field
Radiation therapy (XRT) >= 6 months from involved field radiation to index plexiform neurofibroma(s); >= 6 weeks must have elapsed if patient has received radiation to areas outside index plexiform neurofibroma(s)
Patients may have received prior radiation therapy or surgery; however, at least 14 days must have elapsed since completion of radiation therapy or surgery and patient must have recovered from all side effects at the time of registration (e.g. back to baseline or grade 1)
Radiation therapy within 2 weeks prior to randomization and not recovered to baseline from any AE due to radiation
Patients must not have received previous radiation therapy or investigational therapy for the treatment of advanced metastatic disease.
An interval of at least 12 weeks from the completion of radiation therapy to registration unless there is unequivocal histologic confirmation of tumor progression
Subjects receiving consolidative chest radiation
No prior treatment with radiation or chemotherapy for their GBM
Craniotomy site must be adequately healed and free of drainage or cellulitis, and the underlying cranioplasty must appear intact at the time of radiation; radiation must start within 6 weeks of surgery
Concurrent therapy considered to be investigational; NOTE: patients must not be planning to receive any radiation therapy (except localized radiation for palliative care that must be completed prior to starting cycle 1, day 1)
Prior chemotherapy or radiation therapy is allowed if received >= 3 weeks before study enrollment
Any radiation therapy within 21 days prior to initiating protocol therapy
No prior prostatectomy or prostatic radiation
Prior radiation therapy to the prostate
Prior external beam radiation to the liver
Prior or concurrent ipsilateral radiation therapy for invasive or noninvasive BC.
Currently receiving radiation or chemotherapy
Patients who have received prior radiation or chemotherapy may be enrolled on this study
Any chemotherapy or radiation therapy within 4 weeks of the first dose of study drug
Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within four weeks prior to study entry
Prior history of HNSCC receiving radiation or chemo-radiation.
Patients who have received radiation therapy, major surgery, other locoregional therapy, within 4 weeks prior to the first date of SBRT
Prior radiotherapy to the region of the liver that would result in excessive doses to normal tissues due to overlap of radiation therapy fields
Prior radiation therapy is allowed if completed at least 14 calendar days prior to registration
Any radiation to the target lesions within 6 months of enrollment
Unable to meet radiation treatment plan parameters
Measurable disease by RECIST 1.1 criteria (at least one target lesion outside of previous radiation fields or progressed within a previous radiation field)
Subjects must have a least one site of disease that is accessible to radiation and multiple biopsies; subjects may have disease that is encompassed within the radiation field or may have known disease both inside and outside of the radiation field
Patients may not be less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or 2 progressive scans at least 4 weeks apart or histopathologic confirmation
No prior chemotherapy, radiation therapy, or breast resection within 6 months of study entry
Prior radiation resulting in overlapping radiation fields
cSCC that is curable via radiation or surgery; palliative radiation is allowed as long as measurable disease outside radiation field is present for study
COHORT 1 (PATIENTS RECEIVING HEMITHORACIC RADIATION THERAPY)
Patients must be assessed to be a suitable candidate for hemithoracic radiation therapy per the treating radiation oncologist; if the patient undergoes pleurectomy/decortication, they must initiate hemithoracic radiation therapy within 4 months of the surgery date; patients that do not meet the dose constraints outlined below will be removed from the study prior to radiation therapy
Patients must be assessed to be a suitable candidate for radiation therapy by the treating radiation oncologist; patients that do not meet the dose constraints outlined below will be removed from the study prior to radiation therapy
Patients in which hemithoracic radiation therapy is planned
Prior radiation therapy allowed as long as completed in the following times prior to initiation of trial treatment:\r\n* Definitive curative intent radiation >= 3 weeks prior to trial treatment\r\n* Palliative body radiation >= 1 week prior to trial treatment\r\n* Stereotactic brain radiation >= 1 week prior to trial treatment\r\n* Whole brain radiation >= 2 weeks prior to trial treatment
Prior chest wall radiation
Emergent need for palliative radiation
Patients who have had cranial radiation therapy need to have completed it >= 8 weeks prior to enrollment
Patients must have received prior radiation therapy and must have an interval of greater than or equal to 12 weeks (84 days) from the completion of radiation therapy to study entry except if there is unequivocal evidence for tumor recurrence (such as histological confirmation or advanced imaging data such as positron emission tomography [PET] scan) in which case the principal investigator’s discretion may determine appropriate timepoint at which study therapy may begin
No thoracic radiation > 3000 cGy allowed
Prior radiotherapy to the breast or prior radiation to the region of the ipsilateral breast that would result in overlap of radiation fields
Has had any prior chemotherapy, targeted small molecule therapy, or radiation therapy for their current diagnosis
Radiation oncologist recommends radiation treatment to the supraclavicular and infraclavicular fossa (i.e. RNI)
The last radiation therapy within 4 weeks prior to starting study treatment, or limited field of radiation for palliation within 2 weeks of the first dose of study treatment
Target lesions that have previously received radiation must have shown radiographic progression following radiation or must have other non-radiated lesions present
History of urological surgery or procedures predisposing to genitourinary (GU) complications after radiation, i.e., anastomoses, stricture repair, transurethral resection, etc. (will be determined by radiation oncologist)
Patients must have histologic or radiographic proof of a primary liver malignancy suitable for radiation therapy
Previous cranial SRS/whole brain radiation therapy (WBRT) is allowed if > 3 months prior to single isocenter multi-target (SIMT)
Subjects who have not received radiation therapy as part of their prior treatment are excluded
Palliative surgery and/or radiation treatment within 28 days prior to course 1 day 1 (C1D1) \r\n* Localized therapy of non-target lesions is allowed
Subjects with planned radiation therapy to a target lesion will be excluded
At least 6 weeks must have elapsed prior to enrollment since the patient received any prior radiation therapy, and the target cutaneous neurofibromas have to be in areas outside of a prior radiation field
Radiation therapy is not permitted within 14 days of registration
Patients with a secondary AML (defined as a history of prior radiation therapy or systemic chemotherapy, antecedent MDS, MPN or CMML)
Prior radiation therapy within the field of the target lesion that in the opinion of the treating radiation oncologist would preclude further palliative radiation to a dose of 30 gray (Gy)
Prior history of fractionated radiation therapy
History of prior radiation therapy to the upper abdomen
Subjects who have had radiation therapy within 1 week prior to first dose of drug
Patients who have been treated with any combination of surgical resection and neoadjuvant/adjuvant conventional chemoradiation therapy for resectable disease or conventional chemoradiation as definitive treatment for unresectable or borderline resectable disease are eligible for the study, provided that at least 180 days have elapsed since completing any previous radiation treatment; patients who have been receiving continued chemotherapy following their initial radiation treatment are eligible regardless of when the most recent chemotherapy was received; those patients who have received prior radiation therapy will constitute Cohort A and will receive SBRT as 5 Gy x 5
No prior systemic (chemotherapy or biologic/molecular targeted therapy) or radiation treatment for head and neck cancer\r\n* Patients may have received chemotherapy or radiation for a previous, curatively treated non-HNSCC malignancy, provided at least 2 years have elapsed\r\n* Patients must be untreated with radiation above the clavicles
At least 28 days must have elapsed (at time of starting protocol therapy) since completion of focal radiation therapy for current recurrence for Stratum 2; patients who have already undergone radiation therapy for current recurrence are NOT eligible for Stratum 1
Prior definitive radiation therapy (XRT) is allowed if it has been 2 weeks since the end of definitive XRT; for palliative XRT, protocol-specified treatment can begin at minimum 48 hours after completion of radiation; lesions within the XRT field can only be used as target lesions if definite progression has been demonstrated since the completion of radiation
Prior radiation therapy is allowed provided that no radiation therapy was administered to the urinary bladder\r\n* NOTE: No radiation therapy within 28 days prior to being registered for protocol therapy; laboratory values must be obtained within 14 days prior to being registered for protocol therapy
Major surgery < 4 weeks or radiation therapy < 2 weeks of starting the study treatment; prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been irradiated\r\n* Radiotherapy is defined as whole brain radiation, external beam radiation therapy (EBRT), or stereotactic brain radiation (SBRT)
Radiation therapy within four weeks prior to administration of the first dose of ARQ 751
Therapy-related AML (defined as occurrence of AML due to prior exposure to chemotherapy or radiation for malignancy)
Plan for chemotherapy or targeted therapies during whole brain radiation or within 1 week of completing radiation therapy
Prior radiation therapy to the brain besides radiosurgery
Prior radiation therapy is allowed
Patients who have received prior radiation therapy must have recovered from toxicity of the prior radiation therapy prior to registration, and must have disease evaluable for response outside of the radiation fields or have evidence of post-radiation progression of previously irradiated sites of disease
Planned stereotactic body radiation therapy (SBRT) for the pulmonary metastases
Radiation oncology consultation at enrolling site to confirm that disease can be encompassed in a radiotherapy field =< 56 days prior to registration\r\n* NOTE: Radiotherapy quality assurance rapid review must be performed before the first fraction of radiation therapy (RT) is administered; if RT constraints cannot be met, the patient will be removed from the protocol prior to treatment
Prior radiation to chest or abdomen, or to > 30% of the marrow cavity
Active cancer that requires therapy in the form of chemotherapy or radiation
Patients may have received prior systemic and/or radiation therapy; all adverse events associated with prior systemic therapy or radiation therapy must have resolved to =< grade 1 prior to start of study
Prior therapy with gamma knife or other focal high-dose radiation is allowed, but at least 2 weeks must have elapsed from the time of treatment, and the patient must have subsequent histologic documentation of recurrence, unless the recurrence is a new lesion outside the irradiated field.
Willing to undergo the following therapy: (1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of neoadjuvant androgen deprivation and up to 6 cycles of chemotherapy, (2nd) definitive local tumor control with prostatectomy +/- adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions; additionally, must be willing to be treated with a full year of androgen deprivation
Prior whole brain radiation or conventional radiation to the spine at the site of new lesion
Prior conventional radiation to the same site is allowed as long as there is a greater than 3 months interval
Prior pelvic radiation therapy or patients who have undergone prior radiation to greater than or equal to 25% of the bone marrow within the past year are excluded; patients who received radiation for prostate cancer are also excluded
Progressive disease via Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) on prior study or standard of care therapy utilizing an immunotherapy agent OR a clinical status that requires salvage radiation treatment (e.g.: palliative radiation therapy [RT]) at the discretion of treating physician and/or principal investigator (PI)
Have at least one site of metastatic disease amenable to radiation; all lesions amenable to radiation may be irradiated at the discretion of treating radiation oncologist, depending on the location, size and number of lesions
We will allow prior radiation to other sites, with no washout period, prior to study entry as long as the high dose regions of the prior and proposed radiation fields do not overlap
Has a diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe radiation therapy
Has had prior radiation therapy within the past 3 months where the high dose area of the prior radiation would overlap with the high dose area of the intended radiation based on the judgment of the treating radiation oncologist
Prior standard radiation therapy to a dose ranging from 50 to 60 Gy at 1.8 to 2 Gy per fraction
Radiation therapy for treatment of the primary tumor within 6 weeks of cycle 1, day 1; patients who have received palliative radiation to a single site and recovered are eligible
Patients receiving any other investigational agents for any reason or non-investigational agents administered for the purpose of controlling cancer growth (use of conventional external beam radiation therapy will be allowed during protocol therapy solely for palliation of localized painful lesions or bone lesions at risk of fracture provided the radiation field does not encompass any selected target lesions required for assessment)
At least one brain lesion size >= 0.3 cm in the longest axis amenable to radiation therapy (either via SRS or WBRT)
We will allow prior radiation to other sites, with no washout period, prior to study entry as long as the high dose regions of the prior and proposed radiation fields do not overlap; in patients where the prior high dose area would overlap with the high dose area of the intended radiation, a 4 month washout period will be required; the safety of such treatment will be at discretion of the treating radiation oncologist
Prior central nervous system (CNS) radiation is allowed as long as cumulative radiation doses do not exceed tolerance of critical structures as judged by the treating radiation oncologist
Has received prior radiation therapy to the bladder for the purpose of treating urothelial carcinoma
Previous breast radiation on ipsilateral side or thoracic radiation on the ipsilateral side
Patients who have previously received therapeutic radiation therapy to the chest
Use of chemotherapy within 4 weeks of the planned start of radiation therapy
Radiation therapy within 4 weeks of study enrollment (exception is radiotherapy expansion arm which requires radiation treatment within 2 week period)
Any prior chemotherapy, immunotherapy, radiation therapy or surgeries must have been completed at least 3 weeks prior to initiation of study medication.
History of prior mediastinal radiation
Prior radiation therapy within the last 14 days
Patients must not have received chemotherapy and/or radiation therapy within 2 weeks of start of protocol treatment; hydroxyurea is allowed up to 48 hours prior to starting therapy in the setting of rapidly proliferating disease
Prior radiation therapy, chemotherapy or extirpative surgery for rectal cancer
An index lesion measuring between 1cm – 7cm that is amenable to hypofractionated radiation therapy at the discretion of the treating radiation oncologist\r\n* Index lesions in the pancreas are excluded in the second cohort
Prior liver-directed radiation therapy in cohort 1 (advanced cirrhosis group) or cohort 2 (low functional volume group)
Prior radiation is allowed prior to study start (1st dose of study medication) if at least 21 days must have elapsed since prior large-field radiation therapy and recovered from all treatment related toxicity; at least 3 months must have passed since radio-immunotherapy
Has had prior radiation therapy (defined as > 10% of prior prescription dose) to the area planning to be treated with SBRT
Previous radiation therapy to the lungs and/or to the upper abdomen
Previous therapeutic radiation therapy (RT) that exceeds critical structure tolerance doses as determined by a radiation oncologist
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy.
Patients who have received prior radiation therapy for HNSCC
Subjects who have received radiation therapy targeting > 10% of the bone marrow space must have completed this at least 2 weeks prior to starting therapy with DS3032b
Patient has received prior treatment for RCC including surgery, radiation, thermoablation or systemic therapy
No androgen deprivation therapy (ADT) can be prescribed prior to or during radiation therapy
Prior radiation therapy to the pelvis
The use of androgen deprivation therapy (ADT) prior to registration or during radiation
PHASE I: Any prior radiation therapy must be discontinued at least four weeks prior to enrollment
Local Skin Radiation Therapy (< 10% skin surface): 4 weeks
Prior radiation to the breast or chest wall
Less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or 2 progressive scans at least 4 weeks apart or histopathologic confirmation
Radiation therapy must be completed at least 2 weeks prior to study entry; radiated lesions may not serve as measurable disease unless they have been radiated >= 12 months prior to enrollment
Patients may have had radiation therapy, but must have progressive disease after radiation therapy if the lesions to be treated are within the radiation field. Radiation treatment must be completed ? 4 weeks prior to Cycle 1 Day 1.
Radiation therapy with >= 45 Gy tumor dose, completed >= 8 weeks prior to study entry
Previous radiation therapy with anything other than standard radiation therapy (such as previous stereotactic radiosurgery) or previous treatment with an immune checkpoint inhibitor (i.e., nivolumab, pembrolizumab, ipilimumab)
Prior radiation to the index spine
Prior radiation therapy to the abdomen and/or lower thorax
Radiation therapy - At least 14 days must have elapsed for local XRT. At least 90 days must have elapsed if prior radiation to ?50% of the pelvis, the spine, or other substantial bone marrow radiation including TBI.
Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before the first dose of study treatment; systemic treatment with radionuclides within 6 weeks before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible
Candidate for salvage radiation and ADT treatment
Group 2: must not be a candidate for radiation therapy or surgery
Radiation therapy for bone metastases within 2 weeks, other external radiation therapy within 4 weeks of enrollment
Patients receiving intraoperative radiation therapy (IORT)
Patients are eligible to participate within 6 months of completion of therapy for their breast cancer; this includes prior radiation therapy if needed
No previous anticancer therapy (radiation therapy or chemotherapy) other than use of corticosteroids
No previous anticancer therapy (radiation therapy or chemotherapy) other than the use of corticosteroids
Patients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period
Prior radiation therapy to the same regional nodal basin
>= 2 weeks must have elapsed for local radiation therapy (XRT) (small port); >= 6 months must have elapsed if prior radiation to >= 50% of the pelvis or if other substantial bone marrow irradiation, including total body irradiation
Patients must have at least one measurable site of disease, per RECIST 1.1, that has not been previously irradiated; if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation
At least 2 weeks from prior chemotherapy or radiation therapy to time of start of treatment, except for hydroxyurea or corticosteroid therapy which may be continued through cycle 1
Prior radiation to the liver or other upper abdominal regions
Radiation or chemotherapy within 4 weeks of enrollment
External beam radiation therapy within 4 weeks of registration is prohibited, or anticipated need for radiation therapy (e.g. imminent pathological fracture or spinal cord compression) within 3 months of registration
Prior radiotherapy to the thorax such that composite radiation would significantly overdose critical structures, either per estimation of the treating radiation oncologist or defined by failure to meet normal tissue tolerance constraints
Patients may have received radiation therapy to painful bone metastases or areas of impending bone fracture as long as radiation therapy is completed >= 2 weeks prior to day 1 of cycle 1 of treatment; patients who have received prior radiotherapy must have recovered from toxicity (=< grade 2) induced by this treatment; baseline radiologic scans must be obtained after completion of radiation
Use of systemic chemotherapy and/or radiation therapy =< 14 days prior to first registration; palliative radiation therapy is permitted for irradiating small areas of painful bony metastases that cannot be managed adequately using systemic or local analgesics
Use of systemic chemotherapy and/or radiation therapy after first registration; palliative radiation therapy is permitted for irradiating small areas of painful bony metastases that cannot be managed adequately using systemic or local analgesics
The patient cannot have had prior radiation therapy to the thorax or upper abdomen
Prior radiation to > 30% of the red marrow or to maximal tolerable level for any organ
Have had palliative radiation or biological cancer therapy within 2 weeks prior to the first dose of study drug
Prior radiation therapy that would exclude the use of TMLI
Has a diagnosis of active scleroderma, lupus, or other autoimmune disease which by the opinion of the treating radiation oncologist precludes safe radiation therapy
Has had prior radiation therapy to all available thoracic and liver lesions such that additional radiation therapy is unsafe by the opinion of the treating radiation oncologist
Subject has had radiation therapy to the tumor selected for research collection, or has had radiation therapy to any site within 4 weeks prior to study day 1
Any prior therapy (chemotherapy, radiation or surgery) for pancreatic adenocarcinoma other than biliary decompression
Radiation therapy in the last 14 days
Patients should have histologically confirmed chordoma by the Laboratory of Pathology, National Cancer Institute (NCI), which is advanced and not considered resectable; if the original tissue cannot be retrieved, diagnostic documentation at an outside institution will be acceptable; they must have planned radiation therapy to at least one targeted lesion with evidence of growth prior to enrollment; the tentative radiation plan at enrollment must be in compliance with the required radiation doses; this can be given in standard or hypofractionated dosing with any technique deemed most appropriate by the treating radiation oncologist if other requirements are met
Patients must have fully recovered from prior surgery before enrollment; prior radiation therapy is allowed provided the radiation field can safely be irradiated within the guidelines in the opinion of the treating radiation oncologist
Patients may enter this study with or without salvage therapy for recurrent tumor; patients must have fully recovered from the toxic effects of any prior therapy; \r\n* Myelosuppressive chemotherapy and/or biologics: must not have received within 3 weeks of entry onto this study; (6 weeks in the case of mitomycin C or nitrosourea-containing therapy)\r\n* Radiation therapy (XRT): 6 weeks must have elapsed since completing radiation therapy to any site (6 months in the case of craniospinal, whole lung); patients are excluded if they have received local radiation which includes any of the following:\r\n** 1200 cGy to more than 33% of both kidneys (patient must have at least one kidney that has not exceeded the dose/volume of radiation listed)\r\n** 1800 cGy to more than 30% of liver and/or 900 cGy to more than 50% of liver\r\n** Prior MIBG therapy: should be at least 42 days from previous 131I-MIBG therapy and have recovered completely from all clinically significant treatment associated toxicities; patients must not exceed a lifetime cumulative injected activity of 54 mCi/kg for patients with neuroblastoma and 36 mCi/kg for patients with other MIBG avid diseases; patients must have demonstrated a response to prior MIBG therapy (either clinical, pathological and/or radiographic improvement)
Prior total body irradiation, prior total abdominal or whole liver radiation
Patients who have had chemotherapy or radiation =< 2 weeks of registration
Unresectable low-grade gliomas that have received at least two chemotherapy/biologic regimens; radiation therapy counts as a biologic regimen; patients may not have received radiation therapy to the index lesion within 1 year of enrollment; patients may have tumor spread within the central nervous system (CNS); histologic confirmation of eligibility is required if tissue is available
Candidate for additional therapy consisting of radiation with gemcitabine–radiosensitization
No limit to number prior anti-cancer regimens, including chemotherapy, biologic agents, immunotherapy, vaccines, monoclonal antibodies or radiation therapy; patients who have received prior radiation therapy for this tumor are eligible; there should be at least 2 years time since the completion of radiation therapy
Radiation therapy (RT): patients must have had their last fraction of cranial or craniospinal radiation >= 24 months prior to study entry
Less than 2 years since completion of radiation therapy
Significant prior external beam dose-limiting radiation to a critical organ based on review of the prior radiation treatment records by the Radiation Oncology PI; patients who have had prior external beam radiation > 2000 cGy (at 180 to 200 cGy per day) to the lung will be ineligible; patients with ANY prior radiation to the heart are ineligible; patients with > 500 cGy to the kidney will be excluded from the study; Note: patients who have had electron beam therapy are still eligible and will be evaluated on a case by case basis by the Radiation Oncology PI
Prior radiation therapy is not an exclusion however, patient must have documented progression at the radiation site
Prior abdominal radiation; any prior radiation must be approved by the radiation oncology principal investigator (PI)
History of prior radiation therapy to brain or skeleton is allowed, but should have occurred > 2 months from enrollment
Participants who have received prior radiation therapy to anatomical sites other than brain or skeleton
Must not be receiving external beam radiation therapy at the time of study enrollment; must be at least 12 weeks from prior I131 MIBG therapy
Untreated central nervous system metastases; patients are eligible if they are clinically stable, off all steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, stereotactic radio surgery) ending at least 2 weeks prior to enrollment, or after surgical resection performed at least 2 weeks prior to enrollment
Less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or 2 progressive scans at least 4 weeks apart or histopathologic confirmation
Radiation therapy for bone metastasis within 2 weeks, or any other external radiation therapy within 4 weeks before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible
No prior radiation therapy to the liver
Patients must have received prior external beam radiation therapy to the region proposed for SRS re-irradiation at least 6 months prior to planned re-irradiation\r\n* For patients who were previously treated at an outside institution, adequate records must be available to determine the true dose the cord/cauda received during prior radiation therapy (RT); sufficiency of the treatment records will be assessed and signed-off by the Medical Physics investigator
Patient must be 4 weeks off any palliative radiation or craniospinal radiation
History of previous radiation therapy which would result in overlapping radiation fields
Receipt of radiation therapy within 4 weeks prior to starting investigational product, or limited field of radiation for palliation within 2 weeks of the first dose of investigational product
An interval of at least 12 weeks must have elapsed since the completion of initial radiation therapy
Prior history of abdominal radiation therapy
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Patients with prior radiation to the abdominal cavity or pelvis are excluded
Any prior treatment with radiation therapy, chemotherapy, biotherapy, or hormone therapy for the currently diagnosed breast cancer prior to study enrollment
Prior breast or thoracic radiation therapy (RT) for any condition
Metastatic cancer requiring palliative radiation therapy
Radiation therapy must begin within 12 weeks of surgery
Patients must not have received radiation for a minimum of two weeks prior
Palliative radiation is allowed to sites that will not be used to measure response during this study
The last dose of prior chemotherapy, immunotherapy or radiation must be at least 2 weeks before the leukapheresis procedure
If post-transplant consolidation radiation therapy is given, the patient must be at least 14 days between last radiation treatment and 1st dose of rituximab
XRT: At least 14 days since the last treatment except for radiation delivered with palliative intent to a non-target site.
The subject has received radiation therapy as follows: \r\n* To the thoracic cavity, abdomen or pelvis within 3 months of the first dose of study treatment or has with ongoing complications or is without complete recovery and healing from prior radiation therapy\r\n* To bone or brain metastasis within 14 days of the first dose of study treatment\r\n* To any other site(s) within 28 days of the first dose of study treatment
Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol
Patients with a history of treatment with radiation therapy are excluded
Interval from start of initial radiation therapy to enrollment > 9 months
Participants or their legal guardian must sign consent prior to the initiation of radiation therapy
Patients will be ineligible if any prior therapeutic radiation therapy > 500 cGy has been delivered
Patients will be ineligible if chemotherapy was completed >= 1 year from the planned start date of radiation therapy or if the patient is referred for radiation therapy after a relapse following a regimen with chemotherapy alone
Prior radiation to the site of current primary disease, if re-treatment would lead to violation of known radiation dose tolerance limits for that site
Prior radiation therapy that would exclude the use of TMLI
Prior radiation to liver in form of total body or involved field
Patients must not have received radiation therapy within the past 4 weeks
> 4 weeks since prior radiation, surgery or chemotherapy
Patients who will receive radiation therapy as their primary treatment after surgery
Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy fields
Prior whole brain radiation therapy (WBRT)
The subject has received radiation therapy:\r\n* To the thoracic cavity, abdomen or pelvis within 3 months of the first dose of study treatment that has with ongoing complications or is without complete recovery and healing from prior radiation therapy (CT changes related to radiation treatment which are not clinical significant are allowed)\r\n* To bone or brain metastasis within 14 days of the first dose of study treatment\r\n* To any other site(s) within 28 days of the first dose of study treatment
A history of previous chemotherapy for pancreatic cancer or abdominal radiation therapy
Prior radiation therapy in the planned treatment field
Prior history of abdominal radiation therapy
No prior chemotherapy, radiation therapy, or breast resection within 6 months of study entry
Patient who has had chemotherapy, radiation, hormonal, or biological cancer therapy < 4 weeks prior to the first dose of study drug
Patients must not have any significant toxicity associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy, per principal investigator (PI) discretion
Prior radiation therapy to the pelvis
Patients may have received previous radiation therapy, but it must have been completed at least 21 days prior to enrollment and the patient should have recovered from all associated toxicities. Measurable or non-measurable disease must be present outside the previous radiation field or a new lesion inside the radiation port must be present.
Minimum interval since completion of radiation treatment is 12 weeks
Neoadjuvant chemotherapy will be permitted prior to the initiation of SBRT radiation therapy on this clinical trial; there must be a minimum of 2 weeks between the completion of any neoadjuvant chemotherapy and the beginning of SBRT radiation therapy; furthermore, restaging must be done prior to registration to ensure that patients remain resectable
Screening magnetic resonance imaging (MRI) must be obtained at least 4 weeks after any salvage surgery, and at least 12 weeks after radiation therapy, or at least 4 weeks after radiation for a new lesion outside the prior primary radiation field unless relapse is confirmed by tumor biopsy or new lesion outside of radiation field, or if there are two MRIs confirming progressive disease that are 8 weeks apart
Patients with active cytotoxic chemotherapy or radiation therapy are excluded
Radiation therapy within 2 weeks before the first dose of study treatment
Patients must have discontinued all previous external beam radiation therapy and recovered from side effects due to radiation therapy for more than 14 days starting on treatment
Able to cooperate with radiation safety restrictions during therapy period
Three-months should have elapsed in the case of completing radiation to any of the following fields: craniospinal, total abdominal, whole lung, total body irradiation); for all other sites of radiation, at least 2 weeks should have elapsed
Prior ipsilateral breast or thoracic radiation for any condition
Prior radiation therapy for pancreatic cancer
Surgery or radiation planned within 8 weeks of starting therapy
Previous treatment with surgery, radiation or hormonal therapy is allowed
At least 12 weeks since the completion of radiation therapy to a total of >= 50 Gy
Prior radiation therapy to the ipsilateral breast or thorax.
Radiation therapy within 14 days of screening
Chemotherapy, radiation, or biological or targeted therapy within 3 weeks
Patients must have no history of previous chemotherapy for pancreatic cancer or any abdominal radiation therapy
No prior radiation to the mediastinal structures
Patients must have had no chemotherapy, biologic therapy, or radiation therapy for their malignancy for at least 30 days prior to treatment; patients may have received localized radiation therapy to non-target lesions provided that the radiotherapy is completed 14 days prior to commencing therapy, and the patient has recovered from any toxicity; at least 3 half-lives must have elapsed since monoclonal antibody treatment; at least six weeks must have elapsed between mitomycin C or nitrosourea treatment
Patients must not have received prior radiation therapy to the involved breast at any time for any reason
Patient must have a history and physical within 2 weeks prior to the start of any protocol therapy (radiation and veliparib)
Prior therapeutic radiation to target tissues for protocol radiation
Patients may receive radiation alone if the above criteria is not met
Patients with >= grade 3 sensorineural hearing loss at baseline may receive radiation alone or radiation with carboplatin
Prior to start of treatment must be more than 21 days elapsed from surgery, radiation therapy, or prior chemotherapy; more than 42 days elapsed from prior immune therapy including vaccines
Patients must be at least 3 weeks beyond their previous cytotoxic chemotherapy; patient must be at least 5 half-lives or 3 weeks, whichever is shorter, from their previous targeted or biologic therapy; in addition, patients must be at least 3 weeks beyond the last session of radiation therapy; local palliative radiation therapy that is not delivered to all target lesions is allowed immediately before or during treatment
Patients should be at least four weeks from the last day of therapeutic radiation or cytotoxic chemotherapy or from antibody therapy, or at least five half-lives from non-cytotoxic targeted or biologic therapy; patients may have received palliative radiation immediately before (or during) treatment provided radiation is not to the only target lesion available
Patients must be >= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery; patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol; for biologic/targeted agents patients must be >= 5 half-lives or >= 3 weeks from the last dose (whichever comes first); patients previously treated with vemurafenib monotherapy do not have to stop medication before they start on the protocol
Patient must not have had prior external beam radiation to the liver
Significant prior external beam dose-limiting radiation to a critical organ based on review of the prior radiation treatment records by the radiation oncology PI; patients who have had prior external beam radiation > 2000 cGy (at 180 to 200 cGy per day) to any portion of the lung will be ineligible; patients with ANY prior radiation to the heart are ineligible; patients with > 500 cGy to any portion of the kidney will be excluded from the study
Patients who had previous radiation dose to the site of the current primary disease, which would lead to violation of known radiation tolerance limit of that particular site if treated again
At least 14 days passed since last brain surgery or radiation therapy.
Patients must be at least 12 months from completion of radiation therapy (to be consistent with the \rechallenge\ group from Perry et al. Journal of Clinical Oncology [JCO] 2010 where the median time from completion of adjuvant radiation therapy to the time of progression was 19.69 months)
Patients must have failed prior radiation therapy and must have an interval of greater than or equal to 12 weeks from the completion of radiation therapy to registration; except if patients underwent surgery within 12 weeks and pathology is consistent with recurrent tumor
High-dose chemotherapy or external beam radiation therapy to lung, liver, or kidneys > 20 Gy within the previous 100 days prior to therapeutic 90Y-ibritumomab tiuxetan dose
Participants may have had prior surgery for glioblastoma or gliosarcoma but no systemic or radiation therapy
Previous radiation and/or surgery must have been discontinued or completed at least 2 weeks prior to treatment in this study and adverse effects must have resolved to grade 1 or baseline; lymph node or other diagnostic biopsies within 2 weeks are not considered exclusionary\r\n* CTCL patients who have received localized radiation therapy (RT) as part of their immediate prior therapy may be allowed to enroll with shorter washout period after discussion with the MSK principal investigator
Require concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is allowed up to the evening before starting (but not within 12 hours) of starting treatment on either arm.
External beam radiation therapy =< 28 days prior to registration; note: previous treatment with radiation is allowed if the investigator judges it will not compromise patient safety on the study
Patients must not have had any radiation therapy or chemotherapy for medulloblastoma prior to study enrollment
Prior radiotherapy to the pelvis or abdomen that would result in overlap of radiation therapy fields
Patients must have had prior radiation therapy for treatment of their ependymoma; external beam radiation therapy (XRT) must be >= 3 months prior to registration for craniospinal irradiation (>= 18 Gray [Gy]); >= 4 weeks for local radiation to primary tumor; and >= 2 weeks prior to registration for focal irradiation to symptomatic metastatic sites
In cases of concern about decreased renal function and potential high radiation dose to the kidneys, an optional nuclear medicine kidney function scan may be performed prior to radiation therapy to determine the functional contribution of each kidney
Prior thoracic radiation therapy preventing hemithoracic pleural IMRT
Participants may have had any extent of prior surgery and/or chemotherapy; no prior cranial radiation therapy is allowed
Prior radiation therapy to the upper abdomen or liver
Patients who have previously received therapeutic radiation therapy to the chest
Radiation therapy for the target lesion in the 60 months preceding inclusion in the study
Prior radiation, including brachytherapy, to the region of the prostate that would result in overlap of radiation therapy (RT) fields
Prior whole brain radiation therapy
Prior radiation to the index breast
> 4 weeks since prior radiation, surgery or chemotherapy
Tumor types – tumor type/location:\r\n* Stratum A: newly diagnosed diffuse intrinsic pontine gliomas OR any biopsy proven high-grade glioma involving the brainstem; patients may not have received chemotherapy during or after radiation; patients must be registered within 4-12 weeks of completing radiation\r\n* Stratum B: newly diagnosed, non-brainstem high-grade glioma; patients may not have received chemotherapy during or after radiation; patients must be registered within 4-12 weeks of completing radiation\r\n* Stratum C: unresectable low-grade gliomas that have received at least two chemotherapy/biologic regimens; patients may not have received radiation to the index lesion within 1 year of enrollment \r\n* Stratum D: non-brainstem high-grade gliomas that have recurred following treatment\r\n* Stratum E: newly diagnosed high-grade gliomas or brain stem gliomas who received chemotherapy during radiation therapy; patients may not have received chemotherapy after radiation therapy was completed; patients must be registered within 4-12 weeks of completing radiation  \r\n* Stratum F: newly diagnosed high-grade gliomas with metastatic disease within the central nervous system (CNS) requiring craniospinal radiation therapy; patients may or may not have received chemotherapy during radiation, but cannot have received chemotherapy after radiation therapy was completed; patients must be registered within 4-12 weeks of completing radiation
Prior radiation to the brain
Able to cooperate with radiation safety restrictions during therapy period
Documentation that either: 1) the patient’s medical insurance company has certified that they will pay for the cost of radiation therapy treatments, or 2) a letter from the patient indicating that they explicitly understand the costs of radiation therapy and that the sponsor (Principal Investigator) of this study will not be held responsible for these costs
Unacceptable radiation therapy quality assurance parameters
Radiation therapy, hormonal therapy, biologic therapy or chemotherapy for cancer within the 28 days prior to day 1 of study drug\r\n* For the NSCLC expanded cohort only: palliative radiation therapy =<14 days of day 1 of study drug
Radiation Therapy: Hepatic radiation within 4 weeks of PV-10 administration.
No radiation therapy >= 14 days for local palliative radiation therapy (XRT) (small port): >= 6 months must have elapsed if prior craniospinal XRT or if >= 50% radiation of pelvis; >= 42 days must have elapsed if other substantial bone marrow radiation
Chemotherapy is allowed; if chemotherapy is indicated and brachytherapy boost is planned, it must be administered after the accelerated whole breast irradiation (AWBI) but should begin no earlier than 21 days following completion of radiation therapy; alternatively if chemotherapy is indicated and external beam boost is planned, the chemotherapy can be delivered first, followed by radiation therapy beginning 21-63 days after the last cycle of chemotherapy or the radiation therapy can be delivered first and the chemotherapy can be delivered no earlier than 21 days post radiation therapy
For patients treated with external beam boost, prior chemotherapy if administered less than 3 weeks from start of radiation therapy or chemotherapy < 3 weeks after finishing radiation therapy; for patients treated with brachytherapy intracavitary device, chemotherapy prior to start of radiation therapy (RT)
Patients with a breast technically unsatisfactory for radiation therapy
Patients with tylectomies so extensive that the cosmetic result is low or poor prior to radiation
Patients with prior fractionated radiation to the treated site are allowed; their prior treatment plan with date, fractionation, dose and treatment fields must be obtained; there must be at least a three month interval elapsed from the prior radiation to the treated site and enrollment
Prior radiation therapy with 400c gray (Gy) or more of TBI
No prior abdominal radiation
Prior radiation therapy that prevents further TBI
If subject has not undergone radiation therapy, then subject must have undergone prior consultation with a radiation oncologist (who is not an investigator on this study); if the subject has undergone radiation therapy, then at least 14 days must have elapsed since completion of radiation
Prior radiation to the area of measurable or active tumor.
Subjects may have had prior focal or systemic radiation or chemotherapy; at least 14 days must have elapsed since radiation treatment and 28 days since prior chemotherapy
Has had prior chemotherapy, radiation therapy, or immunotherapy for the diagnosis of iBCL
Prior treatment with the following agents: a) Tumor necrosis factor receptor (TNFR) agonists, including OX40, cluster of differentiation (CD)27, CD137 (4-1BB), CD357 (glucocorticoid-induced TNFR family-related gene) at any time. b) TLR4 agonist at any time. c) Anticancer therapy or investigational therapy within 30 days or 5 half-lives of the drug, whichever is shorter. d) Prior radiation therapy: permissible if at least 1 non-irradiated measurable lesion is available for assessment according to RECIST version 1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. A wash out of at least 14 days before start of study treatment for radiation of any intended use to the extremities for bone metastases and 28 days for radiation to the chest, brain, or visceral organs is required.
Radiation therapy (XRT)/External Beam Irradiation including Protons: ?14 days after local XRT, ?150 days after TBI, craniospinal XRT or if radiation to ?50% of the pelvis, ?42 days if other substantial BM radiation
At least 21 days must have elapsed from prior therapy (chemotherapy or radiation)
Patients must have at least one lesion not previously irradiated (and not within a previously irradiated field) for which palliative radiation to the abdomen and/or pelvis is potentially indicated and could be safely delivered at the radiation doses specified in this protocol; this lesion must not be within the central nervous system (CNS) (brain or spinal cord), bone or liver, and must not require urgent or emergent palliative radiation given the timing of radiation specified on this protocol; furthermore, this lesion must be located in the abdomen or pelvis and measure at least 2 cm (minimum dimension) and no greater than 6 cm (maximum dimension); palliative radiotherapy would entail involved-field radiotherapy to a single lesion or region to encompass gross disease; whole-abdomen radiotherapy would not be permitted; patients who received prior vaginal brachytherapy would be permitted to receive palliative pelvic radiation; in the expansion cohort at the maximum tolerated dose (MTD), this lesion must not be the only measurable lesion so that it is possible to determine the response rate outside of the radiation treatment field
Radiation therapy within 3 weeks prior to entering the study
Prior radiation within 2 weeks of study registration
Tooth extraction prior to radiation
Previous inclusion in a research protocol involving nuclear medicine, positron emission tomography (PET) or radiological investigations with significant radiation burden (a significant radiation burden being defined as 10 mSv in addition to natural background radiation, in the previous 3 years). Exclusion Criteria for Group 1 Has any of the following:
Conventional chemotherapy or radiation within 4 weeks.
Prior radiation therapy within 30 days prior to enrollment.
Conventional chemotherapy or radiation within 4 weeks.
Radiation therapy within 4 weeks of Day 1
Prior abdominal radiation therapy or prior chemotherapy for pancreatic cancer
Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =< 2 weeks prior to cycle 1 day 1 (localized radiation to a single site at least 1 week before cycle 1 day 1 is permissible)
Palliative surgery and/or radiation treatment less than 4 weeks prior to initiation of study treatment.
The patient should be off chemotherapy, biologic therapy and radiation for 28 days.
Patients must be eligible to have all lesions treated as determined by the study radiation oncologist.
Current or prior radiation to the left hemithorax
Prior radiation therapy is allowed to < 25% of the bone marrow; note: no radiation therapy within 30 days prior to registration for protocol therapy
radiation therapy (gamma knife) was completed ? 4 weeks prior to baseline
No radiation therapy to targeted (most painful) tumors in the past two weeks
Patients receiving chemotherapy or radiation (i.e., to the targeted lesion (s)) within the last two weeks
Less than 3 weeks since prior chemotherapy, radiation therapy, or immunotherapy. However, hydroxyurea is permitted up to 24 hours before the study is initiated;
Prior radiation to the breast or chest wall
At least 14 days passed since last brain surgery, or intracranial radiation therapy/radiosurgery
Previous radiation treatment in either breast at any time
Subjects who received radiation therapy within 2 weeks of randomization (C1D1)
Patients who are not able to receive protocol specified radiation therapy
Localized palliative radiation therapy is allowed for symptom management if completed >= 14 days prior to randomization
If they are undergoing or have undergone in the past 4 weeks (28 days) any other therapy for their cancer, including radiation therapy and chemotherapy
Active central nervous system (CNS) metastasis, which has not been treated with radiation therapy. If treated with radiation therapy, treatment must end before 14 days prior to starting study treatment.
Received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (?2 weeks of radiotherapy) to non-central nervous system (CNS) disease.
History of prior breast cancer-specific therapy within the previous 2 years (chemotherapy, radiation, anti-HER2 agents, endocrine agents, everolimus, CDK4-6 inhibitors); previous unilateral radiation of the contralateral side in women scheduled for mastectomy is allowed; study gel will be applied to both breasts
Currently being treated for other cancers with medical or radiation therapy
Patients must not have received radiation for a minimum of two weeks prior to start of vorinostat; for patients with only one site of measurable or evaluable disease, radiation must not have been given to that site unless that site has demonstrated clear progression after radiation
A minimum of 12 weeks prior to start of vorinostat is required following prior large field radiation therapy (i.e., craniospinal, whole abdominal, total lung, > 50% marrow space)
Prior exposure to chemotherapy or radiation for the disease to be treated on this trial not allowed
Therapeutic radiation within 6 weeks of cycle 1 day 1; exceptions are palliative radiation and/or stereotactic radiation to non-target lesions
Patients with a cancer diagnosis, receiving chemotherapy, radiation therapy or the combination
A maximum of one prior radiotherapy regimen, curative or palliative, to the head and neck is allowed; if the radiation is combined with chemotherapy and/or cetuximab, a minimum of 4 months must elapse between the end of radiotherapy and registration; if the radiation is given alone, a minimum of 8 weeks must elapse between the end of radiotherapy and registration; a minimum of 3 weeks must elapse between prior radiation to other areas and registration; treatment areas should be healed with no sequelae from radiation therapy (RT) that would predispose to fistula formation
Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before the first dose of study treatment; systemic treatment with radionuclides within 6 weeks before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible
At least one index lesion to be treated measuring 1-7 cm amenable to hypofractionated radiation therapy
Prior radiation treatment to the index lesion to be treated
Prior radiation treatment to the pelvis
Any radiation therapy within 21 days prior to day 1 of protocol therapy
All sites of disease must be targetable with intensity-modulated radiation therapy (IMRT) with acceptable morbidity and without exceeding normal tissue dose constraints as assessed by a radiation oncologist
Prior radiation or systemic therapy for the diagnosis of liposarcoma
Concurrent malignancy or malignancy within 3 years prior to starting study drug, with the exception of malignancies that have completed therapy and are considered by their physician to be at less than 30% risk of relapse; prior systemic therapy is allowed with the exception of prior eribulin; prior radiation therapy is allowed with the exception of any abdominal, pelvic or retroperitoneal radiation > 10 Gy
Subjects who have had radiation therapy within 2 weeks prior to first dose of drug
Recommendation for combined chemotherapy and radiation therapeutic treatment
Prior radiation therapy resulting in overlap of radiation therapy (RT) fields
The subject must have completed prior radiation therapy at least 28 days prior to registration for protocol therapy\r\n* NOTES: Subjects may have received prior radiation therapy for treatment of endometrial carcinoma; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy; chemotherapy used for radiation sensitization is allowed; chemotherapy used for radiation sensitization will not count as second chemotherapy regimen
Patients who have undergone prior resection, radiation therapy, and/or chemotherapy (except bevacizumab)
Patients must be untreated with radiation above the clavicles
Malignant glioma patients within 12 weeks of completion of radiation concurrent temozolomide will be excluded
Clinically safe to delay radiation for at least 2 weeks
Use of concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol
No prior chemotherapy or radiation for pancreatic cancer
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields (to include Y90)
Part 1 patients must have prior histologically proven glioblastoma that is progressive or recurrent following radiation therapy +/- chemotherapy
At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment
Completed planned breast surgeries and any radiation therapy >= 30 days prior to randomization
Prior surgery and chemotherapy allowed, no prior radiation to the target area (breast or chest and nodes); NOTE: Radiation should occur 3-12 weeks after last chemotherapy or surgery, whichever comes last
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
Resolution of chemotherapy, immunotherapy or radiation-related toxicities.
Treatment with radiation therapy within 3 weeks prior to the initiation of study drug administration.
Prior treatment \r\n* Prior medical therapy is allowed but not required\r\n* No limit on number of prior therapies\r\n* No chemotherapy, other investigational agents within 28 days of study treatment\r\n* No other concurrent investigational agents or other meningioma-directed therapy (chemotherapy, radiation) while on study\r\n* For patients treated with external beam radiation, interstitial brachytherapy or radiosurgery, an interval > 24 weeks must have elapsed from completion of radiation therapy to registration\r\n* Steroid dosing stable for at least 4 days \r\n* Recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or less toxicity from other agents with exception of alopecia and fatigue\r\n* No craniotomy within 28 days of registration
Subjects who have received radiation therapy targeting > 10% of the bone marrow space must have completed this at least 2 weeks prior to starting therapy with AMG-232 + KRd
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Participants who have received prior chest radiation are excluded
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Extensive prior therapy including > 12 months alkylator therapy or > 6 months alkylator therapy with extensive radiation as per the assessment of the radiation oncologist
DOSE ESCALATION COHORT: Subjects who have had prior radiotherapy within 2 weeks of therapy; subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis
DOSE EXPANSION COHORT: Subjects who have had prior radiotherapy within 2 weeks of therapy; subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis
Radiation therapy in the last 14 days; palliative radiation to a localized area without residual toxicity requires a washout of greater than 7 days
Prior radiation therapy is allowed; patients must not have received radiation therapy within 3 weeks prior to the initiation of study treatment
Any prior chemotherapy or radiation therapy for the current diagnosis
Prior chemoembolization or radiation therapy (including Y90) must be performed at least 2 weeks before study enrollment
Extended field radiation within prior 4 weeks or limited field radiation within prior 2 weeks
Patients must have had no chemotherapy, biologic therapy, or radiation therapy for their malignancy for at least 30 days prior to treatment; patients may have received localized radiation therapy to non-target lesions provided that the radiotherapy is completed 14 days prior to commencing therapy, and the patient has recovered from any toxicity; at least 3 half-lives must have elapsed since monoclonal antibody treatment; at least six weeks must have elapsed between mitomycin C or nitrosourea treatment
An interval of at least 6 months after the end of prior radiation therapy is required unless there is a new recurrence outside of the previous radiotherapy treatment field
Has received re-radiation to recurrent disease (other than standard frontline adjuvant radiation therapy)
Patients may have received prior radiation therapy for treatment of endometrial cancer; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, intravaginal brachytherapy and/or palliative radiation therapy; all radiation therapy must be completed at least 4 weeks prior to registration
Radiation therapy (RT): >= 2 weeks for local palliative RT (small port); >= 6 months must have elapsed if prior craniospinal RT or if >= 50% radiation of pelvis; >= 6 weeks must have elapsed if other substantial bone marrow (BM) radiation; Note: patients must have received =< than 13.6 Gray (Gy) prior radiation to the mediastinum
Prior radiation allowed (no restriction on amount); measurable lesion(s) may not have been previously irradiated
Willingness to be treated with radiation therapy and androgen deprivation therapy
Patients who received prior neo-adjuvant, adjuvant chemotherapy or chemo-radiation or radiation with curative intent for non-metastatic NSCLC must have experienced a treatment-free interval of at least 6 months from signing the informed consent since the last chemotherapy or chemo-radiation or radiation treatment/cycle
Has had systemic corticosteroids within 2 weeks of the first dose of protocol-related radiation or MK-3475
Has had radiation therapy within 2 weeks of the first protocol treatment
Planned radiation therapy after transplant
Patients must have a histologic diagnosis of melanoma either from a primary or metastatic site; patients with brain metastases must have completed radiation therapy > 30 days prior to enrollment
No prior intracranial radiation
Patients who have received prior surgical site radiation
No prior radiation to lesions being treated
Contraindications to radiation
No previous chemotherapy or radiation therapy
Radiation: \r\n* Patients must not have received radiation (small port) for a minimum of two weeks prior to protocol therapy\r\n* Except for patients with a history of progressive disease, patients whose only site(s) of disease have been radiated are eligible if at least one lesion meets at least one of the criteria listed in sites of disease above\r\n* A minimum of 12 weeks prior to start of protocol therapy is required following large field radiation therapy (i.e. total body irradiation, craniospinal, whole abdominal, total lung, > 50% marrow space)\r\n* A minimum of 6 weeks must have elapsed prior to start of protocol therapy for other substantial bone marrow radiation
Prior abdominal or pelvic radiation therapy or radiation therapy to > 10% of the bone\n             marrow at any time in the past or prior radiation therapy within the past 3 years to\n             the breast/sternum, dermal lesions, head or neck.
Brain metastases may be treated using gamma knife radiosurgery (GKR) or whole brain radiation therapy (WBRT) per the treating radiation oncologist; total radiation dose and number of fractions will be determined by the treating radiation oncologist based on anatomic and dosing constraints; magnetic resonance imaging (MRI) of the vertebral column is required for all patients with suspected epidural tumor extension
Has received prior radiotherapy within 3 weeks of start of study treatment; participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis; a 1-week washout is permitted for palliative radiation (=< 2 weeks of radiotherapy) to non-central nervous system (CNS) disease
Prior therapy requirements:\r\n* Prior radiation, chemotherapy or biologics NOT allowed
Patients with intracranial metastases, which have been treated by surgery or radiation therapy, may be eligible for study provided there is no evidence of active disease and no requirement for anticonvulsant therapy or steroids following treatment
Prior breast or thoracic radiation therapy (RT) for any condition
Prior local radiation therapy must be completed at least 30 days prior to enrollment and the patient must have recovered from all toxicity
Radiation therapy via external beam or brachytherapy within 28 days of registration
Patients who have received previous chemotherapy or radiation therapy (does NOT include steroids)
Patient must have received no prior radiation therapy or chemotherapy other than corticosteroids; corticosteroids are allowable for all patients
Arm 1 patients must be in first recurrence of glioblastoma following radiation therapy and temozolomide
Patient may have received previous treatment for the brain tumor(s), including radiation (focal brain radiation, whole brain radiation or stereotactic radiosurgery), surgery or chemotherapy
Patients who are currently receiving chemotherapy, radiation therapy or are enrolled in another therapeutic clinical trial
Patients who have not recovered from the toxicities of prior chemotherapy or radiation
Patients must be candidates for palliative radiation
Radiation, chemotherapy, or immunotherapy or any other approved anticancer therapy =< 2 weeks prior to cycle 1 day 1
Prior palliative radiation therapy to bony metastases is allowed; there should be a minimum of 14 days between the end of radiation treatment and start of study treatment
No prior systemic (chemotherapy or biologic/molecular targeted therapy) or radiation treatment for head and neck cancer\r\n* Patients may have received chemotherapy or radiation for a previous, curatively treated non-HNSCC malignancy, provided at least 2 years have elapsed\r\n* Patients must be untreated with radiation above the clavicles
Prior radiation therapy within the last 4 weeks; prior radiation therapy to indicator lesion (unless objective disease recurrence or progression within the radiation portal has been documented since completion of radiation)
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Radiation therapy within 3 weeks prior to enrollment
Prior brain surgery or radiation is allowed as long as the metastatic lesion(s) to be targeted in this study has not previously been treated with radiation
Previous treatment of the target lesions with radiation therapy
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
External beam radiation therapy (XRT): at least 14 days after local palliative XRT (small port); at least 150 days must have elapsed if prior total body irradiation (TBI), craniospinal XRT or if >= 50% radiation of pelvis; at least 42 days must have elapsed if other substantial bone marrow (BM) radiation
Prior radiation therapy within the last 4 weeks; prior radiation therapy to indicator lesion (unless objective disease recurrence or progression within the radiation portal has been documented since completion of radiation)
Prior treatment with gemcitabine alone or 5-fluorouracil with radiation as an adjuvant therapy will be allowed; patient should not have received gemcitabine within 6 months of starting the study treatment; 5-flourouracil or radiation treatment should be received more than 4 weeks prior to receiving the study drug
Patients with prior TBI, craniospinal XRT and/or those with >= 50% radiation of the pelvis are not eligible
Patients who have received prior pulmonary radiation
Must have a skin lesion of at minimum 2 cm, in a location amenable to radiation and a minimum of 2 additional measurable skin lesions distant from the radiation site
Prior radiation therapy to the whole brain (prior stereotactic radiosurgery or fractionated stereotactic radiation therapy to focal areas is allowed)
Unable to reliably be immobilized for safe administration of whole brain radiation therapy
Any prior radiation therapy must be discontinued at least four weeks prior to registration
Prior radiation therapy to the abdomen that would result in overlap of radiation therapy fields
Patients may have received palliative external beam radiation therapy (XRT) for local disease control with no curative intent; XRT must be completed at least 7 days prior to registration
No prior radiation therapy within the last 4 weeks, except as below \r\n* To the thoracic cavity, abdomen, or pelvis within 12 weeks before the first dose of study treatment, or has ongoing complications, or is without complete recovery to < grade 1 toxicity\r\n* To bone or brain metastasis within 14 days before the first dose of study treatment\r\n* To any other site(s) within 28 days before the first dose of study treatment\r\n* Prior radiation treatment may have included no more than 3000 centigray (cGy) to fields including substantial bone marrow
Patients must be completed radiation therapy at least 4 weeks previously
History of external beam radiation therapy to metastatic sites within 1 year of enrollment to the study
Prior radiation therapy, brachytherapy, or cryotherapy
Prior history of radiation to the chest
Prior radiation therapy (RT) > 20 Gray (Gy) to a critical organ within 1 year of enrollment
Prior radiation therapy to the pelvis
Patients may have received prior radiation presuming > 4 weeks since last dose and measurable disease outside the radiation field
Patients cannot have had prior chemotherapy or biologic therapy for SCLC or large cell neuroendocrine NSCLC, or small cell carcinoma of unknown primary or extrapulmonary origin; patients receiving prior radiation cannot register within 7 days after completion of radiation, and must have resolved adverse events attributed to radiation to =< grade 1; no previous irradiation to the only site of measurable or evaluable disease, unless that site had subsequent evidence of progression
Patients receiving prior radiation cannot register within 7 days after completion of radiation, and must have resolved adverse events attributed to radiation to =< grade 1; no previous irradiation to the only site of measurable or evaluable disease, unless that site had subsequent evidence of progression
PHASE II: Patients cannot have had prior chemotherapy or biologic therapy for small cell lung cancer; patients receiving prior radiation cannot register within 7 days after completion of radiation, and must have resolved adverse events attributed to radiation to =< grade 1; no previous irradiation to the only site of measurable or evaluable disease, unless that site had subsequent evidence of progression
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Patients must not have had prior chemotherapy or radiation therapy for esophageal cancer
Patients that have received prior radiation to the lung, excluding prior mediastinal radiation
Patients with prior radiation therapy completed less than 4 weeks prior enrollment
No external beam radiation therapy within 2 weeks of first vaccine administration
No stereotactic radiation therapy within 3 days of first vaccine
Previous radiation therapy to the ipsilateral breast
At least 4 weeks must have elapsed between the patient’s last chemotherapy or radiation treatment and the first vaccination
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
No prior chemotherapy or radiation therapy for HGG or DIPG is permitted; prior chemotherapy or radiation therapy for treatment of other malignancies is permitted
Previous whole brain radiation therapy
Prior radiation therapy for esophageal cancer or prior chest radiotherapy
Prior radiation therapy must have been completed > 2 weeks prior to randomization and the patient must be recovered from any acute toxicities associated with radiation therapy; previously irradiated lesions must not be the sole site of disease
>= 2 weeks (wks) for local palliative radiation therapy (XRT) (small port); >= 6 weeks must have elapsed since treatment with therapeutic doses of MIBG; >= 6 months must have elapsed if prior total body irradiation (TBI), craniospinal XRT or >= 50% radiation of pelvis; >= 6 wks must have elapsed if other substantial bone marrow (BM) radiation
Prior chemotherapy, and/or radiation therapy is allowed if it has been at least 3 years or longer since those therapies were given from the time of registration, with the exception of previous pelvic radiation which is NOT allowed under any circumstances
Subjects must have recovered from the acute side effects of any prior surgery, chemotherapy, or radiation therapy; a minimum time period at least 6 months should have elapsed from prior radiation treatment until enrollment in the study
Radiation therapy within 4 weeks prior to randomization on this study and not recovered to baseline from adverse events due to radiation therapy
Subject has radiation therapy within 4 weeks prior to the first study dose.
Patients who received prior radiation therapy (RT) for treatment of germ cell tumor are eligible for this study as long as there is evidence of progressive disease determined by tumor markers or other sites of metastases outside of the radiated site; radiation must be completed prior to starting chemotherapy with the exception of brain metastases where chemotherapy and radiation can be given concurrently; toxicity from radiation must have recovered to grade 1 or less prior to initiating chemotherapy
Radiation therapy within 4 weeks prior to screening.
Last dose of prior chemotherapy, radiation therapy, or investigational agents occurred at least 4 weeks before the start of therapy;
Regarding radiation therapy, time elapsed prior to first dose of lenalidomide:
2 weeks for local palliative radiation therapy (XRT).
8 weeks if prior craniospinal chemoradiation therapy (CRT) or if ? 50% radiation of pelvis.
Subject has received radiotherapy ? 4 weeks or limited field radiation for palliation ? 2 weeks prior to starting IP, and/or from whom ? 30% of the bone marrow was irradiated. Prior radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.
Radiation therapy within 12 weeks of registration
Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Whole brain radiation must have completed at least 4 weeks prior to study entry.
Previous radiotherapy for palliation of recurrent disease is allowed if > 4 weeks have elapsed since completion of therapy; if radiation therapy was received exclusively for bony metastases the minimum interval between completion of radiation treatments and the first infusion of study drug is 7 days
Patients may not have had radiation within 28 days prior to first dose
Chemotherapy, targeted small molecule therapy, or radiation therapy within at least 2 weeks
Patients may have received prior radiation therapy, including after the surgical resection; all adverse events associated with prior surgery and radiation therapy must have resolved to =< grade 1 prior to registration
Non-CNS site of radiation must be completed > 2 weeks prior to CTL019 infusion
Radiation therapy within 4 weeks (2 weeks for radiation for bone metastases) or radionuclide treatment within 6 weeks of randomization.
PRIOR/CONCURRENT THERAPY CRITERIA: Patients may have had prior radiation therapy as long as it has not affected greater than 25% of the bone marrow and at least one measurable lesion is outside the area of prior radiation; at least 7 days must have elapsed since last radiation treatment; patients must have recovered from any adverse events from prior radiation therapy to =< CTCAE grade 1
Prior radiation therapy within 2 weeks of infusion
At least 2 weeks from end of radiation therapy
Prior receipt of radiotherapy that would result in overlap of the new and old radiation therapy fields
Prior palliative radiation therapy to bony metastases will be allowed; there should be minimum of 14 days between the end of radiation treatment and start of study treatment
Patients undergoing breast conservation therapy (i.e. lumpectomy) must not have any contraindications to radiation therapy
The patient has received treatment with chemotherapy, wide-field radiation, or biologic therapy within 14 days of study entry.
Radiation therapy:\r\n* To the thoracic cavity, abdomen or pelvis within 3 months of the first dose of study treatment or has ongoing complications or is without complete recovery and healing from prior radiation therapy\r\n* To bone metastases within 14 days of the first dose of study treatment\r\n* To any other site(s) within 28 days of the first dose of study treatment
Prior external beam radiation treatment to the liver
Planned liver directed therapy or radiation therapy
Prior radiotherapy to the region of the study cancer that would result in direct overlap of radiation therapy fields
Radiation therapy (other than radiation to bony metastases) as cancer therapy </= 4 weeks before study treatment
Palliative radiation therapy to bony metastases </= 2 weeks before study treatment
Prior radiation therapy to the bladder
Patients may have received prior radiation therapy; radiation therapy must be completed at least 14 days prior to registration, and all toxicities related to prior radiation therapy must have resolved to CTCAE v4.0 grade 1 or lower; patients may not have had > 25% of their bone marrow radiated
Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within 28 days prior to study entry.
If patients have had a potential index lesion radiated, it must have progressed post radiation therapy to be used as a measurable eligibility lesion
Patients may have received prior radiation therapy for treatment of endometrial carcinoma; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy; all radiation therapy must be completed at least 4 weeks prior to the first date of study therapy
Patients must not have received prior chest radiation therapy for NSCLC
Received radiation therapy to the lung that is >30 Gy within 6 months of the first dose of study medication.
Therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment or palliative radiation therapy within 2 weeks before study drug treatment
Prior history of radiation to the pelvis
Palliative radiation therapy within 2 weeks of Day 1 of trial drug treatment
Patients must have recovered from acute toxicities from surgery, radiation or chemotherapy; at least 3 weeks will have elapsed since any prior therapy directed at the malignant tumor
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Participant has received radiation therapy to lung greater than 30 Gy within 6 months, or antineoplastic biologic therapy within 21 days, or major surgery within 21 days, or tyrosine kinase inhibitor therapy within 7 days, or palliative radiation within 7 days of the first dose of study medication.
Radiation therapy within 2 weeks prior to Cycle 1, Day 1
Subject may have 1 course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease if it was administered at least 4 weeks prior to day 1;
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Study Day 1
Completed last cycle of chemotherapy or radiation > 60 days prior to first vaccination
Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to study treatment, or
Tumor mass(es) accessible for intratumoral injection and are being considered for local radiation therapy and at least one additional site of disease outside the radiation field for assessment of distal (abscopal) response
Radiation therapy within 2 weeks prior to enrollment
Radiation therapy within 12 weeks before randomisation.
Patients must not have had any prior treatment with oxaliplatin or irinotecan hydrochloride (irinotecan) within 3 years prior to registration; patients must not have had prior chemotherapy in metastatic setting; prior abdominal radiation therapy is not allowed
Prior radiation therapy is allowed; patients must not have received minimal radiation therapy (=< 5% of their total marrow volume) within 3 weeks prior to the initiation of study treatment; otherwise, patients must not have received radiation therapy (> 5% of their total marrow volume) within 4 weeks prior to the initiation of study treatment; patients who have received prior radiation to 50% or more of their total marrow volume will be excluded
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields. For example, patients with prior breast radiotherapy treatments would likely be excluded.
Received chemotherapy or radiation within 14 days of first dose of study drug, except stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT).
Prior radiation is allowed if the index lesion(s) remains outside of the treatment field or has progressed since prior treatment. Radiation therapy must have been completed at least 4 weeks prior to the baseline scan
Prior radiation therapy of the index tumor <3 weeks prior to the screening visit
Other allowed prior treatment for mHSPC: a) Maximum of 1 course of radiation or surgical intervention; radiation therapy for metastatic lesions must be completed prior to randomization; b) Less than or equal to (<=) 6 months of ADT prior to randomization
Any prior radiation therapy must be discontinued at least four weeks prior to registration.
Prior radiation therapy within 2 weeks prior to Day 1 of Cycle 1
Prior chemotherapy or radiation for pancreatic cancer
Chest radiation ? 24 weeks prior to first dose
Prior treatment:\r\n* Must have completed standard radiotherapy and concomitant TMZ therapy as defined and determined by the study oncologist\r\n* Besides concomitant TMZ with radiation, no other therapy (neo-adjuvant or adjuvant) can be given prior to study registration, including chemotherapy (also including Gliadel/carmustine [BCNU] wafers), biologics, immunotherapy, radiation therapy; the only exception is the Optune device (NovoTTF-100A), which may be started any time after end of radiation therapy up through the initiation of Cycle 1; intent to use Optune must be declared at registration for stratification\r\n* No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation
Surgery or definitive radiation within the four weeks prior to D1 of treatment under this protocol (there is no restriction on timing of palliative radiation)
The subject has had palliative radiation therapy to bone metastases within 14 days prior to the Day 1 visit (side effects from radiation must be resolved).
Radiation therapy to lung >30 Gy within 6 months of first dose of study medication
Total body irradiation (TBI) or craniospinal radiation therapy <6months
Prior radiation therapy within 28 days of starting the study treatment, except radiation therapy for bone metastases or radiosurgery is permitted up to 14 days of starting treatment
Patients who received prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol
Prior external beam radiation treatment to the liver or abdomen
Has received prior treatment including radiation and chemotherapy, with radiation completed > 12 weeks prior to Day 1 (or ? 4 weeks if the recurrence is outside of the prior radiation field).
Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy treatment volumes
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to first dose of study drug
Previous radiation therapy to the pelvis.
Patients who have operable disease with curable intent, and/or are candidates for radiation therapy for local control
Prior radiation therapy within 30 days prior to enrollment.
Toxicities related to biopsy must have resolved prior to proceeding with radiation therapy.
Prior Therapy • Patients must have not received any prior therapy other than surgery, radiation and/or steroids.
Radiation therapy requirements
Timing of Radiation - radiation therapy must begin no later than 30 days after the date of radiographic diagnosis or definitive surgery, whichever is the later date.
Prior hemibody external radiation. Any external radiation therapy must have been completed at least 14 days prior to registration. Any toxicity from such therapy must have recovered to ? grade 1 per CTCAE version 4 criteria by the time of registration.
Previous definitive chemotherapy (chemo)-radiation is permitted for early stage tumors (cisplatin-based chemo-radiation is permitted but only if tumor progression/relapse occurs after 6 months from treatment completion)
The target lesion is one that either has never received external beam radiation or has been previously irradiated and has since demonstrated progression; any local irradiation of the target lesion or any non-target lesions via external beam, conformal or stereotactic radiation treatments must have occurred more than 4 weeks prior to study drug administration; any full craniospinal radiation, whether or not a target lesion is included in the field, must have occurred more than 3 months prior to study drug administration
External beam radiation to both kidneys (scatter doses of < 500 cGy to a single kidney or radiation to < 50% of a single kidney is acceptable)
Patients cannot have evidence of immunosuppression or have been treated with immunosuppressive therapy, such as chemotherapy, chronic treatment dose corticosteroids (greater than the equivalent of 10 mg prednisone per day), or radiation therapy to > 30% of the bone marrow, within 6 months of the first vaccination; treatment or salvage radiation therapy encompassing =< 30% of bone marrow must have been completed 4 weeks prior to the first vaccination
Prior chemotherapy or radiation therapy for any cancer
Have radiation therapy within 14 days prior to randomization.
An interval of at least 6 months after the end of prior radiation therapy is required unless there is a new recurrence outside of the previous radiotherapy treatment field
The patient must have completed chemoradiation (all cohorts) within standards of care established by prior Radiation Therapy Oncology Group (RTOG)/Network Radiotherapy Group (NRG) Oncology studies as follows:\r\n* Radiation therapy\r\n** Modality: either 3-dimensional (3D) or intensity-modulated radiation therapy (IMRT), or proton therapy is allowed\r\n** Time to initiation: radiotherapy must be initiated within or equal to 42 days after surgery\r\n** Target volumes: target volume definition will be based upon postoperative-enhanced MRI; preoperative imaging should be used for correlation and improved identification, as necessary\r\n** Dose guidelines: the initial target volume will be treated to 46 Gray (Gy) in 23 fractions; after 46 Gy, the cone-down or boost volume will be treated to a total of 60 Gy, with seven additional fractions of 2 Gy each (14 Gy boost dose)\r\n* Temozolomide during concomitant radiation therapy\r\n** Temozolomide must have been administered continuously from day 1 of radiotherapy to the last day of radiation (+/- 3 days to take into consideration holidays) at a daily oral dose of 75 mg/m^2 for a maximum of 49 days (except missed doses due to toxicity)
Previous radiation therapy to the ipsilateral breast
At least 4 weeks must have elapsed since the patient received any radiation therapy.
Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment with the exception of patients receiving radiation to more than 30% of the bone marrow which must be completed within 4 weeks of the first dose of study treatment.
Prior systemic therapy or radiation therapy for treatment of the current lung cancer
Prior malignancy requiring systemic therapy or radiation therapy within 1 year of randomization
Prior systemic therapy, radiation therapy, or surgery within 28 days of starting study treatment
Evaluation by a radiation oncologist within 45 days prior to study registration
Patient must have consulted with a radiation oncologist who is planning radiation; radiation should be completed within a 2-week window from start to finish
Systemic anticancer therapy (chemotherapy, “biologics”, immunotherapy) less than two weeks prior to starting radiation
Patients with a history of pituitary irradiation can be included, provided that at least 2 years (stereotactic radiosurgery) or 3 years (conventional radiation) have elapsed from the time of last radiation treatment to the time of enrollment into this study.
Any radiation treatment to metastatic site within 28 days of Cycle 1, Day 1
Patients currently receiving anticancer therapies or who have received anticancer therapies within 28 days from day 1 of study drug (including investigational agents, chemotherapy, radiation therapy, antibody based therapy, etc.); if radiation was received for bone metastases (palliative radiation), the minimum interval between completion of radiation treatment and first dose of study drug is 14 days
Prior therapy for brain metastases is not required; patients may either have refused radiation therapy or have received prior radiation therapy; patients having received prior standard whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS) must have completed treatment greater than 4 weeks prior to study initiation; patients are either inappropriate candidates for surgical resection or they may have refused surgical resection
Patients may receive local palliative radiation therapy immediately before or during the treatment if the radiation therapy is not delivered to the sole target lesions
History of urological surgery or procedures predisposing to genitourinary (GU) complications after radiation (will be determined by radiation oncologist)
Prior radiation therapy (RT) that precludes the delivery of SBRT
Prior single modality radiation therapy is allowed
Prior radiation therapy (RT) > 20 gray (Gy) to a critical organ within 1 year of enrollment
Prior abdominal radiotherapy that would result in overlap of fields; the treating radiation oncologist should review prior radiation therapy (RT) fields as available
Patients must have had no prior chemotherapy or radiation therapy for pancreatic cancer
No prior radiotherapy to the ipsilateral breast or prior radiation to the region of the breast that would result in overlap of radiation therapy fields
Prior radiotherapy to the ipsilateral breast or prior radiation to the region of the breast that would result in overlap of radiation therapy fields
No interim time prior to study entry is required following prior radiation therapy (RT) for non-target lesions; however, patients must not have received radiation for a minimum of 4 weeks prior to study entry at the site of any lesion that will be identified as a target lesion to measure tumor response; lesions that have been previously radiated cannot be used as target lesions unless there is radiographic evidence of progression at the site following radiation or a biopsy done following radiation shows viable neuroblastoma; palliative radiation is allowed to sites that will not be used to measure response during this study
History of urological surgery or procedures predisposing to genitourinary (GU) complications after radiation, i.e., anastomoses, stricture repair, etc. (will be determined by radiation oncologist)
Patients must be >/= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery. Patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol. For biologic/targeted agents patients must be >/= 5 half-lives or >/= 3 weeks form the last dose (whichever comes first).
Previous treatment with external beam radiation
Less than 6 months since the end of previous radiation
Prior radiation to maximally tolerated levels to any critical normal organ, or > 20 Gy prior radiation to large areas of the bone marrow (e.g., external radiation therapy to whole pelvis)
Patient must be considered able to tolerate systemic chemotherapy combined with pelvic radiation therapy, and a radical cystectomy (if necessary) by the joint agreement of the participating urologist, radiation oncologist, and medical oncologist
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
No prior chemotherapy or radiation for this lung cancer.
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
Prior radiation therapy to the bladder
Patients must be a candidate for ipsilateral radiation therapy
Physician recommendation of mucosal radiation
Received radiation therapy within 4 weeks prior to Week 0, Day 1 of study treatment. Patients may not receive or have received any radiation therapy at the biopsy sites.
Subject has radiation therapy within 4 weeks prior to the first study dose.
Has had prior radiation for other diagnoses to the expected treatment field
Patients who have previously received radiation therapy
No previous lung or mediastinal radiation therapy
Any prior chemotherapy, targeted/biologic therapy, or radiation for treatment of the participant’s gastric or GE junction cancer
Chemotherapy or radiation within 3 weeks of the first scheduled study treatment
Prior radiation therapy of any kind is allowed.
Receiving concomitant chemotherapy, radiation therapy, or immunotherapy during the duration of treatment on protocol, or within 21 days prior to enrollment
Palliative radiation must have been completed 2 weeks prior to the initiation of study therapy.
Chemotherapy, biologic anti-cancer therapy, or central field radiation therapy =< 28 days prior to randomization; Note: local or stereotactic radiation =< 14 days prior to randomization
Have undergone chest irradiation within 2 weeks prior to study drug administration, have not recovered from all radiation-related toxicities, or requires corticosteroids. A 2-week washout is permitted for focal palliative radiation to non-central nervous system disease.
Patients may not have received prior cytotoxic chemotherapy; however, nonplatinum/non-taxane chemotherapy used for radiation sensitization is allowed; patients may have received prior radiation therapy (including whole pelvic or vaginal brachytherapy), hormonal therapy, or therapy with biologic agents, but such therapy must be discontinued at least 2 weeks prior to entry on this study
In patients who have received prior radiation, at least 4 weeks should have elapsed since the completion of radiation therapy involving the whole pelvis or over 50% of the spine; if vaginal brachytherapy is planned with chemotherapy, it should be done before or after completion of chemotherapy treatment
Deemed medically fit for stereotactic body radiation therapy by the treating physician
Prior radiation or surgery is allowed, but should be finished at least 2 weeks prior to study enrollment; if a participant has prior radiation therapy, at least one measurable lesion outside of the radiation field should be available for the evaluation of response to chemotherapy
Patients must not receive concomitant radiation
Patients may have received prior definitive radiation therapy provided that at least 28 days (14 days for palliative radiation therapy) have elapsed since the last treatment and patients have recovered (i.e., =< grade 1 or at baseline) from all associated toxicities at the time of registration
No prior treatment with radiation or chemotherapy for their GBM
Any prior treatment for the patient's GBM including radiation or chemotherapy
Prior radiotherapy, including brachytherapy, to the region of the prostate that would result in overlap of radiation therapy fields
Prior radiation to any of the field required to treat the tumor
Chemotherapy, immunotherapy (including interferon), or biological therapy, radiation therapy and/or surgery within 4 weeks prior to first dose of study drug.
History of prior chest radiation therapy
Prior radiation therapy to the ipsilateral breast or thorax
Prior radiotherapy of the mediastinal/pericardial area or whole pelvis radiation.
Prior radiation treatment of > 45 gray (Gy) to the pelvis
Patients must have undergone local treatment via prostatectomy or radiation therapy
Patients must have had their last fraction of:\r\n* Craniospinal irradiation, total body irradiation (TBI), or >= 50% radiation of pelvis > 3 months prior to enrollment\r\n* Focal irradiation > 6 weeks prior to enrollment\r\n* Local palliative radiation therapy (XRT) (small port) >= 4 weeks
Patients with radiation-associated gliomas will not be eligible
Radiation therapy:
Radiation therapy for bone metastases within 2 weeks, other external radiation therapy within 2 weeks of enrollment
Patients should have no contraindications for chemotherapy or radiation, and should receive either definitive chemoradiation therapy or preoperative chemoradiation therapy
Prior radiation to the chest or abdomen
Has received anticancer chemotherapy, surgical treatment, and/or radiation therapy (except palliative radiation therapy for disease-related pain with a consult with the sponsor's medical monitor) within ?2 weeks of first study treatment.
Radiation therapy to bone within 4 weeks before enrollment;
Radiation therapy (or other non-systemic therapy) within 2 weeks prior to randomization or not fully recovered from adverse events due to a previously administered treatment
An interval of at least 12 weeks from the completion of radiation therapy to start of study drug unless there is a new area of enhancement consistent with recurrent tumor outside the radiation field or there is unequivocal histologic confirmation of tumor progression
Subjects who have received extensive radiation therapy, including sternum, pelvis, scapulae, vertebrae or skull, within 4 weeks of the first day of study drug or received palliative low dose radiation therapy limited to limbs within 1 week of the first day of study drug, or subjects who have not recovered from side effects of such therapy.
Radiation therapy =< 2 weeks prior to randomization
History of prior malignancy is acceptable, but prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields is not allowed
Prior radiation therapy or implant in the contralateral breast
Radiation or chemotherapy within 4 weeks of enrollment
Prior radiation or chemotherapy for glioma
Any prior radiation therapy must be discontinued at least 4 weeks prior to study treatment initiation
Patient has had radiation therapy within 2 weeks of beginning study treatment
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1
Patient who has had chemotherapy, radiation, or biological cancer therapy within 14 days prior to the first dose of study drug
Prior radiation is allowed
Radiation, chemotherapy, or immunotherapy or any other approved anticancer therapy =< 2 weeks prior to day -7 (beginning of loading phase)
Patients with a history of prior radiation therapy to the thorax
Patients must have received prior radiation therapy and standard temozolomide
Subject has received chemotherapy and/or radiation therapy (except palliative radiation therapy for disease-related pain) within ?2 weeks of first ADXS11-001 infusion.
The patient has received chemotherapy, surgery, or radiotherapy (for therapeutic purposes) within 3 weeks of initiating study treatment (4 weeks for bevacizumab or investigational drugs) or the patient has not recovered (grade >= 2 from side effects of the previous therapy); patients who receive palliative radiation therapy can be treated immediately after completion of radiation therapy
Radiation oncologist determines that the patient is medically able to undergo palliative radiation therapy and plans to treat the patient’s target lesions with one fraction of high dose palliative radiation therapy utilizing the Scan-Plan-Quality Analysis (QA)-Treat STAT RAD workflow
The target lesions have not previously been treated with external beam radiation; the patient may have previously been treated with external beam radiation therapy to other body sites, as long as the target osseous lesions were not included in that treatment
No recent treatment for thyroid cancer as defined as: \r\n* No prior 131I therapy is allowed < 6 months prior to initiation of therapy on this protocol; a diagnostic study using < 10 mCi of 131I is not considered 131I therapy\r\n* No external beam radiation therapy < 4 weeks prior to initiation of therapy on this protocol; (previous treatment with radiation for any indication is allowed if the investigator judges that the previous radiation does not significantly compromise patient safety on this protocol) \r\n* No chemotherapy or targeted therapy (e.g., tyrosine kinase inhibitor) is allowed < 4 weeks prior to the initiation of therapy on this protocol
No radiation within 4 weeks of mobilization attempt
Subjects who have received prior radiation therapy to any portion of the abdominal cavity or pelvis are excluded; prior intravaginal brachytherapy is permitted; prior radiation therapy for breast cancer is permitted
Received systemic anticancer therapy or radiation therapy within the previous 14 days
Treatment with chemotherapy, radiation therapy, or other immunotherapy =< 4 weeks prior to registration
Prior radiation therapy that at the treating physician's discretion makes SABR unsafe
Tumor progression or recurrence within 6 months of last dose of platinum therapy in the adjuvant (ie with radiation after surgery), primary (ie, with radiation), recurrent, or metastatic setting
Progressive disease if treated with chemotherapy, radiotherapy, surgery or immuno-therapy. If prior radiation was given, the measurable disease should be outside the radiation port.
No prior systemic therapy, immunotherapy, investigational agent, or radiation therapy within the last 4 weeks. Radiation therapy for symptomatic relief is allowed within the last 2 weeks.
Radiation therapy (XRT): >= 6 months from involved field radiation to index plexiform neurofibroma(s); >= 6 weeks must have elapsed if subject has received radiation to areas outside index plexiform neurofibroma(s); subjects who have received radiation to the orbit at any time are excluded
Patients who had radiation to greater than 25% marrow in the past 5 years
Subjects must not have had prior surgery (biopsy allowed) or radiation therapy within 6 months of enrollment.
Conventional chemotherapy or radiation within 4 weeks.
Palliative radiation within 2 weeks.
Prior intraabdominal, intrathoracic, vascular, spinal or intracranial surgery or radiation therapy within 4 weeks of starting treatment
Patients may have received prior radiation therapy or surgery; however, at least 14 days must have elapsed since completion of radiation therapy or surgery and patient must have only grade 2 or less adverse effects at the time of registration
There must be no plans to receive concomitant chemotherapy, biological response modifiers, radiation therapy or hormonal therapy; concomitant radiation therapy is allowed for the palliation of severe pain/neuropathic compression
No prior chemotherapy, radiation, or biotherapy
No radiation therapy =< 4 weeks prior to registration
Patients must be at least two weeks from prior radiation therapy (RT)
PHASE I: Prior chemotherapy or radiation administered within 2 weeks from initiating study treatment
At least 2 weeks since prior chemotherapy or radiation therapy
COHORT A: Current or prior radiation therapy to the prostate; prior radiation to a metastatic site (e.g., palliative radiation) is allowed
Radiation therapy: >= 12 weeks must have elapsed from craniospinal radiation; >= 2 weeks must have elapsed from focal radiation
Participants must have had their last fraction of external beam radiation therapy at least 4 weeks prior to enrollment
Chemotherapy, radiation therapy, or ablative therapy within 3 weeks of randomization
Prior radiation to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed; if patient receives single dose radiation for palliation or radiation to non-target lesion, they may immediately proceed to registration without waiting; acute adverse events from radiation must have resolved to =< Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 grade 1
Brain metastases unless documented to be controlled post completion of local therapy (surgery and/or radiation therapy) for at least four weeks prior to registration
Any prior treatment with radiation therapy or chemotherapy for the currently diagnosed larynx cancer prior to registration
Stratum 1: patients must not have received radiation therapy
Radiation therapy for treatment of the primary tumor within 6 weeks of cycle 1, day 1
Radiation or radionuclide therapy for treatment of metastatic CRPC tumor within 2 or 6 weeks, respectively, of cycle 1, day 1
Patients who received radiation therapy > 5 years ago for malignancies other than pancreatic cancer and whose radiation therapy field is not overlapping with the 20% isodose line of current radiation field are eligible, provided that radiation therapy was completed > 5 years ago and that there is no evidence of the second malignancy at the time of study entry
Completed standard external beam radiation with temozolomide
Subject has radiation therapy within 4 weeks prior to the first study dose.
Primary treatment with radiation therapy
Patients who have had radiation therapy within 1 week prior to entering the study
Neoadjuvant radiation therapy or chemotherapy for cervical cancer
Prior history of radiation therapy to the ipsilateral breast and/or regional nodes is not allowed (prior RT to other sites is permitted).
Previous radiotherapy to thorax (prior breast radiation therapy [RT] is permitted).
Prior radiation therapy precluding SBRT
Patients currently receiving radiation therapy, or who have received radiation within 2 weeks from the start of therapy
Prior radiation therapy =< 14 days prior to registration
No prior radiation therapy or radionuclide therapy for the treatment of metastasis within four weeks prior to enrollment
No prior chemotherapy or radiation therapy; emergent radiotherapy to preserve vital organ function is permitted; participants who receive emergent radiation will not be eligible for window therapy
Prior external beam radiation therapy to the liver
Last radiation therapy within 4 weeks prior starting study treatment, or limited field of radiation for palliation within 7 days of the first dose of study treatment
Prior history of radiation therapy to the affected site
Patients must have failed prior radiation therapy and must have an interval of greater than or equal to 12 weeks from the completion of radiation therapy to study entry
Prior radiation to greater than 25% of the bone marrow or whole pelvis radiation
Study-specific exclusions:\r\n* History of prior radiation to the pelvis\r\n* History of uncontrolled inflammatory bowel disease\r\n* Unable to comply with radiation therapy procedures
Prior radiation to greater than 25% of the bone marrow or whole pelvis radiation
Receiving concomitant chemotherapy, radiation therapy, or immunotherapy during the duration of treatment on protocol
Patients may have received prior radiation therapy; all adverse events associated with prior radiation therapy must have resolved to =< grade 1 prior to registration
Prior radiation therapy to the liver
No prior radiation above the clavicles
Prior therapy: there is no limit on the number of prior surgeries, radiation therapy treatments, radiosurgery treatments, or chemotherapy
Prior external beam radiation therapy (to less than 30% of the bone marrow only) is allowed; at least 28 days must have elapsed since the completion of radiation therapy and the patient must have recovered from side effects; prior treatment with samarium-153 or strontium-86 is allowed if at least eight weeks have elapsed since dosing, and all toxicities have resolved to grade 1; soft tissue disease which has been radiated in the prior 2 months is not assessable as measurable disease
Radiation therapy within 2 weeks prior to first dose
Radiation therapy to a study target lesion within 6 months
Patients who have received radiation therapy, radionuclide therapy or undergone surgery within certain duration (4 weeks) of enrollment
Patients will be excluded if they have had prior radiation to the brain
Patients who have undergone partial breast radiation (duration =< 7 days) prior to registration are eligible; partial breast radiation must be completed prior to 2 weeks before starting protocol therapy; patients who have undergone whole breast radiation are not eligible
Patients undergoing breast conservation therapy (i.e. lumpectomy) must not have any contraindications to radiation therapy
Prior treatment with embolization (including bland embolization, chemoembolization, and selective internal radiation therapy) or ablative therapies is allowed if measurable disease remains outside of the treated area or there is documented disease progression in a treated site; there is no limit on the prior number of procedures; prior liver-directed or other ablative treatment must be completed at least 8 weeks prior to registration; index lesions for the purpose of RECIST 1.1 measurements will not be selected from within the radiation therapy treatment field; however, if there is evidence of disease progression within the radiation treatment field, measurement of the progressing lesions will be documented
Prior palliative radiation therapy to bone sites is allowed as long as it is completed more than two weeks ago
Concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in this protocol
Radiation therapy within the 14 days prior to Day 1.
Prior treatment with chemotherapy or radiation for pancreatic cancer or prior treatment with radiation for other diagnoses to expected pancreatic cancer treatment fields.
Radiation therapy within 2 weeks prior to first dose. Localized radiation therapy within 1 week prior to first dose.
Prior radiation therapy of any kind is allowed
Untreated central nervous system metastases; patients are eligible if they are clinically stable, off all steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, stereotactic radio surgery) ending at least 2 weeks prior to enrollment, or after surgical resection performed at least 2 weeks prior to enrollment
Recipients of prior abdominal radiation therapy (focal splenic radiation is acceptable)
Prior radiation or radiosurgery to the involved level of the spine
Patients must have undergone local treatment via radical prostatectomy\r\n* Patients who have received primary radiation therapy followed by a salvage radical prostatectomy are eligible\r\n* Patients who have had post-operative radiation therapy for presumed locally recurrent disease are eligible
Must be a candidate for surgery and/or radiation therapy
Patients will be ineligible if any prior therapeutic radiation therapy > 200 cGy has been delivered to the target volume
Patients must be >= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery; a confirmation (written or verbal) that there is no risk of surgical complications from a patient’s surgeon has to be obtained prior to starting therapy in patients with a history of major surgery within past 6 weeks; patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol; for biologic/targeted agents patients must be >= 5 half-lives or >= 3 weeks form the last dose (whichever comes first)
The last radiation therapy within 4 weeks prior to starting study treatment, or limited field of radiation for palliation within 7 days of the first dose of study treatment.
Patients receiving palliative radiation will be eligible after a wash-out period of 2 weeks between finishing radiation and initiation of study drugs; palliative radiation will not be allowed during cycle 1 of treatment but is permitted in this study during following cycles as long as there are evaluable lesions that are not being irradiated
Prior radiation therapy to the abdomen or pelvis
Endometrial cancer patients must be at least 3 months post-active chemotherapy and/or maintenance therapy treatment but not greater than 5 years post-active chemotherapy and/or maintenance therapy treatment; they must be at least 4 weeks post-radiation therapy (external beam radiation therapy [EBRT] or intravaginal radiation therapy [IVRT]) but not greater than 5 years post-radiation therapy
Prior history of standard dose CNS radiation of 60 Gy in 30 fractions or 59.4 Gy in 1.8 Gy fractions, or equivalent or lower doses\r\n* Patients who have received prior treatment with non-standard radiation therapy (RT) dose and fractionation, interstitial brachytherapy, stereotactic radiosurgery, etc. are eligible as long as the criterion is met or approved by a principal investigator
Currently receiving cancer therapy (chemotherapy, radiotherapy, immunotherapy, or biologic therapy) NOTE: palliative radiation therapy is permitted for non-target lesions that are either new or present at baseline provided total dose does not exceed 30 grays (Gy); however, radiation skin injury has been reported with concurrent use of dabrafenib and radiation
STEP 2 ENROLLMENT AND RANDOMIZATION: concurrent chemoradiation is permitted as consolidative therapy; the following concurrent therapies are permitted: tyrosine kinase inhibitors (i.e. erlotinib) - can be delivered with both hypofractionated (>= 3 Gray [Gy] per fraction) and standard fractionated radiation therapy (< 3 Gy per fraction); platinum-based chemotherapy - standard fractionated radiation therapy (< 3 Gy per fraction)
STEP 2 ENROLLMENT AND RANDOMIZATION: bevacizumab will not be permitted within 2 weeks of the initiation of the radiation therapy course
External beam radiation therapy within 4 weeks of registration is prohibited, or anticipated need for radiation therapy (e.g. imminent pathological fracture or spinal cord compression) within 3 months of registration
Concomitant anticancer therapy, immunotherapy, or radiation therapy (no radiation within prior 2 weeks)
Patient must not have had any prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Patient must not have had radiation therapy within 14 days of enrollment
Cohort 2: Patients received surgery or biopsy and radiation therapy (RT) (including fractionated external beam radiation therapy and/or stereotactic radiosurgery), which was completed >= 6 months prior to enrollment, and have a baseline MRI scan within 4 weeks prior to the first vaccine that shows stable disease or regression
Patients who develop a recurrence or progression (WHO criteria) of an MPNST in a previously radiated field may be enrolled if it has been at least 4 weeks since the last dose of radiation therapy
Patients previously treated with radiation therapy to the thoracic or lumbar spinal levels of involved disease will not be included
Prior radiation to sites other than the brain is allowed, if completed at least 2 weeks before treatment and provided that all radiation-related toxicities have resolved to =< grade 1
Patients must have been treated previously with radiation therapy and treatment must have been completed at least 8 weeks prior to surgery for catheter implantation
Prior chemotherapy or radiation therapy for any cancer
Patient must have completed any prior cytotoxic chemotherapy or radiation therapy at least 21 days prior to starting the study drug(s), except selective RAF inhibitors (vemurafenib, dabrafenib or LGX818); there is no washout period for prior selective RAF inhibitors; patients must be at least 5 half-lives or 3 weeks, whichever is shorter, from their previous targeted or biologic therapy; local palliative radiation therapy that is not delivered to all target lesions is allowed immediately before or during treatment
Any prior radiation for rectal cancer
Radiation therapy within 2 weeks prior to initiation of study treatment
At least two weeks since receipt of any biological therapy, chemotherapy, and/or radiation therapy
Prior radiation to the esophagus
Prior mediastinal radiation
Any prior chemotherapy, targeted/biologic therapy, or radiation for treatment of the patient's pancreatic tumor
Prior radiation therapy to the bladder
Patients may have received prior radiation therapy or surgery; however, at least 21 days must have elapsed since completion of radiation therapy or surgery and patient must have recovered from all side effects at the time of registration
Concomitant anticancer therapy, immunotherapy, or radiation therapy (no radiation within prior 4 weeks)
Prior radiotherapy to the region of the study cancer:\r\n* Prior radiation therapy for a different cancer or disease process is allowed, provided there will be no overlap of radiation therapy fields between the participant’s prior and current course of radiation therapy, radiotherapy was completed more than four weeks from first fraction of proton therapy administered in this study, and the participant has recovered to grade =< 1 toxicity related to prior radiotherapy
Patients receiving whole brain radiation within 14 days prior to the first dose of study drugs will be excluded; NOTE: patients receiving palliative radiation (other than whole brain) before or during treatment may still be eligible as long as there are evaluable lesions that are not being irradiated
Patients must be at least 28 days from last radiation therapy dose, surgery, or tumor embolization prior to the first dose of pazopanib/PCI-24781
Intraventricular chemotherapy or radiation therapy within 4 days of starting treatment
Current or prior radiation therapy to the prostate
All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study
Prior history of radiation or chemotherapy for MCL
Patients in cohort 1 may not receive chemotherapy, monoclonal antibodies (other than RANK-ligand inhibitors being used for bone protection), HER2 targeted therapy such as lapatinib, or radiation therapy in the 3 weeks before the first injection, during the injection period or for at least 2 weeks after the last injection; in cohort 2, patients may not receive cytotoxic chemotherapy or radiation therapy in the 3 weeks before the first injection, during the injection period or for at least 2 weeks after the last injection; patients may have received prior radiation including for brain metastases
Patients must have no prior chemotherapy or radiation therapy for lymphoma
Patients who have received previous chemotherapy or radiation therapy to treat the current disease
Radiation to any area of the body < 28 days prior to randomization
Prior radiation therapy (RT) within 2 months of study entry
Any prior chemotherapy or radiation for treatment of the patient’s pancreatic tumor
For all patients, >= 4 weeks must have elapsed for local external beam radiation therapy (XRT); >= 6 months must have elapsed if prior radiation to >= 50% of the pelvis or if substantial bone marrow irradiation; patients with a history of prior radiation with field including the heart (i.e. mantle) will be excluded
Patients must have been previously treated with radiation therapy and temozolomide (bevacizumab-naive - groups 1 and 3) or radiation therapy, temozolomide and bevacizumab (bevacizumab-exposed -groups 2 and 4); therapy with these agents may be given together or sequentially in the past
For bevacizumab-naive patients (groups 1 and 3) a minimum of 6 months must have elapsed since completion of radiation therapy for study entry, and there is no minimum time since completion of last chemotherapy; for bevacizumab-exposed patients (groups 2 and 4) no minimum time since completion of last radiation therapy, biologic agents, or chemotherapy will be required for study entry
Patients currently receiving radiation therapy or those having received radiation within 4 weeks of study entry
Previous radiation treatment that includes the liver in the main radiation field
No prior systemic therapy for lymphoma including chemotherapy or immunotherapy. Patients may have received involved-field radiation therapy which has been discontinued at least 4 weeks prior to treatment in this study.
Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%; (ongoing small field radiation therapy for palliation only is allowed)
Previous therapeutic radiation therapy (XRT) to the liver as part of involved-field radiation
Information on previous radiation treatment, including total dose and fractionation must be available; additional information including radiation fields and dose-volume-histogram or isodose lines is preferable
Radiation therapy to brain for DIPG that was completed at least 10 months prior to planned reirradiation
Prior radiation of greater than 60 Gy to > 20% of brainstem
Major surgery or radiation treatment < 4 weeks prior to enrollment; in addition, cannot have received radiation to the thorax or gastrointestinal tract within three months of the first dose of study treatment
No prior radiation therapy, surgery, or other local therapy for target brain lesions
At least one measurable site of disease (>= 1.5 cm) outside of the planned palliative radiation therapy field
Radiation therapy for splenomegaly within 6 months prior to study entry
History of urological surgery or procedures predisposing to genitourinary (GU) complications after radiation (will be determined by radiation oncologist)
Prior history of fractionated radiation therapy
Prior radiation therapy to the brain
DIPG patients only (enrollment plan 2 and 3)\r\n* Diagnosis of diffuse intrinsic pontine glioma (DIPG) by magnetic resonance imaging (MRI); biopsy will not be required for study enrollment\r\n* Completion of standard radiation therapy (not to exceed 5580 centigray [cGy]) with a post radiation therapy (RT) MRI that shows no disease progression when compared with pre-RT MRI; all patients must be treated with intensity modulated radiation therapy (IMRT) or an equivalent conformal technique; the clinical target volume will be defined as the gross tumor volume (full extent of tumor visible on MRI) plus 1 cm margin; patients from an outside institution who are referred after the start of radiation therapy may complete initial radiation therapy at their home institution as long as dosage guidelines are met and the total dose does not exceed 5580 cGy at the time of study registration\r\n* Able to begin vaccination 4 weeks (+/- 1 week) of completion of standard radiation therapy\r\n* Age 18 months and older
Patients who have received prior radiation or chemotherapy may be enrolled on this study
Palliative radiation to bony metastases within 2 weeks prior to initiation of ipatasertib
Prior radiation therapy to the abdominal area which would overlap with the proposed area of treatment
Patients will be ineligible if any prior therapeutic radiation therapy > 200 cGy has been delivered to the target volume
Patients who received investigational chemotherapy prior to radiation therapy are excluded from this study
In order to prevent registering patients with pseudo progression rather than true disease progression, patients must not have received any form of cranial radiation within 12 weeks of study entry; NOTE: patients who have received cranial radiation within 12 weeks of study entry will be allowed to register to trial only if either progressive disease is confirmed via biopsy or there is a new area of enhancement consistent with recurrent tumor outside the radiation field (defined as the region outside the high-dose region or 80% isodose line)
Prior chemotherapy, radiation therapy, immunotherapy, or biotherapy for current breast cancer.
Prior intracranial radiation therapy (whole brain radiation therapy, stereotactic radiosurgery, gamma knife, or equivalent) is allowed, but not required
Patients with no prior treatment with intracranial radiation therapy (ICR) may be included unless ICR is emergently indicated (in consultation with a local therapist, i.e. neurosurgeon or radiation oncologist)
Prior radiation to maximally tolerated levels to any critical normal organ, or > 20 Gy prior radiation to large areas of the bone marrow (e.g., external radiation therapy to whole pelvis)
Any prior radiation therapy must be completed at least 4 weeks prior to registration
Patients must be >= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery; patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol; for biologic/targeted agents patients must be >= 5 half-lives or >= 3 weeks form the last dose (whichever comes first)
If palliative radiation to non-breast sites is required prior to initiation of systemic therapy, scans may be completed within 8 weeks prior to or 4 weeks following the start of radiation therapy
Patients must be judged to be candidates for complete resection with free margins followed by radiation therapy (if radiation therapy is indicated)
If radiation was previously received, the measurable disease must be outside the previous radiation field, unless this area has demonstrated evidence of radiographic growth
No prior radiation therapy or chemotherapy
the radiation field does not encompass a target lesion
No prior radiation therapy to > 25% of bone marrow forming bones (i.e., pelvis) within 30 days prior to registration for protocol therapy. See Study Procedures Manual to calculate percent of prior radiation.
If chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation therapy
Previous breast radiation on either side or thoracic radiation on the ipsilateral side
Subject may have received prior radiation therapy (except to inguinal region) but must have completed such therapy prior to enrollment
Patients may receive concurrent radiation therapy to painful sites of bony disease or areas of impending fracture as long as the radiation therapy is initiated prior to study entry and sites of measurable and non-measurable disease outside the radiation therapy port are available to follow; patients who have received prior radiation therapy must have recovered from toxicity of the prior radiation therapy
Patients who have previously been treated with brain irradiation to the region that would result in overlap of the radiation fields
Major surgery, locoregional therapy, or radiation therapy within four weeks of the first dose of ARQ 087
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Radiation within 14 days of starting study treatment
A history of radiation pneumonitis in the radiation field (fibrosis) is permitted provided that symptoms have resolved
Prior chemotherapy, targeted small molecule therapy, or radiation therapy for current diagnosis of sarcoma
Prior radiation therapy in excess of 20 Gy to the site of the current diagnosis of sarcoma. No overlap with prior radiation fields in excess of 20 Gy is allowed.
Prior radiation to the liver (prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration)
Has received prior chemotherapy, targeted therapy, and radiation therapy within the past 12 months.
Any prior radiation therapy must be discontinued at least four weeks prior to registration
Radiation therapy within 2 weeks prior to first study drug administration.
Patients should be at least four weeks from the last day of therapeutic radiation or cytotoxic chemotherapy or from antibody therapy, or at least five half-lives from non-cytotoxic targeted or biologic therapy; patients may have received palliative radiation immediately before (or during) treatment provided radiation is not to the only target lesion available
No prior radiation to the thorax that would overlap with the current treatment field, prior radiation to other areas is allowed
Patients may receive palliative radiation therapy before or during treatment on protocol, provided that there is measurable or evaluable disease out of the radiation field; patients may receive palliative radiation therapy, if needed, 48 hours after last dose of investigational drug; in addition patients may be enrolled on trial seven days following palliative radiation; we will closely monitor for the appearance of radiation recall reactions; hormonal therapy may continue in patients who have been on such treatment for three months or longer
Previous external beam radiation therapy to the pelvis. Previous external beam radiation therapy for bony disease to the cranium, mediastinum, and axilla, or to two or to more than 3 vertebral bodies
Patients with prior radiation therapy will be excluded
Prior thoracic radiotherapy that would lead to overlap with the current radiation treatment field
Participants or their legal guardian must sign consent prior to the initiation of radiation therapy
Patients will be ineligible if any prior therapeutic radiation therapy > 200 cGy has been delivered to the central nervous system
Patients will be ineligible if chemotherapy was completed >= 1 year from the planned start date of radiation therapy or if the patient is referred for radiation therapy after a relapse following a regimen with chemotherapy alone
History of radiation or chemotherapy
Prior radiation therapy is allowed provided exposure does not exceed an area of 25% of marrow space and occurred ? 6 weeks prior to the first dose of MEDI-551 (Arm A only)
No previous radiation treatment to the head (unless the ports for that radiation entirely excluded the brain) for any condition
Previous treatment with definitive surgery or radiation therapy or both
Patients who have received prior radiation therapy to the brain for any reason
Radiation therapy =< 2 weeks prior to registration
current symptomatic radiation proctitis requiring creams;
Use of concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol
Patients must have shown unequivocal evidence for tumor recurrence or progression by MRI scan and should have failed radiation therapy. The scan done prior to study entry documenting progression will be reviewed by the treating physician to document changes in tumor dimension to confirm recurrence. Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis.
Adequate recovery of drug related toxicities, surgery or radiation therapy
Patients who have already received > 45 gray (Gy) to the craniospinal radiation or > 72 Gy focal brain radiation
Radiation therapy within the last 4 weeks prior to randomization(with exception of palliative radiotherapy)
Craniospinal radiation therapy (XRT) is prohibited during protocol therapy; no washout period is necessary for radiation given to non-CNS chloromas; >= 90 days must have elapsed if prior traumatic brain injury (TBI) or craniospinal XRT
Patients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period
Prior radiotherapy within 2 weeks of therapy; Must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.
Radiation/chemotherapy within 21 days
Prior radiotherapy to the pelvis or abdomen that would result in overlap of radiation therapy fields
Never received radiation therapy at index level(s) (following consult with radiation oncologist re: conventional treatment options) OR Received radiation therapy without adequate relief from metastatic bone pain as determined by the patient and treating physician, their treating physician would not prescribe additional radiation treatments, or refuse additional radiation therapy,
Radiation therapy was completed on the index vertebra(e) ? 28 days before enrollment,
Ongoing radiation therapy, radiation therapy administered within 30 days of enrollment.
Treatment with full field radiation therapy within 4 weeks or limited field radiation therapy within 2 weeks prior to the first dose of study medication
Patients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period.
At least 12 weeks must have elapsed since administration of craniospinal or hemipelvic radiation.
Plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period.
Recurrent or metastatic disease that is not amenable to therapy with curative intent (surgery or radiation therapy with or without chemotherapy)
Radiation therapy (except for localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture): ?4 weeks
Radiation therapy (localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture) ?2 weeks
Prior palliative radiation therapy less than 2 weeks prior to administration of study treatment or prior whole brain radiation therapy (WBRT) less than 4 weeks prior to study treatment
History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
No prior radiation therapy to the chest, breast or supraclavicular fossa that would limit radiation delivery to the full prescription dose
Radiation treatment within 2 weeks.
Radiation therapy within 2 weeks prior to the first dose of study medication
Patients with stable brain metastasis are eligible provided they received definitive therapy (external beam radiation therapy [EBRT], gamma knife, surgery) no sooner than 14 days prior to registration and are off all steroids
Localized radiation therapy within the last 14 days
Prior CNS directed radiation treatment completed within 3 weeks prior to registration
Prior treatment with chemotherapy or radiation for pancreatic cancer or prior treatment with radiation for other diagnoses to expected pancreatic cancer treatment fields.
Patients who have previously received radiation therapy to the chest or abdomen such that there would be overlap between the previous and current radiation field
Prior radiotherapy to the thorax such that composite radiation would significantly over-dose critical structures, either per estimation of the treating radiation oncologist or defined by failure to meet normal tissue tolerance constraints
Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) within 28 days of starting study treatment; palliative radiation is allowed
Carcinoma requiring systemic chemotherapy or radiation therapy
Prior radiotherapy to the region of the liver that would result in overlap of radiation therapy fields
Radiation to primary tumor prior to enrollment in this study
Any prior external beam radiation to the pelvis
The time interval between CNS radiation, whole brain radiation, spinal cord radiation, or radiosurgery, and initiation of protocol specified chemotherapy must be at least 1 week
Therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment; or palliative radiation within 2 weeks before study drug treatment
Previous radiation allowed provided that 2 weeks has passed since radiation and/or the patient has recovered from the side effects
Ongoing radiation therapy or radiation therapy administered within 2 weeks of enrollment
Ongoing radiation therapy, radiation therapy administered within 30 days of enrollment
Insufficient time from last prior regimen or radiation exposure (washout period of 4 weeks)
Prior radiation therapy is allowed but must have been completed >= 4 weeks prior to study entry; patients with history of prior radiation to the liver including radio-labeled microspheres cannot take part in this study
Patients must have had their last fraction of:\r\n* Craniospinal irradiation (> 24 Gray [Gy]) or total body irradiation > 3 months prior to registration\r\n* Local palliative external beam radiation therapy (XRT) (small port) >= 2 weeks \r\n* Other substantial bone marrow (BM) radiation >= 6 weeks must have elapsed
Prior radiation therapy to the prostate
Previous radiation treatment to the tumor
Prior radiation therapy to the bladder
Any prior treatment (chemotherapy, radiation) for pancreatic cancer
Prior external beam radiation therapy to the liver
Radiotherapy: 3 weeks must have elapsed since radiation therapy (XRT)
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Patients must be clinically suitable for radiation therapy
Patients who have undergone prior ablation treatment or radiation therapy of the index tumor
Subjects will not be treated with any radiation, chemotherapy, or investigational agents while enrolled in this protocol.
Received maximal radiation therapy
Radiation therapy or surgery in the past 4 weeks
Prior breast radiation therapy
Prior radiation therapy to the brain
Prior chemotherapy, immunotherapy or radiation for pancreatic cancer
Patients may not have had radiation therapy within the last 4 weeks prior to initiation of study treatment.
Receipt of prior chemotherapy (CT) or radiation therapy (RT) for PTCL, other than a single allowed CHOP regimen, except:
=< 2 weeks since radiation therapy
TREATMENT: Patients with no more than 3 intracranial metastases, which have been definitively treated by surgery or radiation therapy may be eligible for the study, provided there is no evidence of active disease for at least 2 months and no requirement for anticonvulsant therapy or steroids following treatment
Patients with histologically confirmed advanced NSCLC, SCLC and thymic malignancies for whom surgical resection or multimodality therapy with curative intent is not feasible; for patients with stage III NSCLC, who can be encompassed by a radiation port, definitive external radiation therapy (XRT) should have been performed first when possible
Prior radiation treatment to the HN region
Treatment with any chemotherapy, radiation therapy, biologics for cancer, or investigational therapy within 14 days of randomization
Prior Therapy: \r\n* Prior Chemotherapy: Patients who have had a prior chemotherapy regimen for advanced or metastatic disease are excluded\r\n* Prior Radiation Therapy: Patients may have received prior radiation therapy for treatment of endometrial carcinoma; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy, alone or with chemotherapy as a radiation sensitizer; all radiation therapy must be completed at least 4 weeks prior to the first date of study therapy, the prior radiation field, radiation dose, number of fractions and prior radiation start and stop dates must be provided at registration
Radiation therapy within 2 weeks.
Has had prior chemotherapy or radiation.
Prior treatment including surgery, chemotherapy or radiation therapy for the current primary breast cancer
The subject has received radiation therapy:\r\n* To the thoracic cavity or abdomen within 3 months before the first dose of study treatment, or has ongoing complications, or is without complete recovery and healing from prior radiation therapy\r\n* To bone or brain metastasis within 3 weeks before the first dose of study treatment\r\n* To any other site(s) within 28 days before the first dose of study treatment
Radiation and surgery within 4 weeks prior to treatment in this study
Palliative radiation, including whole brain radiation therapy (WBRT), is allowed prior to enrollment as long as it is completed > 2 weeks from initiation of study treatment, and provided patient has recovered from treatment toxicities to =< grade 1
All previous cancer therapy including chemotherapy, radiation, hormonal therapy and surgery, must be discontinued ?2 weeks prior to registration.
Concurrent radiation therapy, except for palliation of a single painful bone lesion or fracture.
Patients currently receiving chemotherapy or radiation therapy.
Any radiation therapy =< 28 days prior to registration
Prior radiation therapy completed >= 4 weeks prior to enrollment
Patients must have received prior radiation treatment to the chest; records of prior radiation treatment must be available
Patients must have received prior chest radiation at least 3 months prior to enrollment in this trial; radiation treatment to other body sites not overlapping with current radiation fields are allowed within the 3 months period (example, brain radiation is allowed)
Patients must be able to receive proton radiation treatment
Patients who have never received radiation to the chest
Patients who received radiation to the chest within the past 3 months (in a region that overlaps with current radiation fields)
Palliative radiation to bone metastases within 2 weeks prior to Day 1
Prior radiation to lung fields
The subject has received radiation therapy:\r\n* To the thoracic cavity, abdomen or pelvis within 3 months of the first dose of study treatment or has with ongoing complications or is without complete recovery and healing from prior radiation therapy\r\n* To bone or brain metastasis within 14 days of the first dose of study treatment
Patients in whom surgery or radiation therapy may be impractical
History of radiation therapy to ipsilateral breast
Radiation for symptomatic lesions within 14 days of study enrollment
Receipt of radiation therapy within 3 weeks of scheduled dosing day 1, unless the radiation comprised a limited field to non-visceral structures (eg, a limb bone metastasis).
Any prior chemotherapy or radiation for treatment of the patient’s pancreatic tumor
Have had prior dissection and/or radiation in pelvis.
At least two weeks since receipt of any biological therapy, chemotherapy, and/or radiation therapy
>= 2 weeks must have elapsed for local palliative radiation therapy (XRT) (small port) and enrollment on study; at least 24 weeks must have elapsed since prior total body irradiation (TBI), radiation to >= 50% of pelvis, or craniospinal radiation; >= 6 weeks must have elapsed if the patient has received other substantial bone marrow (BM radiation); >= 6 weeks for prior metaiodobenzylguanidine (MIBG) therapy; for patients with only one site of measurable or evaluable disease, radiation must not have been given to that site unless that site has demonstrated clear progression after radiation or at least 2 months have elapsed since radiation and their remains evidence of viable tumor on biopsy, fludeoxyglucose (FDG) pet scan or MIBG scan
Washout of at least 2 weeks from the most recent radiation treatment prior to C1D1
Radiotherapy: At least 28 days must have elapsed since and radiation therapy.
Prior radiation to the chest wall or mediastinum if the radiation field involves the heart
Prior chemotherapy or radiation (within 30 days prior to the procedure or the duration of the subject's enrollment);
Patients who have had anti-cancer systemic therapy within 2 weeks prior to entering the study; radiation is allowed
No history of prior whole brain radiation
Radiation while on study is not allowed EXCEPT to a localized region for pain control
After radiation therapy (e.g., external beam radiation, brachytherapy, or salvage/adjuvant radiation therapy after surgery), two post radiation PSA measurements level of nadir plus 2.0 ng/mL at least one week apart.;
Active malignancy currently undergoing chemo or radiation therapy; hormone therapy is acceptable
have stable neurologic status post administration of local therapy (surgery or radiation) for a minimum of 2 weeks following completion of the definitive therapy.
Subject has had radiation therapy within 4 weeks prior to the first study dose.
Any site of disease that is not amenable to definitively local therapy including surgery or radiation therapy
Any medical co-morbidities that would preclude surgery or radiation therapy
Progressive disease after temozolomide and radiation therapy (in \first relapse\)
At least 28 days since chemotherapy or radiation
Patient must have consulted with a radiation oncologist who is planning radiation; their radiation oncologist should have documented plans to administer a dose of at least 30 Gy in 5 or fewer fractions
Patients receiving systemic anticancer therapy (chemotherapy, “biologics”, immunotherapy) less than 2 weeks prior to starting radiation
Subject has received radiotherapy ? 4 weeks or limited field radiation for palliation ? 2 weeks prior to starting investigational product (IP), and/or from whom ? 30% of the bone marrow was irradiated. Prior radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.
Prior liver directed radiation
Prior radiation therapy to the upper abdomen or liver at the discretion of the treating radiation oncologist could impair delivery of the prescribed radiation treatment
Radiation therapy and surgery must be completed 4 weeks prior to therapy, except for limited field radiation therapy, which must be completed 2 weeks before therapy.
Must have stable neurologic status following local therapy (surgery or radiation) for at least 2 weeks after completion of the definitive therapy AND
Radiation is integral to the primary treatment of glioma; all participants on this study must have had prior radiation to the brain; radiation must have been completed 14 days prior to first study treatment
Any radiation within 2 weeks prior to starting treatment on protocol
Recovered from prior radiation therapy or surgery
Previous therapies: prior radiation therapies, immunotherapies, and investigational therapies are allowed as follows:\r\n* Radiation: prior radiation therapy is allowed with the following conditions:\r\n** Patients who have received minimal radiation therapy (=< 5% of their total marrow volume) must have completed it >= 2 weeks prior to the initiation of study treatment\r\n** Patients who have received radiation therapy that constituted > 5% but < 50% of their total marrow volume must have completed it >= 4 weeks prior to the initiation of study treatment\r\n** Patients who have received prior radiation to 50% or more of their total marrow volume will be excluded\r\n** Patients may be biopsied while undergoing radiation therapy as long as biopsy site is not in the radiation portal; however, they still have to wait the required amount of time from radiation to treatment even though the tumor board may have already occurred and a treatment plan assigned\r\n* Other therapies: prior investigational or targeted therapies and immunotherapies may be allowed following discussion with the principal investigator; if the principal investigator (PI) deems the prior treatment acceptable, patients must not have received these therapies for 28 days or five half-lives of the drug (whichever is lesser) prior to the initiation of study treatment and must have full recovery from any acute effects of these therapies; prior therapy with mitogen-activated protein kinase (MEK) inhibitors will not be allowed
Radiation therapy, local therapy (except for surgical re-resection), or systemic therapy following first recurrence/progressive disease. Excluded local therapies include stereotactic radiation boost, implantation of carmustine biodegradable wafers (Gliadel), intratumoral or convection-enhanced delivery administered agents, etc.
Hepatic radiation, chemoembolization, and radiofrequency ablation < 4 weeks prior to study day 1.
Palliative radiation therapy to metastatic sites of disease < 2 weeks prior to study day 1.
within 2 weeks prior to the first dose of KTN3379 in the case of palliative radiation therapy.
Subject has had radiation therapy within 4 weeks prior to the first study dose
Palliative radiation within 2 weeks prior to Day 1.
Any external beam radiation therapy within 6 weeks prior to the first dose of the study drug
Received treatment with any systemic chemotherapy, experimental agent, or radiation therapy (with the exception of palliative localized radiation therapy) following completion of treatment on the ONT-10-001 study
No prior chemotherapy, hormonal therapy, or radiation therapy for this cancer
Patients receiving palliative radiation to skeletal metastases may be registered as early as 1 week after completion of radiation therapy provided toxicities are =< CTC grade I at the time of registration
Radiation to primary tumor prior to enrollment in this study
Radiation treatment within 2 weeks.
Focal radiation therapy within 14 days prior to randomization; radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to randomization (i.e., prior radiation must have been to less than 30% of the bone marrow)
The subject has received radiation therapy within 14 days of the first dose of study treatment
Ongoing radiation therapy and/or radiation therapy administered within 28 days of enrollment or ongoing radiotherapy-related toxicities.
PART II: Oncology participants must be unwilling or ineligible for further radiation or chemotherapy at the time of enrollment into study
PART II: Currently receiving chemotherapy or radiation therapy
History of radiation therapy to the chest
Prior primary or salvage radiation or not a candidate for salvage radiation due to patient preference or clinical assessment based upon disease characteristics and/or patient co-morbidities
Minimum of 14 days have elapsed since any prior radiation therapy, with recovery from any adverse events.
Radiation therapy or immunotherapy in the previous four weeks; localized radiation therapy within 1 week prior to first dose
Radiation therapy within 4 weeks before first dose
Patients must have histologic proof of a malignancy suitable for radiation therapy
Patients must have received prior external beam radiation therapy to the region proposed for HDR brachytherapy treatment; evaluation of doses previously delivered to spinal cord/cauda equina, pelvis, and other critical structures (bowel, kidneys, rectum) will be taken into consideration\r\n* If repeat irradiation would exceed any normal tissue constraint set by Memorial Sloan Kettering Cancer Center (MSKCC) Radiation Oncology Department dose constraint criteria, the patient will potentially be eligible\r\n* If the total prior radiation dose to the cord or pelvis exceeds 100 Gy biological equivalent dose (BED) equivalent, the patient will be potentially eligible, where a total of 100 BED Gy equivalent is determined by the biological equivalent dose (BED) calculation
All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study
Therapeutic or palliative radiation therapy within 30 days of starting treatment
Have received chemotherapy, radiation therapy or other anticancer treatment other than crizotinib within 3 weeks prior to the first dose of study drug
Progressive disease if treated with chemotherapy, radiotherapy, surgery or immunotherapy. If prior radiation was given, the measurable disease should be outside the radiation port. Unequivocal progression of HCC/BTC lesions previously treated with catheter-based therapy including transarterial chemoembolization or radioembolization is allowed.
Patients who have undergone radiation within the past 4 weeks
Prior treatment for MM (prior radiation therapy or dexamethasone up to 160 mg for spinal cord compression is allowed. Other limited field radiation involving ? 1/3 of the pelvic area is also allowed)
Patients must not have received radiation for a minimum of two weeks prior to study enrollment.
Radiation therapy to any Study Lesion within 6 weeks of initial study treatment.
Radiation directed at target lesion within 28 days of registration
Prior radiation therapy to the lungs
Prior external beam radiation therapy to the liver
Patients must have prior histologically proven glioblastoma that is progressive or recurrent following radiation therapy +/- chemotherapy
The subject has received radiation therapy within 4 weeks (=< 2 weeks for palliative radiation therapy)
Radiation therapy for bone or brain metastasis within 2 weeks, any other external radiation therapy within 4 weeks of first dose of study drug; systemic treatment with radionuclides within 4 weeks; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible
Prior radiation to the liver (prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration)
Patients that have had prior ipsilateral chestwall/thoracic radiation
Treatment with prohibited medications (eg, concurrent anti-cancer therapy including other chemotherapy, radiation (local radiation for palliative care is permitted), hormonal anti-cancer treatment, biologic therapy, or immunotherapy) < 28 days prior to the first day of study treatment
Certain drugs or radiation within 2-4 weeks of enrollment
More than four weeks must have elapsed since any prior radiation therapy
Focal radiation therapy within 7 days prior to randomization. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to randomization (i.e., prior radiation must have been to less than 30% of the bone marrow).
Patients must have had at least 1 prior systemic chemotherapy (not just steroids or local radiation); last chemotherapy or radiation must be at least 4 weeks prior to enrollment on this study; patients who decline other potentially curative therapy may be eligible; prior radiation therapy must not have been to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
Prior surgery for the current or another lung cancer is allowed as is prior radiation therapy
Patients may have had radiation therapy, but must have progressive disease after radiation therapy if the lesions to be treated are within the radiation field
Received treatment with radiation therapy or investigational therapy =< 28 days prior to registration
Received local palliative radiation therapy <14 days prior to the first dose of study medication
Unlimited prior treatment with radiation or chemoradiotherapy
Patient who have received chemotherapy, immunomodulatory drugs (e.g., lenalidomide, thalidomide or pomalidomide), immunotherapy, radiation therapy, or any investigational drug(s) within 14 days before enrollment or who have not recovered from the side effects of the therapy to at least grade 1; localized radiation therapy to a single site within 7 days is acceptable
If GBM, greater than or equal to 12 weeks from radiotherapy, or 4 weeks if a new lesion, relative to the pre-radiation MRI, develops that is outside the primary radiation field.
Patients are candidates for stereotactic radiosurgery as determined by the treating radiation oncologist; intra-cranial tumors must measure 4 cm or less in greatest dimension; patients may have received prior neurosurgical resection(s) of intra-cranial metastases if their operation(s) was (were) completed at least 28 days prior to starting study drug; patients may have had prior whole brain radiation therapy (WBRT) if it was completed at least 1 month prior to study enrollment
Prior radiation or surgery is allowed, but should be finished at least 2 weeks prior to study enrollment; if a participant has prior radiation therapy, at least one measurable lesion outside of the radiation field should be available for the evaluation of response to chemotherapy
Patients must not receive concomitant radiation with chemotherapy if they do not have any measurable lesions outside of the radiation field
Therapeutic or palliative radiation therapy within 2 weeks prior to enrollment
Previous radiation therapy is allowed to less than 25% of the bone marrow, but should have been limited and must not have included whole pelvis radiation.
Patients with a prior history of chemotherapy, hormonal ablation therapy and/or radiation therapy.
Prior radiation to ? 30% of bone marrow or any radiation therapy within 28 days prior to randomization
Prior radiation therapy within the last 4 weeks; prior radiation therapy to indicator lesion (unless objective disease recurrence or progression within the radiation portal has been documented since completion of radiation)
Use of concomitant chemotherapy, investigational agents, radiation therapy, or immunotherapy other than as specified in the protocol
Prior radiation for NHL, except for a single course of locally delimited radiation therapy with a radiation field not exceeding 2 adjacent lymph node regions
Has received any external radiation therapy within 28 days prior to enrollment.
Patients must be at least 4 weeks from the completion of any radiation therapy
Prior treatment with other chemotherapeutic agents, trastuzumab, endocrine and radiation therapy is permitted;
External radiation therapy (XRT): Must not have received XRT within 3 months prior to study entry for craniospinal irradiation (> 24 Gy) or total body irradiation or if >= 50% radiation of pelvis; >= 8 weeks for local irradiation to primary tumor; >= 2 weeks for focal irradiation for symptomatic metastatic sites
Patients that have undergone PDT, chemotherapy or radiation therapy within the past 6 months will not be considered for enrollment
Currently receiving other GCTB specific treatment (eg, radiation, chemotherapy, or embolization)
Radiation therapy involving chest (axilla excluded), mediastinum, or abdomen (i.e., small or large bowel) completed within 10 weeks of transplant admission; radiation therapy shortly before the start of the preparative regimen is allowed
No prior medical therapy (chemotherapy, immunotherapy, biologic or targeted therapy) or radiation therapy for MM, unless locoregionally recurrent; if recurrent, no prior medical or radiation therapy is allowed for the latest recurrence
Prior radiation therapy for TCC
Patients may be enrolled if they have had prior palliative radiation therapy; however, this has to have been commenced within 30 days of starting androgen deprivation
Must have recurrent or metastatic disease that is not amenable to therapy with curative intent (surgery and/or radiation therapy with or without chemotherapy).
Has completed pre-RE angiogram up to 3 weeks prior to Y-90 therapy\r\n* Lung shunt fraction =< 20% and anatomy amenable to intra-arterial radiation delivery\r\n* Extrahepatic vessels deemed at risk for radiation injury were successfully embolized
Prior selective internal radiation to the liver
Has received prior chemotherapy for any malignant disorder, thoracic radiation therapy or prior surgical resection of an esophagogastric tumor
Prior radiation of cholangiocarcinoma or gallbladder carcinoma; NOTE: adjuvant radiation therapy is allowed if completed > 6 months prior to the start of registration
Patients with intracranial metastases, which have been treated by surgery or radiation therapy, may be eligible for study provided there is no evidence of active disease and no requirement for anticonvulsant therapy or steroids following treatment
Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =< 2 weeks prior to cycle 1 day 1
Have received between 1-2 prior cytotoxic treatments, not to include belinostat, RDHAP, or autologous or allogeneic stem cell transplant; radiation which was pre-planned to occur at the conclusion of systemic cytotoxic therapy will not be considered a separate prior therapy; radiation administered for potential recurrent or relapsed disease will be considered a separate prior therapy
Prior dose of radiation overlapping the treatment field determined by a study Radiation Oncologist to represent unacceptable risk for additional radiation to be targeted to the field
Radiation therapy within prior 6 months
No prior chemotherapy, radiation therapy or immunotherapy for DLBCL; a short course (< 2 weeks) of corticosteroids is allowed for symptom control
Prior radiation therapy for lymphoma
No prior radiation therapy to the chest, neck or axilla
No prior systemic therapy for advanced NSCLC, including chemotherapy, targeted therapy or immunotherapy; prior palliative radiation permitted; prior adjuvant chemotherapy/radiation is permitted
Have received surgery, chemotherapy, and/or radiation therapy
Have completed all surgery, chemotherapy and/or radiation therapy within the last 2-60 months
Patients must not have initiated chemotherapy or radiation prior to registration to this study
Patient has had surgery or initiated radiation therapy (brachytherapy or external beam radiation) or initiated pre-radiation androgen deprivation therapy within the last 12 months
Sarcomas where radiation is not planned preoperatively
Mean esophageal radiation dose > 45 Gy
Diagnosis of diffuse radiation pneumonitis
Completion of all primary therapy (with the exception of ongoing endocrine or trastuzumab therapy), including surgery, radiation, and/or chemotherapy greater than 4 weeks prior to study enrollment
Patients with prior radiation therapy to the treatment site
Men who have undergone radiation therapy alone will be excluded
Scheduled to receive or receiving unilateral radiation treatment for this cancer
Undergoing only palliative (not curative) radiation treatment
Prior mediastinal or mantle radiation >= 5 years prior to enrollment in the study
those for whom their treating physician would not prescribe radiation or additional radiation treatments
patients who refuse additional radiation therapy.
No radiation therapy to targeted (most painful) lesion in the past two weeks Bisphosphonate intake should remain stable throughout the study duration.
Patients must be clinically stable and off treatment (e.g. radiation or chemotherapy) for >= 6 months
Relapsed/refractory disease within a prior radiation field
Participants may have received prior radiation therapy in either the metastatic or early-stage setting; radiation therapy must be completed at least =< 14 days prior to initiation of study therapy
Radiation therapy as cancer therapy within 4 weeks, or palliative radiation to bony metastases within 2 weeks, prior to starting study treatment
Prior radiation is permitted, provided it does not limit the ability to deliver per-protocol radiation in the opinion of the treating radiation oncologist
After prior curative intent treatment for HNC have estimated risk of recurrence >= 40-50% and fall into one of the below categories (A, OR B, OR C, OR D, OR E, OR F); while exact estimation of the risk of recurrence can be difficult the following categories will be included reflecting patients at substantial risk for tumor recurrence or already with early evidence of recurrence:\r\n* A: Any of the below HNC patients are eligible for treatment on this protocol AFTER completion of curative intent therapy:\r\n** HPV(-) HNC: N2C, N3, bulky N2B disease (>= 5 cm LN/tumor conglomerate)\r\n** HPV(+) HNC: N2C, N3, AND >= 10 pack years of tobacco use\r\n** HPV(+) HNC with multilevel nodal involvement, AND bulky N2B disease (>= 5 cm LN/tumor conglomerate), AND >= 10 pack years of tobacco use\r\n** EBV(+) nasopharyngeal carcinoma (NPC) may be eligible if other criteria under A, or alternative criteria B, or C, or D, or E are met\r\n** HNC with supraclavicular or mediastinal nodal involvement (either HPV+/- or EBV+/-) at the time of curative intent treatment and were treated as part of curative intent therapy (e.g. inclusion in the radiation field)\r\n** Residual mass in area of prior tumor that on biopsy does not show residual tumor, is equivocal/not highly-suspicious on imaging (e.g. positron emission tomography/ computed tomography/magnetic resonance imaging [PET/CT/MRI]), but remains of concern, requires close follow-up AND is not resected/amenable to resection OR immediate palliative treatment\r\n** Non-responders to induction chemotherapy (progressive disease [PD] on induction, or lack of tumor shrinkage (< 15% per Response Evaluation Criteria in Solid Tumors [RECIST])\r\n** Interrupted treatment course or lower than intended radiation dose – i.e. interruption of radiation by >= 3 weeks (cumulative), or delivery of =< 50 Gy as part of a radiation based treatment (that was NOT a de-escalation approach)\r\n* B: Patient treated with salvage treatment (i.e. salvage surgery or re-irradiation) for residual or recurrent tumor after prior radiation based therapy (either HPV+ or HPV- or EBV+) AND not a candidate for additional curative intent therapy (for various reasons including poor performance status, comorbidities, refusal of patient, prior radiation or re-irradiation, etc); positive margins or residual tumor may still be acceptable); patients should also not be appropriate for systemic palliative therapy (e.g. in the case of overt disease)\r\n* C: Mx or indeterminate distant lesions that are not appropriate for either local radiation/stereotactic body radiation therapy (SBRT) treatment and also not appropriate for initiation of palliative system therapy (e.g. in the setting of overt metastatic disease); such lesions should be negative/equivocal by PET imaging and if amenable negative by biopsy, but remain of concern and require close follow-up\r\n* D: Oligometastatic disease treated with SBRT or other curative-intent therapy (e.g. surgery or radiofrequency ablation (RFA), etc) for oligometastatic disease\r\n* E: Microscopic or very low volume residual tumor after surgery or radiation based treatment (including salvage treatment or SBRT for oligometastatic disease), AND not a candidate for either additional curative intent therapy (for various reasons including feasibility, poor performance status, comorbidities, refusal of patient, prior radiation or re-irradiation, etc) AND also not a candidate for systemic palliative therapy (for various reasons including microscopic/non-[RECIST] measurable low volume disease); very low volume disease is defined as non-RECIST measurable)\r\n* F: Patients with multiple recurrences or multiple primaries: specifically patients who had malignant or pre-malignant tumors/changes (with severe dysplasia present), who have undergone surgery >= 2 times, and currently do not have an indication for additional (adjuvant) treatment such as radiation, or surgery, or other treatment; this may include multiple recurrences/incidences of early stage tumors or premalignant lesions, however at least one lesion needs to show squamous cell carcinoma on pathology\r\n* There may be additional scenarios for patients that are considered very high risk for disease recurrence and not appropriate for either curative or standard of care palliative therapy; such patients can be considered for enrollment after discussion and approval by the principal investigator (PI) and/or co-PI
Receipt of radiation to the abdomen for any reason during the planned 10-day treatment time
Have not completed surgery, chemotherapy, or radiation treatment associated with their diagnosis; a washout period of a minimum of 6 weeks is required from the last anti-cancer treatment received except hormonal therapy
Subject has received radiation within the past 6 weeks
Initiating focal cranial radiation therapy (photon or proton)
History of prior cranial radiation therapy
Scheduled to receive preoperative therapy (chemotherapy, radiation or chemoradiation) either on or off-protocol
With prostatic cancer at least 2 months after the end of their radiation therapy
No history of radiation therapy to the tumor and/or surgical area prior to the current treatment being studied
History of radiation therapy to the tumor and/or surgical area prior to the current treatment being studied
Plan for post operative radiation therapy
Patients who have had more than 2 weeks of chemotherapy or radiation for this diagnosis of lung cancer
Radiation plan consisting of regional nodal radiation
Patients who require immobilization with a thermoplastic mask for radiation treatment
Definitive radiation treatment with or without concurrent chemotherapy with curative intent; treatment prior to radiation therapy is acceptable (e.g. surgery, chemotherapy)
Completed local definitive treatment (i.e., surgical treatment, chemotherapy and/or radiation therapy)
Undergoing radiation therapy or chemotherapy
Subjects who have had radiation to one or both breasts in the past
Patients receiving radiation therapy with chemo?sensitization
Chemotherapy or radiation therapy within the last 60 days
Have completed all cancer treatment (including surgery, chemotherapy and/or radiation) at least 4 months prior to enrollment
Treatment with primary radiation (brachytherapy or external beam therapy), radiation + androgen deprivation therapy (ADT) or salvage prostatectomy
Patients who did not enroll during their chemotherapy are still eligible to enroll during subsequent hormonal therapy or radiation as long as it within 6 months of diagnosis
Radiation treatment to pelvis
Gynecologic cancer treatment (e.g., surgery, chemotherapy, radiation therapy) was completed within 5 years prior to date of enrollment
Patients anticipated to receive radiation therapy with protons
Previous radiation therapy to the ipsilateral breast
Radiation therapy naive
Diagnosis of breast cancer, received chemotherapy, and scheduled to receive 4 to 6 weeks of radiation therapy (radiation protocol of 40 Gy+)
Previous radiation therapy to the area to be treated with radiation therapy
Receiving palliative radiation therapy
Radiation protocol of 3-dimensional conformal radiation therapy (3D-CRT)/intensity-modulated radiation therapy (IMRT)/image-guided radiation therapy (IGRT)/stereotactic/proton/electron/accelerated fractionation/hyperfractionation/hypofractionation
Disease-based radiation therapy (not total body irradiation)
Have completed treatment with surgery, radiation, and/or chemotherapy
Participants enrolled in a radiation de-intensification protocol
Ongoing chemotherapy, radiation therapy, or other cancer-related treatment
Patients must have CD4 =< 300 cells/mm^3 in the last week (7 days) of standard radiation + temozolomide treatment (58-60 Gy radiation with temozolomide 75 mg/m2 daily during radiation)
Prior radiation to the index spine
Patients who are receiving chemotherapy and radiation therapy
Undergoing chemotherapy or radiation therapy at any time during the study
Patients must have achieved a complete response to induction chemotherapy (+/- thoracic radiation therapy) assessed according to local habits (at least on a chest x-ray) at the time of study entry
Interval from radiation therapy at least 4 weeks and no more than 1 year
Neurologic deterioration (long tract signs, cranial nerve signs or ataxia) consistent with radiation necrosis or radiation induced injury
MR imaging (MRI) with findings considered consistent with radiation induced injury or radiation necrosis as confirmed by the study radiologist
Prior external beam radiation therapy to the brain or whole brain radiation therapy\r\n* Prior single-fraction or fractionated radiosurgery is permitted
Having received chemotherapy with or without radiation therapy
Radiation therapy (RT) completed >= 6 months
Current chemotherapy or radiation therapy; participants in study may still be receiving hormone or Herceptin treatment
Completion of treatment (e.g., chemotherapy, radiation therapy, surgery, etc.) for gynecologic or breast cancer 6 months or greater in the past
Patients scheduled for radiation less than 6 days from enrollment
>= Ten years post-radiation therapy following an accumulated dose of >= 2000 cGY to the heart/chest
Must be referred to radiation oncology clinic
Completed active treatment (e.g., chemotherapy, radiation therapy, surgery) 6 months-5 years\r\nago (current use of endocrine therapy is acceptable)
Are currently being treated or have decided on their treatment process (radical prostatectomy or radiation therapy)
Completed either radical prostatectomy (Group 1 or Group 3) or radiation therapy (external beam radiation therapy or brachytherapy; Group 2 or Group 3) within the past 12 months
Completed either radical prostatectomy or radiation therapy (external beam radiation therapy or brachytherapy) within the past 12 months
Within one year completion of either radical prostatectomy or radiation therapy (external beam radiation therapy or brachytherapy)
Patients suffering from dysphonia after radiation therapy for glottic carcinoma will be included in the study
Patients fewer than 1 year out from completion of radiation therapy will be excluded
Received a therapeutic intervention with at least one of the following modalities: surgery, cytotoxic chemotherapy, biological or targeted agents, radiation therapy (any modality)
Currently undergoing chemotherapy treatment or within 12 weeks of end of chemotherapy (all participants must have had chemotherapy treatment)\r\n* Any radiation received must also be completed prior to randomization (if radiation treatment follows adjuvant chemotherapy, then the patient must be recruited within 12 weeks of end of radiation)\r\n* Maintenance hormonal therapy in women with breast cancer is allowed; see exclusion criteria regarding hormonal therapy in males with prostate cancer
Prior chemotherapy or radiation therapy of any kind for treatment of pancreas adenocarcinoma
Prior radiation therapy is allowed provided that no radiation therapy was administered to the urinary bladder.
Treatment with radiation within 6 weeks
At the time of day 1 of the study, patients must have completed chemotherapy, targeted therapy, investigational therapy, other immunotherapy, radiation therapy or major surgery (requiring general anesthesia) at least 28 days before administration of the first dose of nivolumab; patients undergoing minor surgical procedures and biopsies that do not require general anesthesia may begin receiving study therapy if sufficiently recovered as determined by the treating investigator; patients may have received prior focal radiotherapy for palliation of an isolated site of disease, which must be completed at least 14 days prior to day 1 of the study; palliative (limited-field) radiation therapy is permitted during treatment with study drug(s), if all of the following criteria are met: \r\n* The lesion being considered for palliative radiation is not a target lesion\r\n* Radiation treatment is administered 12 weeks or greater after their first dose of study drug
Have had palliative radiation or biological cancer therapy within 2 weeks prior to the first dose of study drug
Prior radiation therapy above the umbilicus
Patient is not eligible if radiation was given to the only site of measurable disease unless there has been subsequent disease progression at that site, or a biopsy of that site showed viable tumor at least 4 weeks after radiation was completed. Patients must not have received small field (focal) radiation for a minimum of 2 weeks prior to study entry. A minimum of 6 weeks is required following prior large field radiation therapy (i.e. TBI, craniospinal therapy, whole abdomen, total lung, > 50% marrow space)
Radiation induced oophorectomy with last menses >1 year ago
Radiation (except planned or ongoing palliative radiation to bone outside of the region of measurable disease) =< 3 weeks prior to study drug administration date
No previous chemotherapy, endocrine, therapy or radiation therapy with therapeutic intent for this cancer
Plan to receive radiation therapy, or within 3 days of starting radiation therapy
Prior radiation therapy to the ipsilateral breast/nodes or thorax
Neoadjuvant chemotherapy or radiation therapy
For the esophagitis arm, any patient with thoracic malignancies, which will receive radiation alone or concurrent chemo/radiation; radiation dose must be >= 45 Gy; for the esophagitis arm, induction chemotherapy is allowed
Have received radiation therapy or chemotherapy for any condition other than primary HNC
Undergoing chemotherapy or radiation
Scheduled to begin chemotherapy and/or radiation therapy within the next 2 months (excluding surgery only patients)
Patients must not have had previous radiation therapy to the mediastinum or lungs
Receiving chemotherapy, biotherapy, or radiation therapy for cancer
All patients who are receiving chemotherapy and/or radiation therapy are eligible for study if they have completed > 1 week of radiation therapy, and if they have been approved to go on study by their primary oncologist; the principal investigator (PI)/designated research staff of this study will obtain and document approval from the primary oncologist and principal investigator of the clinical trial in case the patient is on another clinical trial as referenced in the patient's study documents
Patients must not be planning to receive concurrent external beam radiation therapy, including prophylactic cranial radiation
All patients who are receiving chemotherapy and/or radiation therapy are eligible for study if they have completed at least one cycle of chemotherapy or targeted therapy, or > 1 week of radiation therapy, and if they have been approved to go on study by their primary oncologist; the principal investigator (PI)/designated research staff of this study will obtain and document approval from the primary oncologist and principal investigator of the clinical trial in case the patient is on another clinical trial as referenced in the patient's study documents
Prior radiation therapy to the brain
Medical treatment plan includes whole-brain radiation therapy and/or stereotactic radiosurgery
Undergoing definitive treatment with either radiation alone or in combination with systemic therapy
Planned stereotactic body radiation therapy (SBRT)
No prior history of radiation therapy
Prior history of radiation therapy
Prostatectomy with or without radiation for the pilot study patients only
Prior surgery or radiation therapy to the region of interest
Current active treatment with chemotherapy, radiation or surgery in the past 3 months or planned treatment during this study protocol period; hormonal therapy is allowed
Have a plan to receive a continuous course of conventional external beam irradiation delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0 Gy to 2.2 Gy with a cumulative radiation dose ?55 Gy and ?72 Gy. Planned radiation treatment fields must include at least two oral sites (buccal mucosa, floor of mouth, ventral/lateral tongue, soft palate). [Note: the independent RTQA consultant must confirm that the planned radiation treatment meets the protocol criteria]
Has oral mucositis (of any severity) prior to initiation of radiation therapy
Telangiectasias in the radiation field of the treated breast
Currently receiving chemotherapy or radiation
Patients getting radiation therapy are allowed at the discretion of the treating physician
Prior radiation therapy to the ipsilateral chest wall or thorax
Treatment with palliative or pre-operative radiation
Concomitant biologic, hormonal, or radiation therapy are acceptable
Prior radiation therapy of the index tumor <3 weeks prior to screening
Patients who have previously undergone radiation treatment to the pelvis
Current active treatment with chemotherapy, radiation or surgery in the past 3 months or planned treatment during this study protocol period; hormonal therapy is allowed
Were treated with ? 10 Gy of chest radiation therapy (RT) (recent revision with a lower dose threshold)
Radiation to both breasts
The patient’s planned cancer management is radiation to the liver with or without chemotherapy
Women who have had radiation to both breasts
Patients must have a history of stage 0, I, II or III colon or rectal adenocarcinoma that has been treated per standard care with resection alone or in combination with radiation or chemotherapy; adjuvant chemotherapy and radiation therapy (RT) treatment must have been completed at least 30 days prior to registration
Patients must not be expecting to receive radiation or additional chemotherapy
CONTROL (HEALTHY) GROUP: Never received chemotherapy, radiation therapy, immunotherapy, or had breast surgery
Previous radiation to both breasts
Between 12 and 60 months after completion of cancer therapy (chemotherapy, radiation, hematopoietic cell transplant [HCT])
Completed or receiving appropriate radiation therapy if indicated: For patients undergoing total mastectomy surgery as a first intervention, post-mastectomy radiation to the chest wall, infraclavicular and supraclavicular areas is required for patients with ? 4 positive lymph nodes. Radiation to the internal mammary lymph nodes is not required per protocol but is allowed at the discretion of the patient's treating radiation oncologist. For patients with 1-3 positive lymph nodes, post-mastectomy radiation to the chest wall, infraclavicular, supraclavicular, and internal mammary areas is not required per protocol but is allowed at the discretion of the patient's treating radiation oncologist.
Women who have had radiation to both breasts
Participants must be at least 6 months from any prior cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy, hormonal therapy or radiation).
COHORT A2: Diagnosis of breast cancer having completed any cytotoxic chemotherapy, radiation or surgery at least 3 months prior to study entry; may continue to take endocrine therapy and/or maintenance trastuzumab
At least 2 weeks since prior chemotherapy, radiation treatment and/or surgery
Prophylactic medication for the prevention of nausea and vomiting 24 hours prior to the start of radiation therapy through the full course of radiation therapy is prohibited, with the exception of the study drug; corticosteroids will be allowed for treatment of cerebral swelling
At least 3 months after completion of any cytotoxic chemotherapy or radiation or surgery; may continue to take endocrine therapy and/or maintenance trastuzumab
Are currently undergoing treatment for cancer with chemotherapy, hormone therapy, radiation, or biological therapy
Received any chemotherapy (unless anti-hormonal therapy) and/or radiation three months or less prior to the proposed intervention date
Ongoing chemotherapy, radiation therapy, or other cancer-related treatment
PILOTS II and III: Currently receiving radiation therapy or cytotoxic chemotherapy
Prior receipt of ipsilateral breast or chest wall radiation
Have undergone treatment of hormone therapy, immunotherapy, chemotherapy and/or radiation for any malignancies within the past 2 years
History of radiation therapy
Participants must be at least 6 months from any prior cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy, hormonal therapy or radiation)
Ongoing chemotherapy, radiation therapy, or other cancer-related treatment
Patients whose clinical treatment plans include a continuous course of external beam radiotherapy by intensity-modulated radiation therapy (IMRT) and/or image-guided radiation therapy (IGRT), given as a cumulative dose of 5000 – 7000 centigray (cGy) in single daily fractions of 180 - 200 cGy, combined with a concurrent course of weekly or tri-weekly cisplatin or carboplatin chemotherapy
Currently being treated or scheduled to have radiation treatment for bladder cancer during the study
Received prior radical prostatectomy (with or without post-operative radiation) or definitive local radiation for prostate cancer (either external beam radiation, brachytherapy, or combination)
Prior radiation therapy to the breast or ipsilateral regional nodes not allowed (a history of radiation therapy to other sites is permissible)
Subject has contraindications for radiation
Prior radiation therapy is allowed; patients must not have received any radiation within 3 weeks prior to the initiation of study treatment; patients may not have areas of irradiated marrow exceeding 40% of bone marrow volume
Must have received external beam radiation with curative intent
Radiation within 14 days of starting study treatment
Completion of first-line radiation at least 6 months prior to study entry.
Not received radiation to the lung fields within the past 8 weeks.
Prior radiotherapy that overlaps with radiation fields
Focal radiation ? 4 weeks
Whole-brain radiation ? 6 weeks
Radiation within 6 weeks of leukapheresis.
Prior radiation therapy to the contralateral (unaffected) breast
Patients who have had prior radiation to the pelvis
Prior chemotherapy or thoracic radiation within the past 5 years
Clinical treatment plan calls for a minimum of 50 Gy cumulative radiation dose administered via continuous course of external beam irradiation to the oral cavity and/or oropharynx via intensity-modulated radiation therapy [IMRT] and/or image-guided radiation therapy [IGRT], combined with conventional or weekly/tri-weekly cisplatin or carboplatin chemotherapy regimen.
Has received or will receive total body irradiation of radiation therapy to the abdomen or pelvis in the week prior to Treatment Day 1 and/or during the diary reporting period (120 hours following initiation of chemotherapy)
No prior radiation therapy to the head and neck area, and no chemotherapy within the last year except for induction chemotherapy delivered (or to be delivered) prior to the current course of radiation therapy
History of cranial radiation therapy
Prior radiation to the cranium
Completed radiation therapy
planned treatment course to include Cisplatin and radiation therapy, cumulative prescription dose between 50-70 Gy
prior radiation to the sites to be treated
Patients with any history of prior radiation therapy in the affected breast
If prior treatment with radiation or ablative therapy, evidence of recurrence outside the confines of prior treated site(s) is needed.
Patients with biopsy proven (completed and/or reviewed at Memorial Sloan-Kettering [MSK]) adenocarcinoma of the prostate, who will undergo external beam radiotherapy using conventional fractionation image-guided radiotherapy (IGRT) including moderate hypofractionated radiation, low rate brachytherapy alone, low dose brachytherapy combined with supplemental image guided radiation (including IGRT, external beam radiation therapy [EBRT], and stereotactic body radiation therapy [SBRT]), SBRT, or proton radiotherapy
Patients with no prior radiation therapy to the pelvis
Patients receiving stereotactic body radiation therapy
Patient receiving palliative radiation therapy (defined as less than 45 Gy)
Participants with prior mantle radiation
Participants with prior history of ipsilateral breast carcinoma treated with BCS and radiation therapy
There are no limits on prior therapy; patients are allowed to have prior systemic therapy, radiation therapy, radiofrequency ablation, catheter-based therapies, and surgery; patients are allowed to have concurrent chemotherapy with radiation treatment
Participants with prior mantle radiation
Participants must be evaluated by radiation oncology and deemed to be a candidate for stereotactic body radiation therapy for NSCLC
Patients who are offered radiotherapy using a 5-fraction stereotactic body radiation therapy course, at the recommendation of the treating radiation oncologist
Prior radiation therapy which would provide significant dose overlap with the planned target volume(s) delivered within 30 days of enrollment or registration
Complete response by PET achieved with pre-radiation therapy treatment (surgery or chemotherapy)
Planning to undergo proton beam radiation therapy as part of the clinical management of the diagnosed cancer
SUB-STUDY II: Planned salvage external beam radiation therapy
No recent treatment for thyroid cancer as defined as:\r\n* No prior 131I therapy is allowed < 6 months prior to initiation of therapy on this protocol; a diagnostic study using =< 400 MBq of 131I is not considered 131I therapy\r\n* No external beam radiation therapy < 4 weeks prior to initiation of therapy on this protocol; (previous treatment with radiation for any indication is allowed if the investigator judges that the previous radiation does not significantly compromise patient safety on this protocol)\r\n* No chemotherapy or targeted therapy (e.g., tyrosine kinase inhibitor) is allowed < 4 weeks prior to inclusion on this protocol
Prior abdominal radiation therapy with fields overlapping the current fields
Anti-cancer treatment (chemotherapy and/or radiation therapy) within the last 2 weeks
Contraindicated for radiation therapy
No prior history of chest wall radiation
Prior whole brain radiation
Prior radiation therapy treatment in the target lobe
No chemotherapy for at least 4 weeks and no radiation to the index lesion or clear progression in that lesion (greater than 20% increase in longest diameter)
Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy
Previous systemic or radiation treatment for cancer of any type within 1 year
Histologic proof of malignancy suitable for thoracic radiation therapy
Patients should not have received chemotherapy or radiation therapy (localized radiation therapy is allowed to non-evaluable sites) between prior 123I-MIBG scan and 18F-MFBG administration
Study participants must have histologically confirmed primary malignant bone tumor in the sacrum for which surgery and radiation or radiation alone are planned
History of radiation therapy to the brain
Patients must not have received prior chemotherapy or radiation for >= 2 weeks before study enrollment
Pregnancy if the patient is receiving radiation therapy
Lactation if the patient is receiving radiation therapy
Radiotherapy is planned as definitive therapy for prostate cancer; for patients not treated at NCI Radiation Oncology Branch (ROB) patients must have a radiation oncologist who is willing to collaborate with the ROB and provide documentation of treatment
Previous radiation treatment of the pelvis
Completed fractionated radiation therapy (to 60 Gy for high grade gliomas) or stereotactic radiosurgery or hypofractionated radiation therapy (e.g. for brain metastases, anaplastic meningiomas), without or with concurrent chemotherapy
Prior radiation therapy to a symptomatic site of metastatic disease is allowed but patients must have discontinued/completed radiation therapy at least 2 weeks prior to entering the study, and have recovered from adverse events due to that treatment
May undergo radiation therapy
Patients expected to be treated with radiation therapy, chemo-radiation therapy, or chemotherapy
Patients who have received more than one previous therapy regimen (radiation or chemotherapy) are not eligible for this study
The subject has had preoperative radiation therapy
Treatment with whole brain radiation therapy (WBRT) within 3 months prior to screening.
Complete response by PET achieved with pre-radiation therapy treatment (surgery or chemotherapy)
Must be in acceptable health to undergo radiation therapy and curative intent surgery as assessed by UNC surgeons and radiation oncologist
Previous radiation exposure precluding radiation therapy
Prior abdominopelvic radiation or radiation for rectal cancer
No prior radiation to the same area
Prior chest radiation or radiation for esophageal cancer
Subjects who have been treated with radiation therapy on the chest
Untreated low grade gliomas will be imaging-defined gliomas that have not yet been exposed to radiation or systemic chemotherapy; those exposed to therapy will have had radiation and/or systemic chemotherapy more than 1 month prior to scans
At the time of enrollment, patients may not have received any biological, chemotherapy, or radiation therapy
Less than 1 year since cryotherapy, external beam radiation therapy, or HiFU, or 2 years since brachytherapy
Patient must be clinically eligible for and elect to be treated with GK alone without whole-brain radiation therapy (WBRT)
Previous systemic or radiation treatment for another cancer of any type within the last 2 months
Prior radiation therapy to the target lesion
Prior history of radiation therapy that would lead to overlap with new radiation fields
Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug treatment, or palliative radiation therapy within 2 weeks of the first dose of study drug treatment
Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before randomization. Systemic treatment with radionuclides within 6 weeks before randomization. Subjects with complications from prior radiation therapy are not eligible and AEs must return to baseline or ? Grade 1.
Radiation, chemotherapy, or immunotherapy or any other anticancer therapy (including investigational therapies) ? 2 weeks prior to C1D1. Localized radiation to a single site at least 1 week before C1D1 is permitted. Glucocorticoids within 2 weeks of C1D1 are permitted. Patients on long-term glucocorticoids during Screening do not require a washout period but must be able to tolerate the specified dexamethasone dose in this study.
Anticipated use of concomitant chemotherapy (other than the protocol-specified agents), immunotherapy, or radiation therapy
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Myelosuppressive chemotherapy: must not have received within 3 weeks of entry onto this study\r\n* Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with a biologic agent\r\n* Immunotherapies: at least 42 days must have elapsed since a prior therapy that included a monoclonal antibody or any other type of immunotherapy (e.g. chimeric antigen receptor [CAR] T cell therapy)\r\n* Radiation therapy (RT): >= 2 weeks for local palliative RT (small port); >= 6 months must have elapsed if prior craniospinal RT or if >= 50% radiation of the pelvis; >= 6 weeks must have elapsed if other substantial bone marrow (BM) radiation
3 weeks since last chemotherapy or therapeutic radiation therapy
Radiation therapy (except palliative to relieve bone pain) within 7 days of study entry; palliative radiation (=< 10 fractions) must have been completed at least 48 hours prior to study entry; stereotactic or small field brain irradiation must have been completed at least 7 days prior to study entry; whole brain radiation must have been completed at least 2 weeks prior to study entry
Previous treatment (chemotherapy, radiation, or surgery) to both breasts, including hormone therapy
No preoperative treatment for endometrial cancer including radiation or chemotherapy
Patients must have no previous radiation to the abdomen
Must not have received prior radiation therapy or chemotherapy for this diagnosis
The subject has had preoperative chemotherapy, immunotherapy, or radiation therapy within the 30 days prior to Lymphoseek administration
Prior receipt of any therapy, including local excision, radiation or chemotherapy, for the diagnosed rectal adenocarcinoma
ARM II ONLY: For patients status post radiation therapy for prostate cancer, any PSA increase from post radiation therapy nadir OR
Patients must be planned for at least 45 Gy of thoracic radiation
There are no limits on prior therapy; patients are allowed to have prior chemotherapy, radiation therapy, and surgery; patients are allowed to have concurrent chemotherapy with radiation treatment; patients are allowed to have chemotherapy after radiation treatment; patients are not allowed to have planned lung resection after radiation
Patients will typically be enrolled on this trial prior to beginning the radiation treatment course; however, if a patient has had a SPECT/CT 99mTc-MAA and 99mTc-DTPA scan as part of routine medical care within 6 weeks prior to initiation of radiation treatment, he/she is eligible for trial enrollment up to the last day of the radiation treatment course
Patients must not be planned for lung resection after radiation therapy
Patients receiving < 45 Gy radiation
Patients may not have received prior chemotherapy or radiation therapy for lung cancer
Subject has had preoperative radiation therapy to the affected breast or axilla.
Scheduled to receive radiation therapy
Prior definitive radiation therapy must have been completed at least 3 weeks before study drug administration
Prior systemic treatment or radiation therapy is allowed for patients with resectable liver metastases\r\n* The last dose of chemotherapy or radiation must have been administered at least 4 weeks prior to liver surgery\r\n* The last dose of bevacizumab must have been administered at least 6 weeks prior to liver resection
History of radiation therapy for cancer treatment
No prior radiation therapy
Chemotherapy, biologic therapy, radiation therapy or immunotherapy within 3 weeks prior to dosing with amatuximab
Chemotherapy/radiation within the past year
The patients must have no prior chemotherapy or radiation therapy as treatment
Prior use of androgen deprivation therapy or radiation therapy
Therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment or palliative radiation therapy within 2 weeks before study drug treatment.
Prior radiation therapy to the target lesion
chemotherapy or radiation therapy within three weeks
Patients treated with radiation for palliative intent
Undergone chemotherapy or radiation therapy in the past 18 months prior to enrollment
Radiation oncology patients undergoing shorter courses of radiation or undergoing palliative courses of radiation
Tumor previously treated with radiation therapy
Completion of prior chemotherapy, biologic therapy, immunotherapy, or radiation therapy at least 4 weeks prior to enrollment.
Radiation therapy: may not have had radiation therapy to area of tumor planned to be resected w/in 28 days
Expected to require other cancer therapy while on study with the exception of local palliative radiation treatment to the site of bone and other metastasis.
AML secondary to MDS, chemotherapy, or radiation therapy
Patients who are to receive 30 Gy or more of external beam radiation therapy.
Prior major surgical procedure or radiation treatment within 2 weeks of initiation of study treatment (not including limited radiation used for palliation of bone pain)
Subjects may have previously received pre-operative radiation therapy.
Subjects ADT naive or subjects who are already on ADT treatment and scheduled to receive radiation therapy for their adenocarcinoma of prostate are eligible. An 8-week course of ADT is required to be completed prior to NBTXR3 administration and initiation of radiation therapy .
Expected to require other cancer therapy while on study with the exception of local palliative radiation treatment.
Prior treatment with >1 line of chemotherapy for metastatic breast cancer or for locoregional recurrence that was not amenable to resection or radiation therapy with curative intent.
Patients with prior ipsilateral thoracic or breast radiation
